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Eukaryotic cells respond to extracellular stimuli by transmitting intracellular instructions via 
signalling pathways to coordinate appropriate responses. Mitogen-activated protein kinase 
(MAPK) pathways are often used to transmit these instructions to regulate gene expression, 
where Ternary Complex Factors (TCFs) are among their nuclear targets. Elk-1 is the 
founding member of the TCF family of transcription activators. The mechanism of function 
and regulation of Elk-1 has been extensively studied, therefore providing a paradigm for 
signal-induced transcription. The activity of Elk-1 is influenced by Post-Translational 
Modifications (PTMs), such as phosphorylation and sumoylation. Elk-1 ubiquitylation has 
also been reported in vitro, however little work has been done on this modification of Elk-1. 
This thesis sought to reveal the mechanism of regulation and function of Elk-1 ubiquitylation.  
Abstract  
Elk-1 was demonstrated to be both monoubiquitylated and polyubiquitylated in vitro and in 
cells. Using size exclusion chromatography and the dominant negative nedd8 conjugating E2 
enzyme Ubc12, several features of the Elk-1 specific E3 ligases have been revealed in vitro. 
In cells, ternary complex formation was shown to be important for monoubiquitylation. 
Furthermore monoubiquitylated Elk-1 is diminished following ERK-mediated 
phosphorylation, hence activation, in response to mitogen stimulation. It was also 
demonstrated that an Elk-1 derivative that exhibits strong monoubiquitylation level also 
exhibits a reduced capability to transactivate gene expression at the Serum Responsive 
Element (SRE), indicating a negative role of monoubiquitylation on Elk-1 transcriptional 
ability.  
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1. Introduction  
 
1.1. The ternary complex factor Elk-1  
1.1.1. Overview   
Accurate regulation of gene expression is vital for cell differentiation, proliferation, and the 
maintenance of cellular homeostasis. The expression of many genes is induced in response to 
specific stimuli to ensure precise regulation of cellular activity. In order for a regulated gene 
to be expressed, numerous molecular processes are coordinated in an appropriate sequence. 
RNA transcription is the first step of gene expression, where genetic information in DNA is 
copied into messenger RNA, which in turn is used as a template for protein translation. To 
initiate RNA transcription, sequence-specific transcription activators must bind to the 
promoter of the gene to be transcribed. These transcription activators work by recruiting 
proteins that alter the local chromatin structure to a more accessible conformation; and 
transcription mediators that in turn recruit the general transcription machinery to initiate 
RNA transcription (Thomas and Chiang 2006; Kornberg 2007).   
Transcription activators with a similar conserved domain are often members of families, for 
example the ETS-domain protein family. The founding member of this family is ETS-1 
which is homology to the v-ets oncoprotein of the avain erythroblastosis virus E26 (E 
Twenty Six), hence the name of this protein family (Leprince, Gegonne et al. 1983; Nunn, 
Seeburg et al. 1983). ETS-domain proteins comprise a large group of transcription activators 
that are fundamentally important in many cellular processes, such as cell proliferation, cell 
differentiation and apoptosis (Sharrocks 2001; Hsu, Trojanowska et al. 2004). The ETS-
domain proteins can be subdivided based on sequence similarities in the ETS-domain and the 
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presence of further conserved domains. One subfamily is the Ternary Complex Factor (TCF) 
family. Ternary complex factors are characterised by their ability to form a ternary 
nucleoprotein complex with the Serum Response Factor (SRF) dimer at the Serum 
Responsive Element (SRE) to activate gene transcription. This ternary complex is formed 
upon activation of the Mitogen-Activated Protein Kinase (MAPK) signalling pathways 
which relay extracellular stimuli from cell surface receptors to the nucleus. Despite the 
diversity of biological functions of the ETS-domain proteins, many of their regulatory 
mechanisms are conserved among family members, particularly for the TCFs (Shaw and 
Saxton 2003; Buchwalter, Gross et al. 2004). Elk-1 is the founding member of the TCF 
subfamily. By studying Elk-1, the complex regulation of ETS-domain proteins can be 
revealed, therefore providing a paradigm for signal-induced transcriptional regulation.  
 
1.1.2. Historical perspective 
Elk-1 was found as part of a ternary complex in HeLa nuclear extract with the SRF dimer on 
the SRE of the c-fos promoter (Shaw, Schröter et al. 1989). It was initially named p62 due to 
its molecular weight and later shown to be identical to the previously cloned Elk-1, which 
was identified based on sequence homology with the v-ets protein (Rao, Huebner et al. 1989; 
Hipskind, Rao et al. 1991). Two structurally related proteins were subsequently identified, 
Sap-1 (SRF accessory protein 1) (Dalton and Treisman 1992) and Net/Sap-2/Erp (Giovane, 
Pintzas et al. 1994; Lopez, Oettgen et al. 1994; Nozaki, Onishi et al. 1996). Both proteins 
were shown to exhibit similar ability to form ternary complexes. In addition TCF 
homologues have also been identified in other vertebrates (Goldman, Sapru et al. 1998; 
Brown, Yang et al. 1999), however no TCF homologue has been identified in yeast despite 
the availability of the entire genomic sequence of Saccharomyces cerevisiae, indicating this 
family of proteins is only conserved among metazoan.  
 3 
 
 
1.1.3. Domain structure of Elk-1  
All TCFs share a similar domain arrangement with additional functional domains that are 
unique in family members to permit differential regulation and function (Figure 1-1).  Four 
domains (A-D domains) were initially identified based on sequence comparison between 
Elk-1 and Sap-1 (Dalton and Treisman 1992). The N-terminal A-domain corresponds to the 
DNA-binding ETS-domain. Besides DNA binding, the ETS-domain has also been reported 
to exhibit repressive capability by recruiting the mSin3A-histone deacetylase 1 co-repressor 
(Yang, Vickers et al. 2001) and the DNA-binding inhibitor Id helix-loop-helix proteins 
(Yates, Atherton et al. 1999). The B-domain binds to the MADS-box transcription factor 
family member SRF to facilitate ternary complex formation (Shore and Sharrocks 1994). 
The C-terminal C-domain is a transactivational domain with multiple MAPK 
phosphorylation consensus sites (S/T)P, where phosphorylation activates its transcriptional 
ability (Janknecht, Ernst et al. 1993; Marais, Wynne et al. 1993; Gille, Kortenjann et al. 
1995). The D-domain and the FXFP-motif within the C-domain are the MAPK docking sites 
(Yang, Whitmarsh et al. 1998; Yang, Yates et al. 1998; Jacobs, Glossip et al. 1999; 
Sharrocks, Yang et al. 2000).  Beside these domains, which are shared among all TCF 
members, Elk-1 contains an additional R-domain for transcriptional repression (Yang, 
Bumpass et al. 2002). The R-domain contains three lysine residues, which can be 
sumoylated for the recruitment of the histone deacetylase 2 co-repressor (Yang, Jaffray et al. 
2003; Yang and Sharrocks 2004). 
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Figure 1-1, Schematic representation of the domain 
structure of Elk-1. Functions of the domains are as indicated. 
The amino acid residue locations of the domains are presented 
below the boxes.  
 
1.1.4. Ternary complex formation  
1.1.4.1. Serum Response Element  
Despite the similarity between the TCFs, differential binding at the SRE has been reported 
between Elk-1 and Sap-1. Upon mitogen stimulation, Elk-1 cooperates with the SRF dimer 
to form a ternary complex at the SRE of the c-fos promoter (Gille, Sharrocks et al. 1992). 
Binding between Elk-1 and the SRE was not observed in absence of SRF (Shaw, Schröter et 
al. 1989; Hipskind, Rao et al. 1991), suggesting the SRF cooperative binding is essential for 
Elk-1 mediated ternary complex formation, whereas Sap-1 is able to interact with the SRE 
alone (Dalton and Treisman 1992). In addition, autonomous DNA binding of Elk-1 has also 
been reported with a high affinity ETS binding site (E74), however it has not been shown to 
be a physiological target (Sharrocks 1995; Mo, Vaessen et al. 1998; Mo, Vaessen et al. 2000).     
The SRE are often found in the promoter of many Immediate Early Genes (IEGs), a set of 
genes that are rapidly and transiently induced following growth factor or mitogen stimulation 
(Treisman 1992; Treisman 1995). Besides IEGs, the SRE was also found in viral genomes 
(Cahill, Nordheim et al. 1994). The c-fos SRE consists of a weak ETS binding site (EBS) 
adjacent to two SRF binding sites (CArG-box). The EBS is characterised by a purine-rich 
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core sequence of GGA(A/T) surrounded by more variable sequences to allow differential 
binding specificity between ETS-domain proteins. The CArG-box consists of the sequences 
CC(A/T)6GG, which interacts with the SRF dimer. It has been demonstrated that the spacing 
between the EBS and the CArG-box (an addition of 25 bps) and their relative orientation can 
be altered without a significant effect on ternary complex formation (Treisman, Marais et al. 
1992).   
 
 
Figure 1-2 Diagram of ternary complex. The A-domain (ETS-
domain) of a TCF binds to the EBS of the SRE whereas the B-
domain mediates protein-protein interactions with the SRF dimer, 
which in turn binds to the CArG box of the SRE. 
 
1.1.4.2. ETS/DNA binding  
The ternary complex is formed by a combination of protein/DNA and protein/protein 
interactions (Figure 1-2). The DNA binding ETS-domain is 85 amino acids long and usually 
found at the C-termini of most ETS-proteins, whereas it is located at the N-termini of the 
TCFs (Sharrocks 2001; Hsu, Trojanowska et al. 2004). It adopts a winged Helix-Turn-Helix 
(wHTH) VWUXFWXUHZLWKWKUHHĮ-helices and four anti-SDUDOOHOȕ-strands, where the wing is a 
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ORRSEHWZHHQDGMDFHQWȕ-strands (Figure 1-3 & Figure 1-4) (Donaldson, Petersen et al. 1994; 
Donaldson, Petersen et al. 1996; Mo, Vaessen et al. 2000).  
 
 
Figure 1-3 The 2.1Å crystal structure of the ETS-domain of Elk-1 
(Mo, Vaessen et al. 2000). The image was generated using the 
Cn3D software (NCBI).  ɲ-ŚĞůŝĐĞƐĂŶĚɴ-strands are presented as 
green cylindrical arrows and  dark yellow flat arrows respectively. 
Asparagine 69 and tyrosine 66 are indicated by white arrows and 
coloured in light yellow. 
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Figure 1-4 Schematic representation of the secondary structure 
of Elk-1 ETS-domain. ɲ-ŚĞůŝĐĞƐĂŶĚɴ-strands are presented as 
indicated. Asparagine 69 and tyrosine 66 are highlined in light 
yellow. 
 
The crystal structure of the ETS-domain bound to the E74 duplex has revealed that the main 
residues contributing to the ETS/DNA binding are located in the Į helix that lies in the 
major grove of DNA, with additional contacts mediated by WKH ORRS EHWZHHQ Į2  and Į3 
helices and the wing EHWZHHQȕ and ȕstrands  (Mo, Vaessen et al. 2000). It also revealed 
that differential DNA binding between Elk-1 and Sap-1 is due to the orientation of a 
conserved tyrosine residue in the DNA recognition Į helix (Y66 for Elk-1 and Y65 for Sap-
1), positioned by non-conserved residues distal from the helix (asparagine 69 for Elk-1 and 
valine 68 for Sap-1) (Mo, Vaessen et al. 1998; Mo, Vaessen et al. 2000). These two residues 
were previously described to be critical determinants for differential DNA binding between 
TCFs in another study and replacing asparagines 69 in Elk-1 with valine was able to confer 
the Sap-1 DNA binding specificity on Elk-1 (Shore, Whitmarsh et al. 1996).  
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1.1.4.3. TCF/SRF interaction  
In addition to DNA/protein binding, protein/protein interactions are also essential for the 
ternary complex formation. It has been shown that the interaction between Elk-1 and SRF 
enhances their binding to the c-fos SRE (Mueller and Nordheim 1991; Shaw 1992). The B-
domain (amino acids 137 - 169) of Elk-1 was shown to interact with an extended structure 
near the DNA binding domain of SRF (Janknecht and Nordheim 1992), where  the B-domain 
forms an inducible helix to present a hydrophobic region to SRF for their interaction (Ling, 
West et al. 1998). Disruption of the B-domain completely abolishes ternary complex 
formation and SRE-dependent transcription (Hill, Marais et al. 1993). Subsequently direct 
interaction between Elk-1 and SRF in absence of the SRE has also been reported (Shore and 
Sharrocks 1994) and critical amino acids mediating this interaction have been identified 
(Ling, Lakey et al. 1997), namely three aromatic residues tyrosine 153, tyrosine 159 and 
Phenylalanine 162. 
No structural study on Elk-1 ternary complex has been reported, however the crystal 
structure of a ternary complex containing Sap-1 has revealed and confirmed several 
observations (Hassler and Richmond 2001). (i) the B-GRPDLQ DGRSWV D SDUWLDO Į-helical 
structure (two short 310 KHOLFHV OLQNHG E\ D ȕ-strand), where significant contacts were 
observed with the hydrophobic groove of SRF. (ii) the DNA-binding domain of Sap-1 and 
SRF are situated on opposite sides of DNA with some contacts with each other. (iii) the 
linker region between the B-domain and ETS-domain exhibits a loose structure to provide a 
flexible tether, supported by the evidence that the spacing and orientation between the EBS 
and the CArG-box in the c-fos SRE can be substantially altered with little impact on ternary 
complex formation (Treisman, Marais et al. 1992) 
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1.1.5. Regulation of Elk-1 by post-translational modifications  
The transcriptional ability of Elk-1 is influenced by extracellular signal-induced post-
translational modifications (PTMs).  Phosphorylation of Elk-1 triggered by growth factors or 
mitogens has been shown to potentiate ternary complex formation and transactivation (Gille, 
Sharrocks et al. 1992; Janknecht, Ernst et al. 1993; Gille, Kortenjann et al. 1995; Sharrocks 
1995), whereas sumoylation of Elk-1 represses its transcriptional capability  through the 
recruitment of the histone deacetylase 2 co-repressor (Yang, Jaffray et al. 2003; Yang and 
Sharrocks 2004). Moreover PTMs often affect each other, for example Elk-1 
phosphorylation represses its sumoylation (Yang, Jaffray et al. 2003). Elk-1 ubiquitylation 
has also been reported in vitro (Fuchs, Xie et al. 1997), however its regulation and function 
are poorly understood.  
 
1.1.5.1. Elk-1 phosphorylation by MAPKs  
Phosphorylation of Elk-1 is mediated by MAPKs (Janknecht, Ernst et al. 1993; Gille, Strahl 
et al. 1995; Whitmarsh, Shore et al. 1995; Price, Cruzalegui et al. 1996; Enslen, Raingeaud et 
al. 1998). MAPKs are a conserved family of serine/threonine kinases in all eukaryotes that 
transmit signals from cell surface receptors to the nucleus to control eukaryotic gene 
expression in response to extracellular stimuli (Yang, Sharrocks et al. 2003; Turjanski, 
Vaque et al. 2007). There are three major MAPK cascades; the ERK (ERK1 and ERK2; 
Extracellular signal Regulated Kinase); JNK (JNK1, JNK2 and JNK3; c-Jun N-terminal 
Kinase); and p38 SĮSȕSȖDQGSįcascades. The ERK cascade is activated by 
growth stimuli, whereas the JNK and p38 cascades are activated in response to cellular stress 
and cytokines. Elk-1 is phosphorylated by all the three major MAPKs.  ERK was the first 
MAPK shown to phosphorylate Elk-1 (Gille, Sharrocks et al. 1992; Marais, Wynne et al. 
1993; Gille, Kortenjann et al. 1995; Cruzalegui, Cano et al. 1999). Subsequently, Elk-1 was 
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shown to be phosphorylated by JNK and P38 (Cavigelli, Dolfi et al. 1995; Gille, Strahl et al. 
1995; Whitmarsh, Shore et al. 1995; Price, Cruzalegui et al. 1996; Enslen, Raingeaud et al. 
1998).  
To ensure signal specificity, MAPKs recognise their substrates via specific docking sites to 
facilitate phosphorylation (Sharrocks, Yang et al. 2000). The D-domain was the first 
identified ERK docking site in Elk-1 (Yang, Yates et al. 1998). It is located upstream from 
the C-domain that contains multiple MAPK phosphorylation sites. An additional docking 
site (FXFP-motif) for ERK was later discovered (Jacobs, Glossip et al. 1999). This motif is 
situated within the C-domain and shown to form a bipartite docking module.  It was 
demonstrated that JNK also binds to Elk-1 via the D-domain (Yang, Whitmarsh et al. 1998), 
but does not interact with the FXFP-motif, whereas p38 seems to interact with Elk-1 through 
an unidentified region.   
In addition to MAPK recruitment, the docking sites also direct MAPK-mediated 
phosphorylation on the MAPK consensus sites (S/T)P. Phosphorylation on  serine 383 was 
shown to be directed by the FXFP-motif, whereas the D-domain mediates phosphorylation at 
other sites (Fantz, Jacobs et al. 2001). Phosphorylation at the serine 383 residue was shown 
to be most critical for Elk-1 transcriptional ability (Gille, Kortenjann et al. 1995). Despite the 
importance of serine 383 phosphorylation, other phospho-acceptor sites are modified to the 
same stoichiometry (Cruzalegui, Cano et al. 1999), however the functional role of other sites 
remains elusive. 
   
1.1.5.2. The role of Elk-1 phosphorylation  
Phosphorylation regulates several Elk-1 activities. First Elk-1 phosphorylation relieves its 
auto-inhibition by disrupting intra-molecular interaction between the ETS- and the C-domain 
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(Yang, Shore et al. 1999), resulting in the enhancement of its DNA binding capability  (Gille, 
Sharrocks et al. 1992; Gille, Kortenjann et al. 1995; Sharrocks 1995).  
Second, the Id helix-loop-helix (HLH) proteins inhibit Elk-1 DNA binding by masking the 
ETS-domain (Yates, Atherton et al. 1999). Id proteins usually interact with other HLH 
proteins to block their DNA binding. Phosphorylation of Elk-1 was shown to inhibit its 
interaction with the Id proteins, thereby enabling DNA binding. 
Third, Elk-1 transactivational ability is potentiated by phosphorylation (Hill, Marais et al. 
1993; Marais, Wynne et al. 1993; Gille, Kortenjann et al. 1995), presumably by enhancing 
its interactions with co-activators. The CREB binding protein (CBP) is a co-activator for 
Elk-1. CBP acetylates histones to relieve transcriptional repression. It was demonstrated that 
Elk-1 interacts with CBP on the c-fos SRE in a phosphorylation independent manner, 
however functional cooperation between the two proteins requires Elk-1 phosphorylation 
(Janknecht and Nordheim 1996; Nissen, Gelly et al. 2001). Furthermore, a similar histone 
acetyltransferase (P300) was reported to facilitate Elk-1 transactivation in the same manner 
(Li, Yang et al. 2003).  
Fourth, Elk-1 phosphorylation is also implicated in the recruitment of transcription mediators 
(Boyer, Martin et al. 1999). The Srb mediator complex, consisting of 20 - 30 subunits, acts 
as a molecular bridge to connect transcription activators to the general transcription 
machinery to facilitate transcription (Kornberg 2005). A subunit (Sur-2) of the mediator 
complex has been shown be recruited to Elk-1 by phosphorylation (Stevens, Cantin et al. 
2002).  
Finally, besides contributing to transactivation, Elk-1 phosphorylation also mediates 
transcriptional repression. Phosphorylation of Elk-1 recruits the co-repressor mSin3A-
HDAC, which exhibits histone deacetylase ability. Histone deacetylases alter local 
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chromatin conformation to repress transcription. Elk-1 mediates the temporal acute 
expression of many immediate early genes upon stimulation. The recruitment of mSin3A-
HDAC correlates to the kinetics of target gene shutdown, thereby providing a mechanism by 
which Elk-1 phosphorylation mediates a transient burst of transactivation (Yang, Vickers et 
al. 2001).    
 
1.1.6. Elk-1 target genes and biological function 
Elk-1 was initially identified as part of the ternary complex with SRF at the c-fos SRE (Shaw, 
Schröter et al. 1989), which is commonly found in the promoters of many immediate early 
genes, a set of genes that are rapidly and transiently activated when cells are stimulated with 
growth factors or mitogens to mediate cell cycle entry from the G0 to G1 phase (Treisman 
1990; Treisman 1992). Subsequently, other immediate early gene targets for Elk-1 such as 
egr-1 and jun-B have been verified (Hipskind, Baccarini et al. 1994; Hodge, Liao et al. 1998). 
It has also been demonstrated that Elk-1 interacts with Pax5 on a composite element of the 
mb-1 promoter (Fitzsimmons, Hodsdon et al. 1996) and binds to the ETS binding site in the 
71)ĮSURPRWHU(Tsai, Falvo et al. 2000). To date, the full spectrum of Elk-1 target genes is 
not clear. Using an Elk-1 repressor fusion protein to suppress Elk-1 mediated transcription, it 
was demonstrated that Elk-1 target genes are critical for cell proliferation and apoptosis 
inhibition in a SRF dependent manner (Vickers, Kasza et al. 2004). In addition, a recent 
study has reported that Elk-1 also targets many SRF-independent genes and a high degree of 
redundancy between Elk-1 and other ETS-proteins in transcriptional activation was observed 
(Boros, O'Donnell et al. 2009). 
 A role in neuronal function of Elk-1 has been suggested based on its expression pattern 
(Sgambato, Vanhoutte et al. 1998). Elk-1 mRNA was found in various adult rat brain 
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structures including soma, dendrite and axon terminals of neurons. It was demonstrated that 
Elk-1 promotes neuronal cell proliferation through activation of c-fos while a truncated 
isoform of Elk-1 plays an opposite role to full length Elk-1 in neuronal differentiation 
(Vanhoutte, Nissen et al. 2001). However, Elk-1 knockout mice are viable and do not exhibit 
strong phenotypical abnormalities (Cesari, Rennekampff et al. 2004), possibly due to the 
redundant activities of other ETS-proteins.  
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1.2. Ubiquitylation  
1.2.1. Overview and historical perspective  
Ubiquitylation was discovered in the early 1980’s as a post-translational modification, in 
which a small protein (ubiquitin, 76 amino acids, ~8.5kDa) is attached to a protein substrate 
(Pickart 2001; Glickman and Ciechanover 2002; Fang and Weissman 2004). The 
conjugation of ubiquitin is found in a broad range of proteins and impacts in almost all 
cellular activities. Proteins can be conjugated with a single or multiple ubiquitin moieties 
(see chapter 1.2.7), which often confer different activity to the substrate once conjugated. 
Despite the initial finding that polyubiquitylation directs proteins for destruction by the 26S 
proteasome, non-proteolytic roles of ubiquitylation were subsequently revealed. In 2004, 
Aaron Ciechanover, Avram Hershko and Irwin Rose were awarded the Nobel Prize in 
chemistry for their discovery of the ubiquitin system (Giles 2004).   
 
1.2.2. Mechanism of ubiquitylation  
Ubiquitylation is performed by a three-step enzymatic cascade (Pickart 2001; Passmore and 
Barford 2004). In the first step, an E1 activating enzyme activates ubiquitin in an ATP-
dependent manner forming an ubiquitin-E1 thiol ester between its catalytic cysteine and the 
carboxyl-terminal glycine of ubiquitin, thereby activating the ubiquitin for nucleophilic 
attack.  In the second step, the activated ubiquitin is transferred to the catalytic cysteine of an 
E2 conjugating enzyme. The ubiquitin is consequently transferred to WKHİ-amino group of a 
substrate lysine via an isopeptide linkage, facilitated by an E3 ligase through two distinct 
mechanisms, depending on the type of E3 ligase involved. In rare cases ubiquitin is attached 
to the free Į-amino group of the substrate instead of a lysine via a peptide linkage 
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(Breitschopf, Bengal et al. 1998; Aviel, Winberg et al. 2000; Reinstein, Scheffner et al. 2000; 
Kirisako, Kamei et al. 2006; Tokunaga, Sakata et al. 2009). 
 
1.2.3. Ubiquitin enzymes   
Ubiquitylation is a highly regulated process and specific ubiquitylation of substrates depends 
on sequential action of all three types of ubiquitin enzymes. The organization of these 
enzymes is hierarchical, where the human genome encodes two E1 activating enzymes, 38 
E2 conjugating enzymes, and approximate 600 E3 ligases (Petroski and Deshaies 2005; 
Groettrup, Pelzer et al. 2008; Ye and Rape 2009). In this enzymatic cascade, the two types of 
E1 activating enzymes cooperate with a different but overlapping set of E2 conjugating 
enzymes, which in turn work with a much larger number of E3 ligases. E3 ligases can also 
cooperate with more than one E2 conjugating enzyme. 
 
1.2.4. Ubiquitin E3 ligases  
E3 ligases play a crucial role in ubiquitylation by selecting substrates (Ardley and Robinson 
2005). There are two major types of E3 ligases, characterised by the presence of their 
catalytic HECT- or RING-domains which facilitate ubiquitylation through different 
enzymatic mechanisms (Figure 1-5). The HECT-domain E3 ligases initially transfer 
ubiquitin to a catalytic cysteine within the HECT-domain forming an E3-ubiquitin thioester 
and then transfer the ubiquitin to substrates (Kee and Huibregtse 2007). Conversely, RING-
domains do not contain a catalytic cysteine and RING-domain E3 ligases merely act as a 
bridge orienting the E2-ubiquitin thioester and substrates in close proximity for direct 
ubiquitin transfer (Petroski and Deshaies 2005). In addition, two other domains (U-box and 
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PHD-domain) related to the RING-domain are also implicated in ubiquitylation (Aravind 
and Koonin 2000; Capili, Schultz et al. 2001).  
 
 
Figure 1-5 Mechanism of ubiquitylation mediated by 
HECT- and RING-domain E3 ligases. E1 activating enzyme 
utilises energy from ATP hydrolysis to activate ubiquitin. 
Ubiquitin is then carried as an E1- and E2-thioester and 
eventually transferred to substrates, facilitated by E3 ligases. 
HECT-domain E3 ligases form an ubiquitin thioester 
intermediate before substrate conjugation whereas RING-
domain E3 ligases transfer ubiquitin from an E2 conjugating 
enzyme to a substrate directly.  
 
1.2.4.1. RING-domain E3 ligases  
RING-domain E3 ligases can exist either as monomers (e.g. Mdm2 and CBL), or as dimeric 
(e.g. RNF4) or multimeric protein complexes (e.g. the SCFs and the APC). Most RING-
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domain E3 ligases are multimeric, the largest group of E3 ligases are Cullin-RING Ligases 
(CRLs). SCF Cdc4 is the archetype of CRLs and was first described in studies on cell division 
in Saccharomyces cerevisiae (Feldman, Correll et al. 1997; Skowyra, Craig et al. 1997). All 
SCFs contain the cullin scaffold CUL1 and their substrate recognition subunits are usually 
represented in superscript. Other CRLs are named after their cullin subunits and substrate 
recognition subunits. Characterisation of SCFs has revealed the typical components of CRLs 
which include a cullin family member, a RING-domain protein and a variable substrate 
receptor (either a single or multiple subunits) (Kamura, Koepp et al. 1999; Seol, Feldman et 
al. 1999; Tan, Fuchs et al. 1999).   
The scaffold protein cullin is evolutionary conserved from yeast to mammals with the 
highest conservation in the C-terminal cullin homology domain. The human genome encodes 
seven cullins (CUL1, 2, 3, 4a, 4b, 5 and 7) and two other proteins that contain the cullin-
homology domain (APC2 Subunit in the APC E3 ligase complex and PARC)(Yu, Peters et al. 
1998; Zachariae, Shevchenko et al. 1998; Nikolaev, Li et al. 2003). Structural and sequence 
comparison studies revealed that all cullins adopt a curved structure with an N-terminal stalk 
that is comprised of three repeats of a five helix bundle (cullin repeat [CR] 1-3) and a C-
terminal globular domain (Zheng, Schulman et al. 2002). The substrate receptor associates 
with the N-terminal CR1 region, while the C-terminal globular domain binds to the catalytic 
RING-subunit which in turn associates with an E2 conjugating enzyme. 
The RING-domain is defined by a distinct arrangement of eight conserved cysteine and 
histidine residues that coordinate two zinc ions in a crossed-braced fashion (Borden and 
Freemont 1996). One common feature of CRLs is that most of them utilise the same catalytic 
RING-subunit.  Most cullins bind to the same RING-subunit RBX1, except for CUL5, which 
interacts with RBX2 (Ohta, Michel et al. 1999). Despite the similarity in the catalytic core, 
the substrate receptors of CRLs are more diverse to accommodate their vast substrate 
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spectrum and often these receptors are comprised of an adaptor protein and a substrate 
recognition unit.  
For the archetypal SCFSKP2, the adaptor protein SKP1 associates with CUL1 via its N-
terminal BTB-domain (Broad complex, Tramtrack and Bric-à-Brac domain), whereas its C-
terminus binds to the substrate recognition F-box protein SKP2 (Schulman, Carrano et al. 
2000; Zheng, Schulman et al. 2002). Besides CUL1, SKP1 can also recruit a substrate 
receptor to CUL7 (Dias, Dolios et al. 2002). Subsequently, other adaptor proteins have been 
shown to interact with cullins via a domain structurally similar to the F-box. For example, 
the adaptor protein Elongin C has been demonstrated to associate with CUL2 and CUL5 
(Stebbins, Kaelin et al. 1999). 
Substrate recognition units typically contain adaptor interacting domain at the N-terminus. 
Two adaptor interacting domains were reported (F-box or SOCS-box). The F-box was 
demonstrated to associate with Skp1, which in turn associates with CUL1 and CUL7 (Bai, 
Sen et al. 1996). The SOCS box was found to interact with Elongin C, which in turn binds to 
CUL2 and CUL5 (Kamura, Sato et al. 1998). Conversely, the receptor recognition unit of 
CUL3-based ligases is able to interact directly with CUL3 via its BTB-domain (Geyer, Wee 
et al. 2003). On the other hand, substrate binding is usually mediated by the WD40-motif or 
Leucine Rich Repeats (Kipreos and Pagano 2000). 
 
1.2.4.2. CRLs regulation by neddylation  
The activity of CRLs is regulated by several mechanisms, one of which is cullin neddylation 
(Merlet, Burger et al. 2009). Nedd8 is an ubiquitin-like modifier. The three-step enzymatic 
mechanism of neddylation is similar to ubiquitylation, mediated by the Nedd8 specific E1 
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activating enzyme (Ula1/Uba3), E2 conjugating enzyme (Ubc12) and E3 ligase (DCN1) 
(Gong and Yeh 1999; Kurz, Ozlu et al. 2005). 
Neddylation is essential for CRL activity (Podust, Brownell et al. 2000; Read, Brownell et al. 
2000; Wu, Chen et al. 2000). All known cullin proteins can be neddylated (Hori, Osaka et al. 
1999) at a conserved lysine residue at the C-terminus (Osaka, Saeki et al. 2000). Neddylation 
was initially thought to activate CRLs by enhancing ubiquitin E2 recruitment (Kawakami, 
Chiba et al. 2001; Sakata, Yamaguchi et al. 2007). However, structural studies revealed a 
50Å gap between the activated E2 and the substrate and some ubiquitin E2s (e.g. CDC34) 
simply lack the putative Nedd8 binding site, which draw doubts to the proposed mechanism 
of activation. It was later clear that neddylation activates CRLs by weakening the auto-
inhibitory interaction between its E2-bound RING-domain and the cullin scaffold (Yamoah, 
Oashi et al. 2008), resulting in a flexibly linked E2-bound RING-domain to position E2-
bound ubiquitin and the substrate in close proximity for ubiquitin conjugation (Duda, Borg et 
al. 2008; Saha and Deshaies 2008).   
 
1.2.4.3. HECT-domain E3s 
The first identified HECT-domain E3 ligase was E6-AP, which mediates p53 ubiquitylation 
in cells expressing the human papillomavirus E6 oncoprotein, resulting in p53 degradation 
by the 26S proteasome (Scheffner, Huibregtse et al. 1994). Subsequently, other proteins 
were found to share similarity with the C-terminus of E6-AP and such regions were named 
HECT (Homologous to the E6-AP Carboxyl Terminus) (Huibregtse, Scheffner et al. 1995).  
There are approximately 50 HECT-domain E3 ligases in humans with a size range from 90 
kDa to over 500 kDa (Kee and Huibregtse 2007; Rotin and Kumar 2009).  The 350 amino 
acid long HECT domain is invariably located at the C-terminus of HECT-domain E3 ligases, 
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whereas their N-terminus contains determinants for substrate recognition and regulation. 
Structural studies have revealed that HECT is a bi-lobal domain (Huang, Kinnucan et al. 
1999; Verdecia, Joazeiro et al. 2003; Ogunjimi, Briant et al. 2005) where the smaller C-
terminal lobe contains the catalytic cysteine residue and the larger N-terminal lobe interacts 
with an E2 conjugating enzyme. The two lobes are connected by a short linker, which is 
critical for juxtaposing the two catalytic cysteine residues of an E2 conjugating enzyme and 
an E3 ligase for the transthiolation. The mechanism of ubiquitin transfer between HECT-
domain E3 ligases and substrates is still largely unknown, however the phenylalanine residue, 
four residues from the end of the protein, was shown to be important in the positioning of 
E3-linked ubiquitin for substrate conjugation in most HECT-domain E3 ligases (Salvat, 
Jariel-Encontre et al. 1998).    
 
1.2.5. E2 conjugating enzymes  
Much of the investigations in ubiquitylation were carried out on E3 ligases due to their 
ability to confer substrate specificity and E2 conjugating enzymes were thought to play an 
auxiliary role as activated-ubiquitin carriers. However, increasing evidence has suggested 
that E2 conjugating enzymes play a crucial role in determining the processivity of the 
ubiquitin chain assembly and the topology and the length of ubiquitin chain (Ye and Rape 
2009; David, Ziv et al. 2010). There are 13 different E2 conjugating enzymes (Ubc 1-13) in 
Saccharomyces cerevisiae and 38 in humans (van Wijk and Timmers 2010). Some of those 
facilitate ubiquitin-like modifier conjugation rather than ubiquitylation, for example Ubc9 
and Ubc12 mediate sumoylation and neddylation respectively. All E2 conjugating enzymes 
share a 150 amino acid conserved ubiquitin-conjugating domain (UBC) that contains a 
catalytic cysteine residue. Ubiquitin E2 variants (UEV) also contain the UBC domain but 
lack this residue. The UBC domain adopts a structure of fouUĮ-helices, an anti-SDUDOOHOȕ-
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sheet formed by four strands and a short 310-helix (Lin, Hwang et al. 2002; Ozkan, Yu et al. 
2005; Eddins, Carlile et al. 2006) where the catalytic cysteine is located in a shallow groove 
formed by a short loop linking the Į2-helix with the Į3-helix and a long loop proximal to the 
active site. In addition, it has been demonstrated that linkage specific E2 conjugating 
enzymes often function as heterodimers where one subunit positions the desired lysine in 
ubiquitin to another subunit to facilitate linkage-specific elongation (David, Ziv et al. 2010). 
 
1.2.6. E1 activating enzymes  
To date, two E1 activating enzymes for ubiquitylation have been identified (Groettrup, 
Pelzer et al. 2008). Traditionally Ube1 was thought to be the only E1 enzyme since its 
discovery in 1981. Recently another E1 activating enzyme (Uba6) has been demonstrated to 
activate both ubiquitin and the ubiquitin like modifier FAT 10 (Jin, Li et al. 2007; Pelzer, 
Kassner et al. 2007). The two E1 activating enzymes cooperate with only a partially 
overlapping pool of E2 conjugating enzymes, suggesting another level of regulation on 
protein ubiquitylation distinguished by different E1-mediated ubiquitin activation. However 
at present the redundancy and specificity of the two E1 activating enzymes or the dual 
functions of Uba6 are not clearly understood.   
 
1.2.7. Ubiquitylation linkage  
The ubiquitin system is involved in diverse cellular activities and ubiquitin conjugation can 
change the fate of the protein. To accommodate a plethora of different activities, protein 
ubiquitylation can exist in many forms to increase its versatility. Proteins can be 
monoubiquitylated with a single ubiquitin attachment at a single lysine residue, or multi-
monoubiquitylated where several single ubiquitins are attached to multiple lysine residues. 
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Ubiquitin can also be self-conjugated, there are seven lysine residues in ubiquitin, each of 
which can serve as an acceptor site to form ubiquitin polymers. Furthermore ubiquitins can 
be linearly linked via their N-terminus and C-terminus (Kirisako, Kamei et al. 2006; 
Tokunaga, Sakata et al. 2009). To add to the complexity, ubiquitin polymer linkage can be 
homologous, heterogeneous or even branched, where two ubiquitin moieties are conjugated 
and branched out on a single ubiquitin (Komander 2009).  
 
1.2.7.1. Multiple mono- and mono-ubiquitylation  
Multiple mono- and mono-ubiquitylation generally leads to non-proteolytic activity. It has 
been reported that multiple monoubiquitylation of cell surface receptors triggers their 
internalisation and subsequent degradation in lysosomes or recycling to the cell surface 
(Haglund, Sigismund et al. 2003). This process is mediated by a multimeric protein complex, 
ESCRT (Endosomal Sorting Complex Required for Transport), which facilitates the sorting 
of endosomal cargos into vesicles of multivesicular bodies (Williams and Urbe 2007).   
Monoubiquitylation has been shown to be impacted in translesion synthesis, protein 
trafficking and transcription (Bienko, Green et al. 2005; Ferdous, Sikder et al. 2007; 
Marchenko and Moll 2007). Most DNA lesions block the progression of replicative forks 
because replicative DNA polymerases are unable to accommodate damaged bases in their 
active site, resulting in the recruitment of a specialised set of DNA polymerases to carry out 
translesion synthesis (Friedberg, Lehmann et al. 2005; Lehmann, Niimi et al. 2007).  DNA 
lesion induces monoubiquitylation of Proliferating Cell Nuclear Antigen (PCNA) which 
recruits the specialized DNA SRO\PHUDVHȘ via its ubiquitin binding domain to replicate past 
DNA lesion (Hoege, Pfander et al. 2002; Kannouche, Wing et al. 2004; Watanabe, Tateishi 
et al. 2004). Interestingly, monoubiquitylation can also play an opposite role in this process 
 23 
 
depending on the modified substrate. Monoubiquitylation of DNA polymerase Șwas shown 
to induce an intramolecular interaction with its ubiquitin binding domain, inhibiting its 
PCNA interaction and translesion synthesis (Bienko, Green et al. 2009). 
Monoubiquitylation also mediates p53 trafficking (Li, Brooks et al. 2003; Marchenko, Wolff 
et al. 2007). In unstressed cells, p53 is rapidly polyubiquitylated by Mdm2 and  degraded 
(Kubbutat, Ludwig et al. 1998), whereas stress inhibits Mdm2-mediated p53 
polyubiquitylation stabilising p53. At low level of Mdm2, p53 was shown to be 
monoubiquitylated resulting in its nuclear exportation (Li, Brooks et al. 2003). Furthermore 
following stress-induced stabilisation, a pool of monoubiquitylated p53 in the cytosol is 
translocated to the mitochondria, where it is deubiquitylated to become active to initiate 
mitochondrial apoptosis (Marchenko, Wolff et al. 2007).  
Monoubiquitylation also impacts on transcriptional activation (Ferdous, Sikder et al. 2007; 
Archer, Burdine et al. 2008; Archer, Delahodde et al. 2008), where 26S proteasome ATPase 
mediated-destabilisation of the promoter-activator complex is prevented by 
monoubiquitylation of the transcription activator Gal4. This provides a model that 
monoubiquitylation of activators limits the lifetime of active transcription complexes until 
they are stripped off by ATPases or elongated to an ubiquitin polymer for destruction. 
Furthermore, monoubiquitylation also serves as a priming event for ubiquitin chain 
elongation (Hoege, Pfander et al. 2002; Rodrigo-Brenni and Morgan 2007; Windheim, 
Peggie et al. 2008). 
 
1.2.7.2. Polyubiquitylation 
Lysine 48- and lysine 63-linked polyubiquitylation are the most extensively studied forms of 
polyubiquitylation, ubiquitin polymers via other lysines (atypical linkages) were largely 
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neglected until recent years. A quantitative study of the ubiquitin polymer linkage of the 
yeast “ubiquitome” using mass spectrometry revealed the abundance of atypical linkages 
(Xu, Duong et al. 2009), indicating that they may play bigger roles in regulation of cellular 
activities than previously appreciated.  The lysine 48 linkage was found to be the most 
abundant, accounting for 29 % of all ubiquitin linkages in yeast. Interestingly, the lysine 11 
linkage was the second most abundant with the relative abundance of 28 %. Linkage via 
lysine 63 accounted for 17 %. Other linkage via lysine 6, lysine 27, lysine 29 and lysine 33 
accounted for the relative abundance of 11 %, 9 %, 3 % and 3 % respectively.    
 
1.2.7.2.1. Lysine 48-linked polyubiquitylation  
Protein degradation is traditionally associated with the lysine 48-linked ubiquitin polymer. 
Lysine 48-linked polyubiquitylated proteins are rapidly degraded by the 26S proteasome (see 
chapter 1.2.8 for 26S proteasome). It has been demonstrated that tetra-ubiquitin is sufficient 
to trigger proteolysis by increasing proteasomal affinity (Thrower, Hoffman et al. 2000). 
Enzymes specific for lysine 48 linkage were described and analysed, for example the E3 
ligase SCFCdc4 cooperates with the E2 conjugating enzyme Cdc34 to attach lysine 48-linked 
ubiquitin polymer to the CDK inhibitor Sic1 (Petroski and Deshaies 2005).  
 
1.2.7.2.2. Lysine 63-linked polyubiquitylation  
Asides from protein degradation, polyubiquitylation can also lead to non-proteolytic 
activities. Numerous studies have demonstrated that lysine 63-linked polyubiquitylation 
occurs during endocytosis, DNA damage and kinase activation in signal transduction. A set 
of E2 conjugating enzymes (Ubc13/Uev1A) has been shown to specifically facilitate the 
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formation of lysine 63-linked ubiquitin polymers (Hofmann and Pickart 1999; Deng, Wang 
et al. 2000). 
The most studied lysine 63 polyubiquitylation mediated activities are in the NFkB pathway, 
reviewed by (Skaug, Jiang et al. 2009). Stimulation of cells with cytokines such as Tumor 
Necrosis FaFWRUĮor interleukin 1 sequentially triggers activation of two kinase complexes, 
the TAK1 and the IKK complex. The TAK1 complex activates the IKK complex and 
eventually leads to the activation of the NFkB transcription factor. The TAK1 complex 
assembly is mediated by the lysine 63-specific ubiquitin binding domains of TAB2 and 
TAB3 and is dependent on TAK1 lysine 63-linked polyubiquitylation (Wang, Deng et al. 
2001; Kanayama, Seth et al. 2004). Many other components within the receptor complexes , 
including TRAFs, RIP1 and IRAKs are also lysine 63-linked polyubiquitylated (Wang, Deng 
et al. 2001; Ea, Deng et al. 2006; Lamothe, Besse et al. 2007; Ordureau, Smith et al. 2008), 
which contributes to receptor complex assembly. In addition, the regulatory subunit ,..Ȗ of 
the IKK complex was also shown to bind lysine 63 ubiquitin polymers for its receptor 
association (Wu, Conze et al. 2006). 
Endocytosis was initially linked with mono- and multiple monoubiquitylation (see chapter 
1.2.7.1), however increasing evidence has suggested lysine 63-linked polyubiquitylation is 
also implicated in these processes (Geetha, Jiang et al. 2005; Duncan, Piper et al. 2006; 
Kamsteeg, Hendriks et al. 2006). For example, lysine 63-linked polyubiquitylation of the 
nerve growth factor receptor Trka triggers its internalisation. Moreover a deubiquitinase 
specific for lysine 63 linkage has also been reported to mediate endocytosis, supporting the 
involvement of lysine 63 polyubiquitylation in endocytosis (McCullough, Clague et al. 2004).  
Lysine 63 polyubiquitylation has also been shown to regulate DNA repair. Regulation of the 
DNA damage tolerance pathway known as post-replication repair is mediated by 
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ubiquitylation of PCNA. Monoubiquitylation of PCNA has been reported to trigger 
translesion synthesis, an error prone way for DNA replication (Hoege, Pfander et al. 2002). 
The single ubiquitin attachment can be extended via lysine 63, which switches DNA repair 
to the error free template switching pathway, reviewed by (Moldovan, Pfander et al. 2007).  
In addition, lysine 63 polyubiquitylation has been reported to mediate repair in DNA double-
strand breaks (Panier and Durocher 2009). The E3 ligase RNF8 is recruited to damaged 
chromatin to monoubiquitylate histone H2A (Huen, Grant et al. 2007; Mailand, Bekker-
Jensen et al. 2007). The E3 ligase RNF168 is in turn recruited by monoubiquitylated histone 
H2A to mediate lysine 63 chain extension, resulting in recruitment of the DNA repair 
proteins 53BP1 and BRCA1 (Doil, Mailand et al. 2009; Stewart, Panier et al. 2009).   
 
1.2.7.2.3. Polyubiquitylation via other linkages  
Ubiquitins can be linked through a peptide bond between the N-terminal Į-amino group and 
the C-terminal carboxyl group. Such head to tail ubiquitin polymers are the source of cellular 
free ubiquitin encoded by four genes in the human genome (Kimura and Tanaka 2010), 
which need to be hydrolysed into single unit by deubiquitinases before substrate conjugation 
(Komander, Clague et al. 2009).  Linear ubiquitin chain conjugation to a protein substrate 
has also been described in the IKK kinase complex activation of the NFkB pathway 
(Kirisako, Kamei et al. 2006; Tokunaga, Sakata et al. 2009).  
Proteins implicated in diverse cellular processes were reported to be modified by lysine 11-
linked ubiquitin polymer (Xu, Duong et al. 2009), indicating its physiological importance. 
Although protein degradation was commonly associated with lysine 48-linked 
polyubiquitylation, lysine 11-linked ubiquitin polymer can also serve as a potent degradative 
signal (Baboshina and Haas 1996; Jin, Williamson et al. 2008). Many studies on protein 
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degradation were done without any validation of the chain type. Together with the 
abundance of lysine 11-linked ubiquitylated proteins in yeast (Xu, Duong et al. 2009), this 
suggests that lysine 11 linkage may play a bigger role in proteolysis than previously thought. 
In addition, assembly of heterogeneous and branched ubiquitin polymers was reported  using 
certain sets of purified E2 conjugating enzymes and E3 ligases (Kim, Kim et al. 2007) 
Ubiquitylation is relatively promiscuous in vitro compared to that under physiological 
conditions, currently the in vivo abundance and relevance of these linkages are uncertain. 
However it is worth noting that branched ubiquitin polymers cannot be processed efficiently 
by the proteasome (Kim, Kim et al. 2009), suggesting their non-proteolytic roles. Branched 
ubiquitin polymer is also involved in E3 ligase activation. Autoubiquitylation of lysine 6/ 
lysine 27/ lysine 48-branched ubiquitin chains to the E3 complex Ring1B/BMI1 is essential 
for its ability to monoubiquitylate its physiological target histone H2A in vitro (Ben-Saadon, 
Zaaroor et al. 2006). To add to the complexity, cyclin B1 was shown to be  conjugated with 
multiple mono- and short-polyubiquitin polymers leading to its degradation (Kirkpatrick, 
Hathaway et al. 2006)  
 
1.2.8. 26S proteasome-mediated proteolysis  
Degradation of lysine 48-linked polyubiquitylated proteins is mediated by the 26S 
proteasome, reviewed by (Glickman and Ciechanover 2002). The proteasome complex 
consists of a 19S regulatory cap and a 20S proteolytic core. The 19S cap in turn comprises of 
two subcomplexes; the lid, containing 10 subunits that relate to the Constitutively 
Photomorphogenic 9 (COP9) signalosome; and the base, composed of six AAA-type 
ATPases (Rpt1-6) and two non-ATPase subunits. Both the lid and base subcomplexes are 
responsible in the recognition of polyubiquitylated proteins (Elsasser, Chandler-Militello et 
al. 2004; Verma, Oania et al. 2004). Following recognition, the substrate is deubiquitylated 
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(Verma, Aravind et al. 2002; Guterman and Glickman 2004). The ATPases then unfold the 
substrate and mediate its translocation into the cavity of the 20S core to be degraded by the 
proteases in the proteolytic core or in some cases of protein processing, where protein 
precursors are partially degraded to create mature proteins (Benaroudj, Zwickl et al. 2003; 
Liu, Corboy et al. 2003). 
 
1.2.9. Deubiquitylation  
Deubiquitylation is a reversal process of ubiquitylation, carried out by about 100 
deubiquitinases (DUBs) encoded in the human genome. DUB activity can be divided into 
three categories. Firstly, DUBs generate free ubiquitin from ubiquitin precursors, expressed 
from four ubiquitin genes. Secondly, ubiquitylation of protein substrates can be removed by 
DUBs, counteracting E3 ligase activity. Finally, DUBs are involved in ubiquitin chain 
linkage editing. 
There are five classes of DUBs; Ubiquitin C-terminal Hydrolases (UCHs); Ubiquitin-
Specific Proteases (USPs); Ovarian Tumor Proteases (OTUs); Josphins and 
JAB1/MPN/MOV34 (JAMM) metalloenzymes. A common feature of DUBs is the presence 
of Ubiquitin Binding Domains (UBDs), for example: the Zinc Finger Ubiquitin-specific 
Protease domain (ZnF-UBP-domain), the Ubiquitin-Interacting Motif (UIM) and the 
Ubiquitin Associated (UBA) domain. These UBDs directly regulate DUB activity or 
specificity. It has been demonstrated that the UIMs of DUBs (USP25, DUBA and Ataxin-3) 
are essential for their hydrolytic activity (Mao, Senic-Matuglia et al. 2005; Kayagaki, Phung 
et al. 2007; Meulmeester, Kunze et al. 2008). The UIM also imparts ubiquitin polymer 
linkage specificity. For example, the proteasome associated USP14 preferentially targets the 
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lysine 48 linkage, while Ataxin-3 has been shown to cleave specifically lysine 63 linkage 
(Winborn, Travis et al. 2008).   
DUB activity is regulated by several mechanisms. For example, the IKK complex mediated 
phosphorylation of the DUB CYLD inhibits its capacity to deubiquitylate TRAF2, resulting 
in the activation of the NFkB pathway (Reiley, Zhang et al. 2005). Phosphorylation of 
another DUB, USP8, recruits the phospho-binding protein 14-3-3, resulting to the inhibition 
of its activity during interphase (Mizuno, Kitamura et al. 2007).  In addition, most DUBs are 
cysteine proteases, therefore it is not surprising that reactive oxygen species regulates some 
DUB activity. For example, hydrogen peroxide inhibits deubiquitylating activity of the DUB 
Cezanne to RIP1, resulting in the activation of the NFkB pathway (Enesa, Ito et al. 2008). 
DUBs are also regulated through subcellular separation. For example, USP8 has been 
demonstrated to undergo epidermal growth factor (EGF)-dependent translocation to 
endosomes (Row, Prior et al. 2006).    
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1.3. Regulation of ubiquitylation  
1.3.1. Regulation of ubiquitylation by phosphorylation  
Ubiquitylation is often regulated by phosphorylation. Phosphorylation can affect 
ubiquitylation in three different ways. First, phosphorylation of substrates can create an 
inducible interaction surface to allow E3 ligase recognition, namely a phosphodegron. 
Second, phosphorylation of either substrates or ubiquitin enzymes may alter their subcellular 
localization, whereby restricting their interactions. Third, phosphorylation of ubiquitin 
enzymes can modulate their activity allosterically or through recruiting accessory proteins. 
Alternatively, similar regulations can be applied on deubiquitinases to regulate their 
hydrolytic ability.  
 
1.3.1.1. Phosphodegron  
Protein phosphorylation often leads to its instability. Many cell cycle regulators are 
sensitised for destruction by phosphorylation, for example; the G1 cyclin Cln2 and the CDK 
inhibitor Sic1p in Saccharomyces cerevisiae (Lanker, Valdivieso et al. 1996; Verma, Annan 
et al. 1997); cyclin E and the CDK inhibitor p27Kip1 in human (Clurman, Sheaff et al. 1996; 
Won and Reed 1996; Sheaff, Groudine et al. 1997). Phosphorylation at serine or threonine 
residues creates a phosphodegron, which can be utilised as a signal for ubiquitylation-
mediated protein degradation. In most cases, such phosphorylation induced proteolysis is 
mediated by a subgroup of RING-domain E3 ligases, SCF (see chapter 1.2.4). These 
multimeric E3 ligases often contain a F-box substrate receptor  to target specifically 
phosphorylated substrates (Kipreos and Pagano 2000). Although the majority of substrates 
recognised by SCFs are phosphorylated, a member of this family, SCFȕ-TrCP , was also 
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reported  to interact with a non-phosphorylated motif of  the Cdc25A phosphatase (Kanemori, 
Uto et al. 2005).  
Besides cell cycle regulation, phosphorylation inducible proteolysis is also observed in 
cytokine signalling pathways. In non-stimulated cells, NFkB proteins are sequestered by IkB 
in the cytosol. Upon stimulation, the IKK kinase complex is activated and phosphorylates 
two serine residues at the regulatory domain of the IkB protein creating a phosphodegron, 
resulting in its ubiquitin-dependent degradation and the release of the NFkB protein to the 
nucleus to elicit transcription (Yaron, Hatzubai et al. 1998; Karin and Ben-Neriah 2000).   
Phosphorylation of substrates can sometimes converge responses from two signalling 
pathways. In other words, distinct phosphorylation of substrates triggered by different 
pathways may be required to facilitate phosphorylation-dependent degradation. For example, 
the interaction between the E3 ligase SCFCdc4 and its substrate cyclin E requires 
phosphorylation at multiple sites mediated by the kinases CDK2 and GSK3 (Welcker, Singer 
et al. 2003). A similar regulatory mechanism has also been demonstrated on the hedgehog 
signalling effector Ci in Drosophila melanogaster, where phosphorylation by three different 
kinases is required for its ubiquitylation-dependent processing (Price and Kalderon 2002). 
Conversely, ubiquitylation of a substrate can be triggered by phosphorylation mediated by 
different kinases alone. For example, Gcn4 can be targeted for degradation by either Srb11-
Srb10 or Pcl1/2Pho85-CDK mediated phosphorylation in Saccharomyces cerevisiae 
(Meimoun, Holtzman et al. 2000; Chi, Huddleston et al. 2001).   
In some cases, multiple phosphorylation of a substrate is required for ubiquitylation.  
SCFCdc4-mediated degradation of the CDK inhibitor Sic1 is dependent on phosphorylation of 
Sic1 on at least six of its nine phosphorylation sites (Orlicky, Tang et al. 2003). Remarkably, 
the substrate receptor Cdc4 only contains a single phospho-epitope binding motif, thus such 
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multiple phosphorylation requirement cannot be explained by the traditional model of 
binding cooperation. This requirement was explained by a mathematical model that the 
probability of rebinding increases exponentially with the number of phosphodegrons on 
substrates (Klein, Pawson et al. 2003). This effect was coined ‘allovalency’, providing a 
mechanism by which accumulation of phosphorylation to a threshold on substrates acts as a 
molecular switch to determine interactions with their corresponding E3 ligases.    
 
1.3.1.2. Regulation of ubiquitin enzymes by phosphorylation 
Besides phosphodegrons, phosphorylation of E3 ligases can either enhance or inhibit their 
activity. Phosphorylation at different residues on the same E3 ligase can elicit different 
responses or phosphorylation of different E3 ligases by the same kinase can result in 
different outcome.  For example, the HECT-domain E3 ligase Nedd 4-2 is responsible for 
regulating the level of epithelial sodium channel (ENaC). Nedd 4-2 mediated ENaC 
ubiquitylation leads to the degradation of this channel protein. Upon serum stimulation, the 
protein kinase SGK1 phosphorylates Nedd 4-2 in its WW domain, masking this substrate 
recognition domain by recruiting the phospho-binding protein 14-3-3, whereby inhibiting 
ENaC ubiquitylation and its subsequent degradation (Ichimura, Yamamura et al. 2005). 
Alternatively, Nedd 4-2 can also be phosphorylated by the stress-induced MAPK JNK at 
different residues which potentiates its E3 ligase activity to ubiquitylate ENaC for 
degradation (Hallows, Bhalla et al. 2010).  
Apart from recruiting accessory proteins, phosphorylation can also elicit allosteric effects 
which change protein conformation that alters E3 ligase activity. The HECT-domain E3 
ligase Itch facilitates T-cell activation through ubiquitylation of JunB. The activity of this E3 
ligase is constitutively repressed by intramolecular interaction between its WW-domain and 
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the HECT-domain. JNK-mediated phosphorylation within the proline-rich region upstream 
of the WW-domain relieves this intramolecular repression, permitting its E3 ligase activity 
(Gallagher, Gao et al. 2006). JNK is recruited to Itch by D-domain like sequences within the 
N-lobe of the HECT-domain. The presence of D-domain like sequences in the HECT-
domain provides a mechanism by which the MAPK pathways could regulate the catalytic 
activity of HECT-domain E3 ligases. Alternatively, phosphorylation of Itch by the kinase 
Fyn at another residue reduces its substrate (JunB) interaction, thereby decreasing 
ubiquitylation of its substrate (Yang, Zhou et al. 2006).  
Beside E3 ligases, phosphorylation also regulates the activity of some E2 conjugating 
enzymes. Phosphorylation of the E2 conjugating enzyme Rad6 has been shown to be 
essential for its ability to facilitate histone H2B monoubiquitylation (Sarcevic, Mawson et al. 
2002; Wood, Schneider et al. 2005).  
 
1.3.2. Regulation of ubiquitylation by subcellular location 
Phosphorylation of either E3 ligases or substrates can often alter their subcellular location, 
providing a mechanism by which spatial restriction regulates protein ubiquitylation. For 
example, phosphorylation of the CDK inhibitor p27kip1 promotes its nuclear export by 
CRM1 to permit its ubiquitylation-dependent degradation mediated by the E3 ligase complex 
KPC in the cytosol (Kamura, Hara et al. 2004; Besson, Gurian-West et al. 2006). Activation 
of the IKK complex in the NFkB pathway is also regulated by this manner in response to 
genotoxic stress. Upon DNA GDPDJH WKH ,.. UHJXODWRU\ VXEXQLW ,..Ȗ LV VXPR\ODWHG, 
leading to its nuclear localisation. In the QXFOHXV ,..Ȗ LV SKRVSKRU\ODWHG E\ Whe kinase 
ATM, which triggers its monoubiquitylation, and in turn leads to the QXFOHDUH[SRUWRI,..Ȗ
and ATM, and eventually the activation of cytosolic IKK complex (Wu, Shi et al. 2006).  
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1.3.3. Regulation of ubiquitylation by complex formation  
E3 ligases often target a selective pool of substrates as mentioned above that CRLs 
preferentially select phosphorylated substrates. It has been reported that complex formation 
may also facilitate ubiquitylation. Ubiquitylation of the CDK inhibitor Xic1 has been shown 
to require the formation of pre-replication complex in Xenopus (You, Harvey et al. 2002). In 
addition, ubiquitylation of p27 is dependent on both its phosphorylation and its trimeric 
complex with cyclin E and CDK2 (Montagnoli, Fiore et al. 1999).     
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1.4.  Roles of ubiquitylation in transcription  
1.4.1. Proteolysis-coupled transcription  
In the past decade, mounting evidence has revealed the involvement of the ubiquitin system 
in the regulation of transcription, reviewed by (Conaway, Brower et al. 2002; Lipford and 
Deshaies 2003; Kodadek, Sikder et al. 2006; Leung, Geng et al. 2008). The most obvious 
connection between transcription and the ubiquitin system is the destruction of transcription 
activators when they are no longer needed for transcription. In this case, activator proteins 
are most abundant when they are active. For example, the tumour suppressor p53 level and 
activity are inhibited by the E3 ligase Mdm2 (Haupt, Maya et al. 1997; Fuchs, Adler et al. 
1998).  However this mode of regulation does not apply in all situations, studies in the past 
decade have revealed a more complex intervention, in which the ubiquitin system facilitates 
and regulates transcription. The oncogenic transcription activator Myc appears to be 
sensitive to proteolysis when it is activated. The region of Myc that mediates transcriptional 
activation is also found to be essential for its degradation (Salghetti, Kim et al. 1999). The 
overlapping feature of transactivation domains and degrons was later found to be a common 
feature in other transcription activators with transactivation domains rich in acidic residues, 
suggesting this functional connection is evolutionarily conserved (Salghetti, Muratani et al. 
2000). Subsequently, about 30 transcription activators, for example: E2F-1, Fos, Gcn4, Jun 
and p53 were reported to contain such overlapping correlation.  
It is now clear that transcription and degradation is intrinsically coupled for some cases. In 
those cases, transcription activators are degraded as part of the transcription process as a 
mechanism to restrict their ability to initiate unlimited rounds of transcription, therefore 
ensuring the acute regulation of activators. Many transcription activators have been 
demonstrated to possess such connection. For example, SREBP degradation was reported to 
be dependent on both its transactivation and promoter binding ability (Sundqvist and 
 36 
 
Ericsson 2003). In addition, the phosphorylation dependent degradation of Gcn4 is triggered 
by Srb10, a kinase in the transcription mediator complex (Chi, Huddleston et al. 2001), 
supporting the notion that transcription and degradation are intrinsically connected.   
It is logical that potent transcription activators are degraded to ensure timely regulation of 
transcription. Ubiquitin conjugation to substrates by E3 ligases can trigger their degradation, 
indicating the essential role of E3 ligases in the regulation of transcription. Deletion of the 
E3 ligase gene (Met30) inhibits its substrate (LexA-VP16) mediated transactivation and 
degradation (Salghetti, Caudy et al. 2001). Interestingly, fusing an ubiquitin protein at the N-
terminus of LexA-VP16 was able to rescue both activities, indicating the sole purpose of 
Met30 in Lex-VP16 activity is to ubiquitylate it. Subsequently, a similar requirement of E3 
ligases for transcription has been reported for other activators (von der Lehr, Johansson et al. 
2003; Muratani, Kung et al. 2005) and co-activators (Kurosu and Peterlin 2004; Barboric, 
Zhang et al. 2005; Wu, Feng et al. 2007).   
 
1.4.2. The roles of 26S proteasome in transcription  
The 26S proteasome was first linked to transcription in yeast genetic studies. Deletion of the 
Sug2/Rpt4 and Sug1/Rpt6 genes allows the transcriptionally defective activator Gal4 to 
activate transcription (Swaffield, Bromberg et al. 1992; Russell, Sathyanarayana et al. 1996). 
They were initially thought to be transcription mediators, bridging the gap between 
transcription activators and the RNA Polymerase II (Kim, Bjorklund et al. 1994; Swaffield, 
Melcher et al. 1995). Subsequently, the discovery of Sug1 as a component of the 26S 
proteasome led to the idea that Sug1 mediates transcription indirectly by facilitating 
degradation of transcription regulatory proteins (Rubin, Coux et al. 1996). However it is now 
clear that the 26S proteasome facilitates transcription at multiple levels.  
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The 26S proteasome possesses both proteolytic and chaperone activity, conferred by its 20S 
core and 19S regulatory subunits respectively. The association of both proteolytic and non-
proteolytic components of the 26S proteasome with active genes in a genome-wide study 
indicates both activities are essential for transcription (Auld, Brown et al. 2006).  
For proteolysis-coupled transcription, protein degradation is required for RNA polymerase ll 
recruitment, transcription co-factor exchange and termination of transcription. Inhibition of 
the 26S proteasome was found to repress both progesterone receptor- and Gcn4-mediated 
transcription by reducing RNA polymerase ll recruitment to their cognate promoters (Dennis, 
Lonard et al. 2005; Lipford, Smith et al. 2005). Another involvement of proteolysis with 
transcription is facilitated through altering the composition of transcription complexes. In 
other words, the transcriptional co-factor exchange is often mediated by proteolysis (Kramer, 
Zhu et al. 2003; Metivier, Penot et al. 2003; Perissi, Aggarwal et al. 2004). For example, in 
LIM-HD-mediated transcription, destruction of the CLIM co-activator mediated by the 
RING-domain ligase RLIM (Ostendorff, Peirano et al. 2002). Furthermore, events following 
initiation also require proteolysis. For example, destruction of Gal4 ensures appropriate 
phosphorylation of RNA polymerase II, which is essential for transcription initiation and 
subsequent mRNA processing (Muratani, Kung et al. 2005). It is thought that proteolysis of 
Gal4 and co-factors post initiation allows RNA polymerase II to abandon its interacting 
proteins properly in order to recruit mRNA processing proteins. Finally, proteolysis has also 
been demonstrated to facilitate transcription termination. Inhibition of the proteasome leads 
to increased read through of termination sites and together with the presence of 20S 
proteasome at the 3’end of active genes indicate the importance of proteolysis in 
transcription termination (Gillette, Gonzalez et al. 2004). 
There is also a significant amount of work demonstrating the importance of non-proteolytic 
function of the19S proteasome in transcription, particularly through its ATPase subunits. The 
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ATPases of the 19S regulatory complex possess the classic protein chaperone activity (Braun, 
Glickman et al. 1999), giving rise to the idea that ATPases may mediate transcription by 
facilitating complex assembly or disassembly. Like the 20S proteasome, the 19S proteasome 
facilities transcription at different levels. It has been demonstrated that the 19S proteins are 
important for transcription elongation (Ferdous, Gonzalez et al. 2001). Mutations of 19S 
proteins display phenotypes consistent with an elongation defect in yeast. Immuno-depletion 
of 19S proteins significantly inhibited the synthesis of long transcripts, but did not influence 
the rate of transcription initiation. Furthermore, 19S proteins were found to associate with 
elongation factor, supporting their role in transcription elongation.  
Besides elongation, 19S proteins were also reported to facilitate histone H3 methylation, a 
signal commonly found at transcription active sites (Ezhkova and Tansey 2004). The 
ATPases Rpt4 and Rpt6 are recruited by histone H2B ubiquitylation to transcription active 
sites to facilitate subsequent histone H3 methylation. 
Another role of 19S proteins in transcription is to recruit SAGA histone acetyltransferase 
complex recruitment (Lee, Ezhkova et al. 2005). The SAGA complex recruitment is one of 
the early steps in Gal4-mediated transcription. It was suggested that the ATPases utilise the 
energy from ATP hydrolyse to drive stable complex between Gal4 and SAGA.  
 
1.4.3. Hypothesized mode of proteolysis coupled transcription initiation 
A general consensus of how the ubiquitin system intervenes with transcription has now 
emerged. A licensing/black widow model has been proposed by several groups (Lipford and 
Deshaies 2003; Kodadek, Sikder et al. 2006; Leung, Geng et al. 2008). In this model, 
activators are responsible for recruiting co-activators, the general transcription machinery as 
well as ubiquitin ligases and the 26S proteasome to promoters. Concurrently with the 
initiation, the activators and co-activators are ubiquitylated and eventually degraded, 
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followed by promoter escape and transcription elongation. In addition, the proteasome also 
facilitates transcription at different stages following initiation of transcription.    
Although the licensing model provides a general mechanism of proteolysis-coupled 
transcription, clearly it cannot explain situations in which activity of activators is inhibited 
by proteolysis. One explanation is that activators can be ubiquitylated by different E3 ligases 
under different conditions. In other words, sometimes protein degradation merely serves to 
down-regulate abundance thus is uncoupled from transcription, while others are integral to 
transcription. Gal4 has been shown to be regulated by two distinct F-box proteins (the 
substrate recognition unit of some CRL E3 ligases), Grr1 and Mdm30 under different 
conditions (Muratani, Kung et al. 2005). When Gal4 is inactive, its degradation is mediated 
by Grr1 with a sole purpose to keep Gal4 protein at low basal level. However, when Gal4 is 
activated, the Grr1 mediated proteolytic process is shut down. Gal4 degradation is now 
mediated by Mdm30 during transcription-coupled proteolysis. 
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1.5. Research aims and objectives  
In response to extracellular signalling through the MAPK pathways, Elk-1 forms a ternary 
nucleoprotein complex with the SRF dimer at the SRE of the c-fos promoter to activate 
transcription. As a final effector of multiple signalling pathways and a regulator of gene 
promoters, Elk-1 represents a key element in the complex and dynamic regulation of 
transcription, therefore providing a paradigm for the study of signal-induced gene expression.  
The molecular mechanisms that underlie the function and regulation of Elk-1 have been 
extensively studied. Elk-1 activity is regulated partly by PTMs. Phosphorylation of Elk-1 
regulates its transcriptional ability through several mechanisms, such as relief from 
intramolecular inhibition, enhanced DNA binding and recruitment of transcription co-
activators (Gille, Sharrocks et al. 1992; Hill, Marais et al. 1993; Marais, Wynne et al. 1993; 
Gille, Kortenjann et al. 1995; Sharrocks 1995; Yang, Shore et al. 1999; Stevens, Cantin et al. 
2002). Sumoylation of Elk-1 is associated with transcription repression through recruitment 
of the histone deacetylase 2 co-represssor (Yang, Jaffray et al. 2003; Yang and Sharrocks 
2004). Preliminary data from the group showed the presence of Elk-1 specific E3 ligase 
activity in HEK293 cell lysate and that Elk-1 is ubiquitylated in HEK293 cells. Elk-1 
ubiquitylation has also been reported in vitro (Fuchs, Xie et al. 1997). This study sought to 
understand the nature of Elk-1 ubiquitylation by investigating its regulation, function and the 
enzymes involved in this modification.   
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2. Materials 
 
2.1. Antibodies  
Table 1. Antibodies used in this study 
Antibody Manufacturer Manufacturer reference   
Į+$ 
 
Į+LV 
 
Į(ON-1(H-160) 
 
Į3-Elk-1 
 
Į(5. 
 
ĮP-ERK 
 
Į$FWLQ 
 
Į7%3 
 
Į7XEXOLQ 
 
Į3$53 
 
Į5DW+53conjugated 
 
Į0RXVH+53FRQMXJDWHG 
 
Į5DEELW+53FRQMXJDWHG 
 
Į*RDW+53FRQMXJDWHG 
Roche 
 
AbD  SeroTec 
 
Santa Cruz Biotechnology 
 
Cell Signalling  
 
Santa Cruz Biotechnology 
 
Cell Signalling  
 
Sigma Aldrich 
 
Santa Cruz Biotechnology 
 
Santa Cruz Biotechnology 
 
Cell Signalling  
 
Sigma Aldrich 
 
Sigma Aldrich 
 
Sigma Aldrich 
 
Sigma Aldrich 
11 867 423 001 
 
MCA1396GA 
 
SC22804 
 
9181 
 
SC154G 
 
9106S 
 
A-2066 
 
SC204 
 
SC8035 
 
9542 
 
A9037 
 
A6782 
 
A0545 
 
A5420 
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2.2. Chemicals and commercial kits  
ECL detection reagent and ECL advance detection reagent (Amersham) 
Emerald (Applied Biosystems) 
Gel filtration molecular weight markers (Sigma-Aldrich) 
MicroBio-Spin Chromatography Columns (Bio-Rad) 
Page Ruler pre-stained protein ladder (Fermentas) 
Protease inhibitor cocktail, complete (Roche) 
Galacton (Applied Biosystems) 
[35S]-methionine (Perkin Elmer) 
Quick Change Site-directed mutagenesis kit (Stratagene)  
Superose 6 beads (GE Healthcare) 
TNT T7 Quick Coupled Transcription/Translation System 
U0126 (Sigma-Aldrich) 
Ubiquitin aldehyde (Biomol) 
Ubiquitin from bovine erythrocytes (Sigma-Aldrich) 
SB202190 (Sigma-Aldrich) 
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2.3. Bacterial Strains  
All bacterial works were undertaken using NM522 cells, and plasmids were propagated in 
this strain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 44 
 
2.4. Plasmid Constructs 
Table 2. Plasmids used in this study 
Plasmid Description Constructed by/ 
Reference 
 
pcDNA3.HA.Elk-1 
 
 
 
pcDNA3.HA.Elk-1  
lysine substitution 
derivatives (see Figure 2-1) 
 
 
 
pcDNA3.HA.Elk-1.DM 
(DNA binding defective 
derivative) 
 
 
pcDNA3.HA.Elk-1.SM 
(SRF binding defective 
derivative) 
 
 
 
pCMV5.HA.Elk-1 
 
 
 
pCMV5.HA.Elk-1 
phosphorylation site 
derivatives 
 
 
pCMV5.HA.Elk-ǻ' 
 
 
 
 
pCMV5.HA.Elk-1.FXLA 
 
 
 
 
Cell-free and mammalian expression 
vector for N-terminal HA-tagged 
human wild-type Elk-1 cDNA 
 
Cell-free and mammalian expression 
vector for N-terminal HA-tagged 
human Elk-1 cDNA with the 
indicated substitutions of lysine with 
arginine 
 
Cell-free and mammalian expression 
vector for N-terminal HA-tagged 
human Elk-1 cDNA with the double 
amino acid mutation of R65A/Y66F 
 
Cell-free and mammalian expression 
vector for N-terminal HA-tagged 
human Elk-1 cDNA with the double 
amino acid mutation of 
L158P/Y159A 
 
Mammalian expression vector for N-
terminal HA-tagged human wild-
type Elk-1 cDNA 
 
Mammalian expression vector for N-
terminal HA-tagged human Elk-1 
cDNA with the indicated amino acid 
substitution 
 
Mammalian expression vector for N-
terminal HA-tagged human Elk-1 
cDNA with the deletion of amino 
acid residue 312 to321 
 
Mammalian expression vector for N-
terminal HA-tagged human Elk-1 
cDNA with the mutation of 
F395L/Q396A 
 
(Janknecht and 
Nordheim 1992) 
 
 
Leo Chow, 
this work 
 
 
 
 
Leo Chow, 
this work 
 
 
 
Leo Chow, 
this work 
 
 
 
 
Peter Shaw’s 
group  
 
 
(Gille, 
Kortenjann et al. 
1995) 
 
 
 
(Zhang, Li et al. 
2008) 
 
 
 
(Zhang, Li et al. 
2008) 
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Plasmid    Description Constructed 
by/ 
Reference 
 
pCMV5.HA.Elk-1.  
ǻ')4/$ 
 
Mammalian expression vector for N-
terminal HA-tagged human Elk-1 
cDNA with the mutation of 
F395L/Q396A 
 
(Zhang, Li et al. 
2008) 
 
 
pCMV5.Elk-1 Mammalian expression vector for 
human Elk-1 cDNA  
Peter Shaw  
    
pCMV5.Elk-1  
lysine substitution 
derivatives  (see Figure 
2-1) 
 
Mammalian expression vector for 
human Elk-1 cDNA with the 
indicated substitutions of lysine with 
arginine 
Peter Shaw’s 
group 
 
    
pCMV5.Elk-1.DM 
(DNA binding defective 
derivative) 
Mammalian expression vector for 
human Elk-1 cDNA with the double 
amino acid mutation of R65A/Y66F 
 
Leo Chow  
this work  
 
pCMV5.Elk-1.SM  
(SRF binding defective 
derivative) 
Mammalian expression vector for 
human Elk-1 cDNA with the double 
amino acid mutation of 
L158P/Y159A 
Leo Chow 
this work 
 
    
pCMV5.HA.Sap-1a Mammalian expression vector for N-
terminal HA-tagged human wild-type 
Sap-1a cDNA 
 
Peter Shaw’s 
group 
 
pCMV5.HA.Net Mammalian expression vector for N-
terminal HA-tagged human wild-type 
Net cDNA 
 
Thomas Strahl   
pCMV5.HA.Ub Mammalian expression vector for N-
terminal HA-tagged human wild-type 
ubiquitin cDNA 
 
Peter Shaw’s 
group 
 
pCMV5.His6.Ub Mammalian expression vector for N-
terminal His-tagged human wild-type 
ubiquitin cDNA 
 
Peter Shaw’s 
group 
 
pCMV5.His6.Ub.K0 
 
 
 
 
 
Mammalian expression vector for N-
terminal His-tagged human wild-type 
ubiquitin cDNA with all lysines 
substituted with arginines 
Sam Shelton 
Peter Shaw’s 
group 
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Plasmid Description Constructed by/ 
Reference 
 
p(SRE)x3Luc 
 
 
p(E74)x3Luc 
 
 
pCHll 
SRE-dependent luciferase reporter 
vector 
 
E74-dependent luciferase reporter 
vector 
 
ȕ-galactosidase reporter vector 
R.A. Hipskind 
 
 
R. Janknecht 
 
 
Peter Shaw’s 
group 
 
 
  
Figure 2-1 Table of the location of the substitutions in Elk-1. 
Lysine residues and arginine substitutions are represented with 
green circles and open circles respectively 
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2.5. Oligonucleotides 
All oligonucleotides used in this study were synthesized at the Biopolymer synthesis and 
analysis unit (BSAU), School of Biomedical Sciences, the University of Nottingham  
 
Table 3.Primers used in site-directed mutagenesis  
Oligo name  Sequence Base 
pairs 
 
K35R For. 
K35R Rev. 
 
K50/52R For. 
K50/52R Rev. 
 
K59R For. 
K59R Rev. 
 
K70R For. 
K70R Rev. 
 
K75R For. 
K75R Rev. 
 
K80R For. 
K80R Rev. 
 
K84R For. 
K84R Rev. 
 
R65A/Y66F For. 
R65A/Y66F Rev. 
 
L158P/Y159A For. 
L158P/Y159A Rev. 
 
Sp6 promoterFor. 
Sp6 promoterRev. 
 
T7 promoter For. 
T7 promoter Rev. 
5’-ggatggtggtgaattccggctggtggatgcagagg-3’ 
5’-cctctgcatccaccagccggaattcaccaccatcc-3’ 
 
5’ggctgtggggactacgccggaaccggaccaacatgaattacg3’ 
5’cgtaattcatgttggtccggttccggcgtagtccccacagcc3’ 
5’-agaccaacatgaattacgacaggctcagccggg-3’ 
5’-cccggctgagcctgtcgtaattcatgttggtct-3’ 
 
5’-gcggtactactatgacaggaacatcatccgcaagg-3’ 
5’-ccttgcggatgatgttcctgtcatagtagtaccgc-3’ 
 
5’-aggaacatcatccgcagggtgagcggcc-3’   
5’-ggccgctcaccctgcggatgatgttcct-3’ 
 
5’-gggtgagcggccagaggttcgtctacaagtt-3’ 
5’-aacttgtagacgaacctctggccgctcaccc-3’ 
 
5’-ccagaggttcgtctacaggtttgtgtcctaccctg-3’ 
5’-cagggtaggacacaaacctgtagacgaacctctgg-3’ 
 
5’-gctcagccgggccttggcgttctactatgacaagaaca-3’ 
5’-tgttcttgtcatagtagaacgccaaggcccggctgagc-3’ 
 
5’-gtacatgcgctcgggccccgcttccaccttcaccatcc-3’ 
5’-ggatggtgaaggtggaagcggggcccgagcgcatgtac-3’ 
 
5’-atttaggtgacactatag-3’ 
5’-ctatagtgtcacctaaat-3’ 
 
5’-taatacgactcactataggg-3’ 
5’-ccctatagtgagtcgtatta-3’ 
35 
35 
 
42 
42 
 
33 
33 
 
35 
35 
 
28 
28 
 
31 
31 
 
35 
35 
 
38 
38 
 
38 
38 
 
18 
18 
 
20 
20 
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3. Methods 
 
3.1. Nucleic Acid Techniques 
3.1.1. DNA extraction 
3.1.1.1. Small scale DNA preparation  
A strain of bacteria, either from a single colony or glycerol stock, was inoculated into 5 ml 
Luria-Bertani broth (LB), supplemented with the appropriate antibiotic. The bacteria were 
cultivated overnight at 37oC on a rotating wheel (New Brunswick Scientific).  Two millilitres 
of the bacterial culture were collected by centrifugation at 7000g at room temperature for 2 
mins (Eppendorf) The DNA was extracted using the Qiaprep miniprep kit (Qiagen), 
according to the manufacturer’s instructions.  
 
3.1.1.2. Large scale DNA preparation  
Bacterial culture was set up as described (section 3.1.1.1) and cultivated for 8 hrs at 37oC on 
a rotating wheel (New Brunswick scientific). The 5 ml bacterial culture was scaled up to 150 
ml and cultivated overnight at 37oC in a shaking incubator (New Brunswick Scientific). The 
bacteria were collected by centrifugation at 4200g at 4oC for 20 mins (Sorvall). The DNA 
was extracted using the Nucleobond AX PC500 kit (Machery Nagal Germany), following to 
the manufacturer’s instructions. 
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3.1.2. Restriction digestion of DNA  
Digests of 1 µg – 2 µg of DNA were performed in a 10 µl reaction volume, using 5 U of 
restriction enzyme in the buffer recommended by the manufacturer, supplemented with 
bovine serum albumin (BSA) where required. The digests were incubated for 1 hr 30 mins at 
37oC in a heat incubator (New Brunswick Scientific).   
 
3.1.3. Alkaline phosphatase treatment of DNA 
Removal of the 5’end phosphate groups from digested vectors was performed using 1 U calf 
intestinal alkaline phosphatase (Fermentas) in a 10 µl reaction volume, supplemented with 1 
µl of 1 M Tris HCl pH 9.5. The reaction mixtures were incubated at 37oC for 20 mins in a 
heat incubator (New Brunswick Scientific). The enzyme was inactivated at 65oC for 5 mins 
before subjecting the DNA to agarose gel electrophoresis (section 3.3.1.1). 
 
3.1.4. Ligation of DNA  
Ligation of DNA was performed using 1 U ligase (Fermentas Life Sciences) in 10 µl buffer 
provided by the manufacturer. Restriction digested recipient vector and DNA fragment 
insertion (section 3.1.2) were kept in a 1:2 ratio. The reaction was incubated overnight at 
16oC in a water bath. The entire ligation was transformed into competent NM522 bacteria 
(section 3.2.2).   
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3.1.5. Oligonucleotide 323>Ȗ@$73ODEHOOLQJ 
The 5’-terminal of oligonucleotide was labelled with the phosphate group from 323>Ȗ@$73
Two microlitres of 20 ng/µl oligonucleotide (40 ng) were mixed with 14 µl spermidine 
buffer (20 mM Tris-HCl pH9.5, 1 mM spermidine, 0.1 mM EDTA). The mixture was 
incubated at 95oC for 2 mins, followed a pulse vortex and a 2 mins ice incubation to remove 
secondary structure from the oligonucleotide. The oligonucleotide was incorporated with 32P 
by 10 U of T4 polynucleotide kinase (Promega) in 25 µl reaction volume in the presence of  
2.5 µl kinase buffer (500 mM Tris-HCl, 100 mM MgCl2, 50 mM DTT and 50% glycerol) 
and 30-50 µCi 323>Ȗ@$73 (Perkin Elmer). The reaction was incubated at 37oC, followed by 
10 mins 65oC incubation to inactivate the kinase. The radio-labelled oligonucleotides were 
stored on ice for the production of 32P labelled double stranded oligonucleotides (section 
3.1.6). 
 
3.1.6. Production of  [32P]-labelled double stranded oligonucleotides 
Radio-labelled double stranded oligonucleotides were produced by annealing [32P] Ȗ ATP- 
labelled oligonucleotides (section 3.1.5) with the complementary oligonucleotides in a 1:50 
ratio. The complementary oligonucleotides were made up in spermidine buffer (section 3.1.5) 
to 100 ng/µl. The complementary oligonucleotides were incubated at 95oC for 2 mins, 
followed a pulse vortex and 2 mins ice incubation. Twenty microlitres of 100 ng/µl prepared 
complementary oligonucleotides (2 µg in total) were incubated with 40 ng of the 323>Ȗ@ ATP 
labelled oligonucleotides at 95oC for 5 mins. The mixture was placed in 2 l boiling water and 
allowed to cool down to room temperature slowly.   
Unincorporated 323 >Ȗ@ $73 LQ WKH UHDFWLRQ PL[WXUH ZDV HOLPLQDWHG XVLQJ WKH QXFOHRWLGH
removal kit (Qiagen), according to the manufacturer’s instructions. The 32P labelled double 
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stranded oligonucleotides were eluted from the Qiagen column in 100 µl Qiagen EB buffer 
and stored at -20oC.   
 
3.1.7. Site-Directed Mutagenesis  
Single or double nucleotide mutations were introduced into plasmids using the QuickChange 
Site-Directed Mutagenesis Kit (Stratagene), according to the manufacturer’s protocol. The 
mutant plasmids were transformed into the NM522 competent cells (section 3.2.2) and 
produced by small scale DNA preparation (section 3.1.1.1). The desires mutations were 
examined by restriction digestion (section 3.1.2) and agarose gel analysis (section 3.3.1.1). 
The site specific mutations were verified by sequence analysis using the T7 promoter and 
SP6 promoter primers (Table 3).  
 
3.2. Bacterial Techniques 
3.2.1. Preparation of competent cells  
NM522 competent cells used for transformation (section 3.2.2) were generated by chemical 
treatment. Bacteria from a glycerol stock was inoculated in 5 ml LB and cultivated at 37oC 
overnight in a rotating wheel (New Brunswick Scientific). 
A millilitre of overnight culture was used to seed a 100 ml culture. The bacteria were grown 
at 37oC until mid-log phase, indicated by an optical density of 0.4 measured at a wavelength 
of 600 nm using a spectrophotometer (Pharmacia Biotech). The bacteria were collected by 
centrifugation at 4200g for 10 mins at 4oC and incubated in 30 ml sterile transformation 
buffer 1 (10mM MOPS pH7, 10mM RbCl) for 10 mins on ice. The bacteria were collected 
by centrifugation under the same conditions as above and resuspended in 4 ml 
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transformation buffer 2 (100 mM MOPS pH6.5, 50 mM CaCl2, 10 mM KCl, 15% glycerol). 
The competent cells were aliquoted into 200 µl and stored at -80oC. 
  
3.2.2. Transformation of competent cells with plasmid DNA  
NM522 competence cells (section 3.2.1) were transformed with plasmid DNA by heat shock 
treatment. Either ligation reaction or intact plasmid DNA was mixed with 50 µl competent 
cells. The mixture was incubated on ice for 30 mins. The cells were heat shocked at 42oC for 
2 mins in a hot water bath, before returning to ice for 5 mins. The transformed cells were 
grown in 1 ml of LB at 37oC for an hour in a bench top shaker (Eppendorf). Two different 
portions of the culture with at least 10-fold volume difference were evenly distributed to pre-
warmed LB/agar plates containing the appropriate antibiotic. The plates were incubated at 
37oC overnight in a heat incubator (Sanyo).  
 
3.3. Gel Electrophoresis  
3.3.1. Agarose gel electrophoresis  
3.3.1.1. DNA agarose gel 
DNA was separated according to its size by electrophoresis in agarose gels, ranging from 0.8% 
(Biorad Laboratories) - 3% (2% Nusieve GTG agarose, Cambrex and 1% agarose, Biorad 
laboratories). Agarose was suspended in TAE buffer (40 mM Tris-acetate pH8, 1 mM EDTA) 
and solubilised by heat using a microwave. The solubilised agarose was casted into a Biorad 
gel tank (Biorad Laboratories), according to the manufacturer instructions.  
DNA samples were mixed with 6X DNA loading dye (0.25% bromophenol blue, 0.25% 
xylene cyanol FF and 15% Ficoll in ddH2O) before loading into the wells of the gel. The 
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DNA was subject to electrophoresis at 80-100V in TAE buffer for 40 - 60 mins, depending 
on the size of the DNA samples and the percentage of gels, until DNA fragments were 
resolved. The gels were equilibrated in an ethidium bromide bath (0.5 µg/ml in TAE) for 10 
mins on a gentle shaker. The stained DNA was visualised using a UV gel documentation 
system (Syngene).   
 
3.3.1.2. Extraction of DNA from agarose gels  
DNA fragments from restriction digestion (section 3.1.2) were extracted for ligation (section 
3.1.4). Separated fragments in agarose gels (section 3.3.1.1) were visualised using an UV 
light box. The regions of agarose gels containing the desire DNA were excised by a scalpel. 
The DNA was extracted using the Jetsorb gel extraction kit (Genomed), following the 
manufacturer’s instructions.  
 
3.3.2. Polyacrylamide gels  
3.3.2.1. Non-denaturing polyacrylamide gel electrophoresis 
Protein/DNA interactions were examined using Non-denaturing polyacrylamide gel 
electrophoresis. A 5% polyacrylamide gel (12.5 ml 29:1 acrylamide:bis-acrylamide [Sigma], 
15 ml 5X TBE [445 mM Tris-HCl, 445 mM boric acid, 10 mM EDTA], 60 µl TEMED, 700 
µl 10% APS, 47 ml H2O) was pre-run in 1X TBE buffer at 20 mA for 30 mins. Samples 
were mixed with 6 X DNA loading dye (0.25% bromophenol blue, 0.25% xylene cyanol FF 
and 15% Ficoll in ddH2O) before loading onto the gel. The gel was run in the same condition 
until the loading dye had migrated approximately 2/3 of the gel.     
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3.3.2.2. SDS polyacrylamide gel electrophoresis 
Proteins were separated according to their molecular weight using SDS polyacrylamide gel 
electrophoresis (SDS-PAGE). Gels were casted and run based on the ‘discontinuous’ buffer 
method (Laemmli, 1970) using the Mini Protean II System (Biorad), set up according to the 
manufacturer’s instructions. A 7.5% resolving gel (7.5% acylamide [29:1 acrylamide:bis-
acrylamide, Sigma], 500 mM Tris-HCl pH 6.8, 0.4% SDS, 0.25% TEMED, 0.0375% APS) 
was polymerised under a layer of water-saturated butanol, which was washed off with 
distilled water before casting the stacking gel (4% acylamide [29:1 acrylamide:bis-
acrylamide], 1.5 mM Tris-HCl pH 8.8, 0.4% SDS, 0.2% TEMED, 0.025% APS) on top of 
the resolving gel.  
Protein samples were prepared by the addition of SDS loading buffer (3X SDS loading 
buffer: 150 mM Tris-HCl pH8, 6% SDS, 30% glycerol, 432 P0ȕ-mercaptoethanol, 0.025% 
bromophenol blue, 6 mM EDTA) and heat incubation at 95oC for 5 mins using a bench top 
heat block. Unsolubilised proteins were removed by centrifugation at 13000g at room 
temperature for 1 min. The supernatants were loaded onto the wells of the gels. The proteins 
were subjected to electrophoresis at 160 V in SDS buffer (25 mM Tris-HCl, 192 mM glycine, 
1% SDS), until the dye reached the bottom of the gel.    
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3.4. Protein Techniques 
3.4.1. Protein extraction  
3.4.1.1. Preparation of whole cell extracts  
Medium from each plate of 70% confluent HEK293 cells was removed. Adherent cells were 
washed once with ice-cold PBS and scraped off the dish in 1ml PBS. The cells were 
collected by centrifugation at 1000g for 2 mins at 4oC. The Cell pellet was resuspended in 
100 µl lysis buffer (0.1 M Tris-HCl pH 8, 0.1 M NaCl, 1% NP40, 1 mM DTT, 1 mM PMSF 
and 1X Protease Inhibitor Cocktail, Roche) and lysed on ice for 30 mins with 10 quick 
vortex pulses before and after the incubation. The cell lysate was then cleared by 
centrifugation at 13000g for 20 mins at 4oC. The whole cell extract was frozen in liquid 
nitrogen and stored at -80oC. 
 
3.4.1.2. Preparation of HeLa cytosolic extracts from suspension 
culture  
HeLa cytosolic extracts, provided by Mark Dear, were prepared as described below, 
modified from the method published by Dignam et al., 1983.  
HeLa cells were cultivated to approximately 8 X 105 cells/ml in a 2.5 l suspension culture. 
The cells were washed twice with ice-cold PBS + V + F (PBS, 1 mM Na3VO4, 5 mM NaF) 
and collected by centrifugation at 1000g for 15 mins at 4oC (Sorvall). The cell pellet was 
washed with buffer A, 5X volume (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl; 
supplemented just before use: 10 mM NaF, 2 mM Na3Vo4, 10 P0ȕ-glycerophosphate, 10 
mM pNPP, 0.5 mM DTT) and resuspended with the same buffer, 2X the volume, before 10 
mins ice incubation. The cell membrane of the cells was disrupted using a dounce 
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homogeniser by ten repetitions of strokes. The nuclei were collected by centrifugation at 
2500g for 10 mins at 4oC (Heraeus). The supernatant was supplemented with buffer B, 
0.11X the volume (300 mM HEPES pH 7.9, 30 mM MgCl2, 1.4 M KCl) and cleared by 
centrifugation at 34,000rpm for 60 mins at 4oC (Centrikon, T2070). HeLa cytosolic extracts 
were dialysed against buffer A (0.1 M Tris-HCl pH 8, 0.1 M NaCl, 1 mM DTT and 1 mM 
PMSF) as described in section 3.4.6. The HeLa cytosolic extracts were frozen in liquid 
nitrogen and stored at -80oC.     
 
3.4.1.3. Preparation of nuclear extracts  
Medium from each plate of cells was removed. The adherent cells were washed with ice-cold 
PBS + V + F (PBS, 1 mM Na3VO4, 5 mM NaF) and hypotonic buffer (20 mM HEPES pH7.9, 
20 mM NaF, 1 mM Na3VO4, 1 mM Na4P2O7, 1 mM EDTA, 1 mM DTT, Protease Inhibitor 
Cocktail [ Roche]) on the plates. The cells were lysed with 0.5 ml hypotonic buffer + 0.1% 
NP40 in situ and collected by centrifugation at 13000g for 20 s at 4oC (Eppendorf). The 
supernatant of cytosolic extract was supplemented with 120 mM NaCl and 10% glycerol, 
before storing at -80oC. The nuclear pellet was resuspended in 150 µl high salt buffer (1X 
hypotonic buffer, 420 mM NaCl, 20% glycerol) and rocked gently for 60 mins at 4oC. The 
nuclear extract was cleared by centrifugation at 13000g for 20 mins at 4oC (Eppendorf) and 
frozen in liquid nitrogen, before storing at -80oC.     
 
3.4.2. Transfer of proteins to Polyvinylidene Fluoride membrane  
Proteins resolved by SDS-Polyacrylamide Gel Electrophoresis (section 3.3.2.2) were 
transferred onto 0.2 µm Polyvinylidene Fluoride (PVDF) membranes (Schleicher and 
Schuell) using the Semi-Dry Transfer System (Biorad). The PVDF membranes were wet 
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with methanol. The polyacrylamide gels, filter papers (Whatman) and the PVDF membranes 
were soaked in transfer buffer (24 mM Tris-HCl, 192 mM glycine, 20% methanol). The 
PVDF membranes were laid under the gels with three layers of filter papers on both the top 
and the bottom. The stack was laid on the platinum plate of the transfer system. Proteins 
were transferred at 100 mA/gel at 12 V for 1 hr 45 mins, before proceeding to western blot 
analysis (section 3.4.3).   
 
3.4.3. Western blotting 
PVDF membranes with transferred proteins (section 3.4.2) were blocked in 5% milk (5% 
non-fat milk powder[Marvel] and 1X TBST [50 mM Tris-HCl, 150 mM NaCl, 0.05% 
Tween]) at room temperature for 1 hr. Primary antibodies, with concentration diluted in 5% 
milk according to the manufacturer’s recommendation, were applied onto the membranes 
overnight at 4oC. The membranes were washed three times in 1X TBST with gentle rocking 
at room temperature for 10 mins on the next day, before applying the corresponding 
secondary antibodies for an hour at room temperature. The membranes were washed with 1X 
TBST as described above, before applying the ECL Detection Reagent (GE Healthcare). The 
blots were developed using the LAS-3000 chemiluminescence camera (Fuji-Film).  
 
3.4.4. Electrophoretic Mobility Shift Assay (EMSA)  
Nuclear extracts (section  3.4.1.3) and 32P labelled double stranded oligonucleotides (section 
3.1.6) were used to examine Protein/DNA interaction in vitro in the EMSAs. A 10 µl 
reaction in FPE buffer (35 mM KCl, 2 mM spermidine, 2.35 mM EDTA ) containing nuclear 
extract, recombinant core SRF (provided by Prof. Peter Shaw, University of Nottingham), 6 
µg salmon sperm (Amersham), 1.2 µg poly dI:dC (Amersham) were incubated on ice for 20 
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mins. A microlitre of radio-labelled double stranded oligonucleotides was added to the 
mixture and incubated at room temperature for 15 mins to allow protein/DNA complex 
formation. The mixture was subject to non-denaturing 5% polyacrylamide gel 
electrophoresis (section 3.3.2.1) after the addition of 2.5 µl 1.5X DNA loading buffer 
(0.0625% bromophenol blue, 0.0625% xylene cyanol FF and 3.75% Ficoll in ddH2O). The 
gel was soaked in fixing buffer (10% glacial acetic acid, 40% methanol) for 10mins and 
dried at 90oC for 45 mins using a vacuum gel drier (Bachoffer). Radioactivity from the gel 
was exposed to a phosphor imager plate overnight and visualised using the FLA-2000 
phosphorimager (Fuji-Film).   
 
3.4.5. Fast Performance Liquid Chromatography (FPLC) 
Proteins of different sizes were separated by FPLC using a size exclusion chromatography 
column packed with superose 6 matrix (GE Healthcare). The column was pre-washed and 
run with filtered and degassed buffer (0.1 M NaCl, 0.1M Tris, pH7.5) at 0.2 ml/min using a 
high precision pump (Pharmacia). Gel filtration molecular weight markers (Sigma) were run 
through the column to create a molecular weight elution profile. Eluted proteins were 
detected by an UV detector (Pharmacia). Proteins were collected in 280 ȝODOLTXRWVXVLQJD
fraction collector (Amersham Biosciences). Size of eluted proteins was elucidated from the 
elution profile.   
 
3.4.6. Dialysis  
Cellulose dialysis membrane tubing with 3,500 Dal molecular weight cut off (Spectrum) was 
soaked in ddH2O at room temperature for 30mins and rinsed thoroughly to remove glycerine 
coating. Sample was injected into the dialysis membrane tubing with either ends secured by 
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clamps. The sample was then placed in appropriate dialysis buffer with the volume 100X of 
the sample volume. The dialysis buffer was stirred gently for three hrs at 4oC with fresh 
dialysis buffer replacement after the first 90 mins.   
 
3.4.7. Immobilized metal affinity chromatography (IMAC) 
Histidine-tagged proteins were retrieved from cells using IMAC. The cell lysate (section 
3.8.3) was mixed with Ni2+ beads (Qiagen) for an hour at room temperature on a rotating 
wheel. The beads were collected by centrifugation at 13000g for 2 mins at room temperature 
and successively washed with washing buffer 1 to 5. Contents of the washing buffers are 
described below. Proteins on the beads were eluted by addition of 35 µl SDS elution buffer 
(200 mM imidazole 50 mM Tris-HCl pH8, 2% SDS, 10% glycerol, 144 P0 ȕ-
mercaptoethanol, 0.008% bromophenol blue, 2 mM EDTA). The mixture was incubated at 
room temperature for 10 mins, followed by heat incubation at 95oC for 5 mins. The elution 
was cleared by centrifugation at 13000g for 10 mins at room temperature, before subject to 
7.5% SDS PAGE (section 3.3.2.2) and western blot analysis (section 3.4.3).  
WB1: 6 M guanidinium-HCl, 0.1 M phosphate buffer pH8, 0.01 M tris pH8, 10 P0 ȕ-
mercaptoethanol*. WB2: 8 M urea, 0.1 M phosphate buffer pH8, 0.01 M tris pH8, 10 P0ȕ-
mercaptoethanol*. WB3: 8 M urea, 0.1 M phosphate buffer pH6.3, 0.01 M tris pH6.3, 10 
P0ȕ-mercaptoethanol*. WB4: WB3 + 0.2% triton X-100. WB5: WB3 + 0.1% triton-X100. 
ȕ-mercaptoethanol was added just before use.  
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3.5. Eukaryotic cell culture  
3.5.1. Determination of cell numbers 
The density of cell suspensions was estimated using a haemocytometer (Hawksley) under a 
light microscope (Zeiss).   
 
3.5.2. Eukaryotic cell culture  
HEK293, HeLa and NIH3T3 cells were cultivated on 10 cm Falcon tissue culture dishes (BD 
Biosciences) in the low glucose (5.5 mM) Dulbecco’s Modified Eagle Medium (Sigma 
Aldrich), supplemented with 10% foetal calf serum (Bioclear), 200 mM glutamine(Sigma), 
100 U/ml penicillin and 100 µg/ml streptomycin (Sigma). Cells were passaged at a dilution 
of between 1:8 to 1:10 every 3 to 4 days and cultivated using a humidified incubator (Revco), 
set at 37oC and 7.5% CO2 for HEK293 and NIH3T3cells, 5% CO2  for HeLa cells.  
 
3.5.3. T-REx-293 cells with tetracycline-inducible expression of dnUbc12-HA  
Tetracycline-inducible dnUbc12-HA T-Rex-293 cell line, provided by Thilo Hagen 
(Wolfson Digestive Disease Centre, University of Nottingham), was generated as described 
below (Chew, Poobalasingam et al. 2007).  
Tetracycline-inducible dnUbc12-HA T-Rex-293 cell line was generated using the T-Rex 
System (Invitrogen). The plasmid pcDNA4/TO encoding the dnUBC12 cDNA with the 
C111S mutation, was stably transacted into T-Rex-293 cells. Successfully stable transfected 
cell was isolated using zeocin selection. Tetracycline-dependent protein expression was 
confirmed by western blot analysis.   
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3.6. Transfection of eukaryotic cells  
 
3.6.1. Calcium phosphate  
During this study, HEK293 cells were transfected using DNA CaPO4 co-precipitation. Cells 
were passaged to 50% confluent the day before transfection. The culture medium on cells 
was replaced with fresh full medium 4hrs prior transfection. A total of 10 µg of plasmid 
DNA was diluted in 500 µl 300 mM CaCl2 and incubated on ice for 10 mins. Following the 
incubation, 550 µl of 2X HEPES buffered saline (280 mM NaCl, 50 mM HEPES pH7) was 
added drop-wise to the mixture while mixing slowly using a vortex mixer. The mixture was 
incubated on ice for 30 mins before applying evenly onto the cells.  The cells were serum 
starved or administrated with stimulator or inhibitor where required before harvesting, 
approximately 48 hrs post-transfection.  
 
3.6.2. Polyethylenimine (PEI) 
During this study, HeLa cells were transfected using PEI.  Cells were passaged to 7 X 105 
cells/plate the day before transfection. The culture medium on cells was replaced with fresh 
full medium 4 hrs prior transfection. A total of 10 µg of plasmid DNA and 30 µl of 20 mM 
PEI were diluted into 250 µl of PBS separately. The diluted PEI was added drop-wise to the 
diluted DNA while mixing slowly using a vortex mixer. The mixture was incubated at room 
temperature for 30 mins. During the incubation, the cells were washed and the full medium 
replaced with serum-free Optimem (Invitrogen) prior to applying the mixture evenly onto the 
cells. The optimem was replaced with full medium 5 hrs post transfection. The cells were 
serum starved or administrated with stimulator or inhibitor where required before harvesting, 
approximately 48 hrs post-transfection.  
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3.7. Luciferase reporter DQGȕ-galactosidase reporter gene assay  
Elk-1 mediated transcription activity was examined using reporter gene assays in this study. 
NIH3T3 cells were passaged to 1.5 X 105 cells/well in 6 well plates (Corning Incorporated) 
the day before subjecting to PEI transfection (section 3.6.2). The transfection was done in 
triplicate for each experiment. The cells were collected by centrifugation at 13000g for 2 
mins at 4oC, 48 hrs post transfection and stored at -80oC. 
The cells were thawed for 10 mins and lysed in 65 µl lysis buffer (250 mM KCl, 50 mM 
Hepes pH7.5, 0.1% NP40 and 10% glycerol) for 25 mins on ice. The debris was removed by 
centrifugation at 14,000rpm for 10 min at 4oC.  
For the luciferase assays, 300 µl luciferin buffer (for 10 ml buffer: 0.5 ml 1 mM luciferin, 
100 µl 0.2 M ATP, 100 µl 1 M MgCl2 and 25 mM gly-gly pH7.8) was injected into 10 µl 
lysate. )RU WKH ȕ-galactosidase assays, 100 µl reaction buffer (for 5 ml buffer: 1 ml 0.5M 
NaPO4 pH8, 5 µl 1M MgCl2, 5µl Galacton [Tropix], 3.99 ml H2O), followed by 300 µl 
enhancer buffer (for 15 ml of enhancer buffer: 1.5 ml 2 M NaOH, 750 µl Emerald enhancer 
[Tropix], 12.75 ml H2O) was injected into 10 µl lysate using an automatic luminometer 
(Berthold). The intensity of emitted luminescence from both assays was measured in 
duplicate. The OXFLIHUDVHPHDVXUHPHQWZDVQRUPDOL]HGWRWKHȕ-galactosidase measurement. 
 
3.8. Ubiquitylation assays  
3.8.1. In vitro expression of L-[35S]-methionine labelled protein 
Radio-labelled Elk-1 was generated with the pcDNA3.HA.Elk-1 expression plasmid in 
presence of 20 µCi L-[35S]-methionine (Perkin Elmer), using the TNT T7 Quick Coupled 
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Transcription/Translation System (Promega), following the manufacturer's instructions. 
Unincorporated L-[35S]-methionine was eliminated using Micro Bio-spin P-6 
chromatography columns (BioRad), pre-equilibrated in 25 mM Tris-HCl and 50 mM NaCl 
pH7.5. 
 
3.8.2. In vitro ubiquitylation assay 
In vitro ubiquitylation assays were performed in a 20 µl reaction volume. One microlitre L-
[35S]-methionine labelled Elk-1 (section 3.8.1), 850 ng Ubiquitin aldehyde (BIOMOL), 500 
ng Ubiquitin (Sigma), 2 mM MgCl2, 2 mM ATP, 0.5 mM DTT, HeLa cytosolic extract or 
HEK293 whole cell extract as a source of E3, 25 ng recombinant ubiquitin activation 
enzyme E1 and 25 ng ubiquitin conjugating enzyme E2 were incubated for 1 hr at 30oC. 
Recombinant enzymes E1 and E2 were provided by Olivier Coux (Centre de Recherches de 
Biochimie Macromoléculaire, Montpellier). The reaction was terminated by addition of 10 µl 
3X SDS loading buffer (150 mM Tris-HCl pH8, 6% SDS, 30% glycerol, 432 P0 ȕ-
mercaptoethanol, 0.025% bromophenol blue, 6 mM EDTA), followed by heat incubation at 
90oC for 5 mins. Proteins in the mixture were then resolved using a 7.5% SDS-PAGE. The 
gels was dried and exposed to a phosphor imaging plate overnight and visualised using a 
phosphor imager (Fujifilm, FLA-2000).  
 
3.8.3. In vivo ubiquitylation assay  
Elk-1 ubiquitylation in vivo was examined using the in vivo ubiquitylation assay. Either 
HEK293 or HeLa cells were transfected as described (section 3.6.1 & 3.6.2 ). The cells were 
washed with PBS and collected by centrifugation at 14,000rpm for 1 min at 4oC (Eppendorf). 
A tenth of cells was lysed in 3X SDS loading buffer (150 mM tris-HCl pH8, 6% SDS, 30% 
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glycerol, 432 P0ȕ-mercaptoethanol, 0.025% bromophenol blue, 6 mM EDTA), followed 
by SDS-PAGE (section 3.3.2.2) and western blot analysis (section 3.4.3). The rest of cells 
were resuspended in lysis buffer (6 M guanidinium-HCl, 0.1 M phosphate buffer pH8, 0.01 
M tris-HCl pH8, 5 mM imidazole, 10 P0 ȕ-mercaptoethanol) and sonicated for 5 s 
(Jencons). The lysate was subjected to IMAC (section 3.4.7), followed by SDS-PAGE 
(section 3.3.2.2) and western blot analysis (section 3.4.3).  
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4. Identification of Elk-1 specific E3 ligase(s)  
 
4.1. Elk-1 specific ligase activity is presented in HEK293 cells.  
To identify the Elk-1 specific E3 ligase(s), an ubiquitylation assay was established to 
reconstitute Elk-1 ubiquitylation in vitro. The assay was modified from an established 
method (Linares, Hengstermann et al. 2003). For efficient visualization, Elk-1 was 
synthesized in vitro and labelled with [35S]-methionine. The E1 activating (Ube1) and E2 
conjugating enzyme (UbcH5c) were recombinant proteins, initially provided by Olivier 
Coux (Centre de Recherches de Biochimie Macromoléculaire, Montpellier). UbcH5c 
belongs to the UbcH5 family and members of this family are known to interact with a broad 
range of E3 ligases with little specificity on E3 ligase partner selection (Jensen, Bates et al. 
1995; Hatakeyama, Jensen et al. 1997; Lorick, Jensen et al. 1999; Brzovic and Klevit 2006; 
Brzovic, Lissounov et al. 2006; Kirkpatrick, Hathaway et al. 2006). Ube1 was the only 
identified ubiquitin E1 activating enzyme at the time and it cooperates with UbcH5c to 
facilitate protein ubiquitylation (Groettrup, Pelzer et al. 2008). Whole cell extracts (WCE) 
prepared from HEK293 cells were used to provide the E3 enzymatic activity. The essential 
components required for ubiquitylation were incubated to allow ubiquitin conjugation. The 
presence of Elk-1 specific E3 ligase activity in HEK293 WCE was examined. 
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Figure 4-1 Elk-1 specific E3 ligase activity is present in 
HEK293 whole cell extracts. In vitro expressed [35S]-labelled 
Elk-1, recombinant E1, E2, and HEK293 WCE as a source of 
E3 and ubiquitin were incubated under standard ubiquitylation 
conditions (see method) with different components missing as 
indicated. The reaction products were resolved by SDS-PAGE 
followed by autoradiography. Molecular weights are indicated 
on the left. Short Elk-1, an Elk-1 isoform lacking the first 54 
amino acids, is presented as sElk-1. 
 
Two species of [35S]-labelled proteins with distinct molecular weights were visualised in all 
reactions. Elk-1 corresponds to the top species located just under the 72 kDa molecular 
weight marker (lanes 1 - 4, Figure 4-1), the bottom species may present a truncated version 
of Elk-1 due to either internal transcription initiation or premature termination.  An Elk-1 
isoform lacking the first 54 amino acids, sElk-1, appeared under the 55 kDa marker (lane 5, 
Figure 4-1). The size of the bottom species remained unchanged for sElk-1, suggesting the 
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bottom species came from internal transcription initiation as premature transcription 
termination would have yielded truncated proteins with size reduction in proportion to that of 
sElk-1.  After an hour incubation of [35S]-labelled Elk-1, a high molecular weight (M.W.) 
species of approximately 300 kDa accumulated (lane 4, Figure 4-1). Conversely, these high 
M.W. species did not appear when sELk-1 was incubated under the same condition (lane 5, 
Figure 4-1), suggesting the truncated region of sElk-1 is critical for the accumulation of this 
high M.W. species. Although sElk-1 was not expressed to the same level as the full length 
Elk-1, the absence of high M.W. species in lane 5 excludes the possibility that the high M.W. 
species observed are the modified forms of the bottom species and indicates the high M.W. 
species are modified Elk-1. Elk-1 remained unmodified when either ubiquitin, E2 
conjugating enzyme or HEK293 whole cell extract was left out (lanes 1 - 3, Figure 4-1). 
Exclusion of each key component required for ubiquitylation abolished the modification of 
Elk-1 indicating that the high M.W. species is likely to be polyubiquitylated Elk-1. Despite 
the evidence indicating Elk-1 was modified with multiple ubiquitins, densitometry readings 
on either the top or the bottom species of [35S]-labelled proteins did not show significant 
alteration (data not shown), suggesting only a small portion of Elk-1 was modified under the 
conditions of this in vitro assay.  
 
4.2. Elk-1 specific ligase activity is present in HeLa cells  
To identify Elk-1 specific E3 ligase(s), proteins in cell extracts were separated by size or 
biochemical properties into a number of fractions by Fast Performance Liquid 
Chromatography (FPLC).  Enzymatic activity of ligase(s) in the fractions was followed using 
the in vitro ubiquitylation assay with the aim of obtaining a sufficiently purified active 
fraction(s) for protein identification by mass spectrometry.  
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The majority of E3 ligases in humans are multimeric protein complexes (Petroski and 
Deshaies 2005). To enable high preservation of the biological activity and protein complex 
formation of E3 ligases, size exclusion chromatography was first chosen as it is relatively 
gentle compared to other methods. Although size exclusion chromatography offers a gentle 
separation, there is an inevitable dilution of the protein concentration. To help retain 
sufficient ligase activity in the fractions, a good source of cell extract was used. These were 
obtained using a suspension HeLa cell culture system which had been previously established 
by members of our group to allow generation of cell extracts with high protein concentration. 
Nuclear (NXT) and cytosolic extracts (CXT) from HeLa cells following serum stimulation 
were already available. Separation of cytosolic and nuclear proteins was examined.  
 
 
Figure 4-2 Protein extractions from the suspension HeLa cell 
culture system. Western blot analysis of nuclear and cytosolic 
extracts from HeLa cells stimulated with serum using the 
antibodies indicated. 50 µg of protein were examined in each lane.  
 
A relatively large amount of TATA binding protein (TBP) was found in the NXT compared 
to a trace amount of TBP in the CXT (top panel, Figure 4-2), verifying the separation of 
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nuclear proteins from the CXT. The presence of tubulin in the nuclear extract indicates 
contamination of cytosolic proteins in the NXT (bottom panel, Figure 4-2).  
Previous experiments conducted by Prof. Peter Shaw demonstrated the presence of the Elk-1 
specific E3 ligase activity in both HeLa nucleus and cytosol (unpublished data). 
Transcription activators could be ubiquitylated in both the cytosol and the nucleus (Joseph, 
Zaika et al. 2003). To verify Elk-1 ubiquitylation in the cytosol, the presence of an Elk-1 
specific E3 ligase activity in HeLa CXT was examined using the same in vitro ubiquitylation 
assay.  
 
                         
Figure 4-3 Elk-1 specific E3 ligase activity is present in HeLa 
cytosolic extract. In vitro expressed [35S]-labelled Elk-1, 
recombinant E1, E2, HeLa CXT as a source of E3 and ubiquitin 
were incubated under standard ubiquitylation conditions (see 
method) with different components missing as indicated. The 
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reaction products were analysed by SDS-PAGE followed by 
autoradiography. Molecular weights are indicated on the left.  
 
Similar results were obtained when HEK293 WCE was replaced with HeLa CXT, suggesting 
the presence of Elk-1 specific E3 ligase in HeLa cell cytosol (lanes 1 & 3 - 5, Figure 4-3). 
Interestingly, exclusion of the E1 activating enzyme did not affect Elk-1 ubiquitylation, 
which may indicate an abundance of endogenous E1 activating enzyme in the cytosol of 
HeLa cells (lane 2, Figure 4-3).  
 
4.3. Elk-1 specific ligase(s) is approximately 29-50 kDa 
After confirming the presence of Elk-1 specific E3 ligase activity in the HeLa CXT, proteins 
in the extract were separated using a size exclusion chromatography column of superose 6 
matrix which has an optimal separation range of 5 - 5000 kDa. A set of markers were run 
through the column and detected at an optical density of 280 nm to generate a molecular 
weight elution profile. Proteins in the extract were separated into 30 fractions.  
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Figure 4-4 Elk-1 specific E3 ligase activity is present in HeLa 
cytosolic fractions containing proteins with molecular weight 
between 29 – 50 kDa. Top: HeLa CXT was fractionated by size 
exclusion chromatography, the curve represents the relative 
amount of eluted protein in different fractions with the average 
protein size indicated on the top of the graph; Bottom: in vitro 
expressed [35S]-labelled Elk-1 and HeLa CXT/fractions were 
incubated under standard ubiquitylation conditions (see method). 
The reaction products were resolved by SDS-PAGE followed by 
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autoradiography. Molecular weights are indicated on the left. Lane 
15 represents the assay with full (un-fractionated) HeLa CXT.  
 
A relatively large amount of protein was present in fractions 2 - 4, which contains protein 
species of just under 2,000 kDa. The high molecular weight indicates that the species are 
likely to be multimeric protein complexes as the median length of proteins in the Homo 
sapiens proteome is 375 amino acids, which is equivalent to approximately 50 kDa 
(Brocchieri and Karlin 2005). This observation indicated that the intermolecular interactions 
between proteins were preserved during the size exclusion chromatographic separation.  
Alternative fractions (odd numbers from 1 to 27) were examined using the in vitro 
ubiquitylation assay. The results indicated the presence of Elk-1 specific E3 ligase activity in 
fractions 21 - 25, which contain proteins of an estimated size range of 29 – 50 KDa (lanes 11 
- 13, Figure 4-5). The peak of E3 ligase activity was found in fraction 23. To confirm this 
result, fractions 7, 15 and 23 were examined again. 
 
 73 
 
                   
Figure 4-5 Confirmation of Elk-1 Specific E3 ligase activity in 
HeLa CXT fraction 23. In vitro expressed [35S]-labelled Elk-1 
and HeLa CXT/fractions were incubated under standard 
ubiquitylation conditions (see method). The reaction products were 
resolved by SDS-PAGE followed by autoradiography. Molecular 
weights are indicated on the left. Lane 1 represents the assay using 
full (un-fractionated) HeLa CXT, lane 2 - 4 represents the assay 
using fraction 32, 40 & 48 respectively and lane 5 - 8 represents 
the assay using fraction 48 with different components missing as 
indicated.  This experiment was repeated three times.  
 
Consistent with the previous results, the strongest Elk-1 E3 ligase activity was detected in 
fraction 23 (lane 4, Figure 4-4), whereas a relatively low level of ligase activity was 
observed in fractions 7 and 15 (lanes 2 & 3, Figure 4-5). Exclusion of E2 enzyme, ubiquitin 
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or ubiquitin aldehyde abolished polyubiquitylation (lanes 5, 6 & 8, Figure 4-4), confirming 
Elk-1 is polyubiquitylated.  
Surprisingly, Elk-1 was still polyubiquitylated without the addition of E1 enzyme (lane 7, 
Figure 4-4). Both of the Ube1 and Uba6 E1 activating enzymes have a molecular weight of 
118 kDa (Groettrup, Pelzer et al. 2008) and fraction 23 contains proteins with an estimated 
size range of  38 kDa – 44 kDa. Although size exclusion chromatography offers a gentle 
approach to protein separation by size, the separation is not precise. The estimated size range 
only represents the average protein size presented in the fractions. The abundance of E1 
activating enzyme activity was already demonstrated in HeLa CXT (lane 2, Figure 4-3). It is 
possible that enough E1 activating enzyme was present in fraction 23 to support Elk-1 
ubiquitylation, which could be verified by western blot analysis. 
E3 ligases can be monomeric or multimeric. The multimeric Cullin-RING ligases (CRLs) 
comprise the largest group of ubiquitin E3 ligases (Petroski and Deshaies 2005; Merlet, 
Burger et al. 2009). All CRLs contain a cullin scaffold that has a molecular weight of 
approximately 90 kDa (Michel and Xiong 1998). Together with its variable substrate 
recognition module and RING-protein subunit, the size of CRLs considerably exceeds the 
estimated size range (38 kDa – 44 kDa) of proteins presented in fraction 23, therefore it is 
rational to exclude the possibility that the Elk-1 specific E3 ligase present in fraction 23 is a 
CRL.  
Monomeric E3s characterize with either a 40 – 100 amino acid RING (~8 kDa) or a 350 
amino acid HECT (~45 kDa) catalytic domain, together with additional substrate recognition 
and regulatory regions which can be varied in size (Fang and Weissman 2004). The HECT-
domain alone reaches the estimated upper protein size limit of fraction 23. Given that a 
HECT-domain E3 ligase must contain regions for substrate interaction and activity 
regulation, it would easily exceed the estimated size range in fraction 23. On the other hand, 
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E3 ligases containing a small RING-domain would fit into this size range, therefore it is 
more likely that the potential Elk-1 specific E3 in fraction 23 is a monomeric RING-domain  
E3 ligase.  
  
4.4. Elk-1 polyubiquitylation is inhibited by dominant negative 
Ubc12  
In parallel with the identification of Elk-1 specific E3 ligase(s) using chromatographic 
approach, additional experiments were performed to examine whether a CRL is able to 
ubiquitylate Elk-1. It has been shown that neddylation, facilitated by the Nedd8 conjugating 
enzyme Ubc12 (Gong and Yeh 1999), is essential for the activity of CRLs (Podust, Brownell 
et al. 2000; Read, Brownell et al. 2000; Wu, Chen et al. 2000). Therefore, if the Elk-1 
specific E3 ligase belongs to the class of CRLs, inhibiting neddylation would restrain Elk-1 
ubiquitylation.   
To examine this possibility, a cell line was utilized, kindly provided by Thilo Hagen 
(Department of Biochemistry, Nation University of Singapore), that expresses the HA-
tagged dominant negative nedd8 conjugating enzyme (DN Ubc12) in order to block CRL 
activity (Chew, Poobalasingam et al. 2007). The DN Ubc12 contains a single C111S 
mutation which prevents cullin neddylation by sequestering Nedd8, thereby reducing CRL 
activity (Wada, Yeh et al. 2000). Expression of the HA-tagged DN Ubc12 was induced by 
treating cells with tetracycline (TC) and verified by western blot analysis (Figure 4-6). 
Whole cell extracts were prepared from cells with or without prior TC stimulation and 
examined for Elk-1 specific E3 ligase activity using the in vitro ubiquitylation assay. 
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Figure 4-6 Tetracycline inducible HA-tagged dominant 
negative Ubc12 expression in HEK293 cells. Western blot 
analysis of WCE from HEK293 cells treated with or without TC.  
 
                                                
Figure 4-7 Dominant negative nedd8 conjugating enzyme 
inhibits Elk-1 polyubiquitylation. In vitro expressed [35S]-
labelled Elk-1 and HEK293 WCE with or without TC inducible 
dominant negative Nedd8 conjugating enzyme were incubated 
under standard ubiquitylation conditions. Lane 1 represents the 
assay without an addition of cell extract; lane 2 & 3 represents the 
assay using HEK 293 WCE with or without TC-induced DN 
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Ubc12. The experiment was repeated three times. Molecular 
weights are indicated on the left.  
 
High molecular weight species representing polyubiquitylated Elk-1 accumulated when Elk-
1 was incubated with HEK293 WCE, as previously observed in Figure 4-1 (lane 3, Figure 
4-7), suggesting Elk-1 specific E3 ligase(s) is active in the cells. This modification was 
diminished when DN Ubc12 was present (lane 2, Figure 4-7), indicating that neddylation is 
essential for Elk-1 polyubiquitylation, hence at least a type of CRL is able to conjugate 
polyubiquitin to Elk-1 in vitro.  
In addition to the high molecular weight species, a lower molecular weight species of 80 kDa 
also accumulated (lanes 2 & 3, Figure 4-7), regardless of the presence of DN Ubc12, 
suggesting that neddylation is not required for this modification. The approximate 8 kDa 
increase in molecular weight fits with a single ubiquitin attachment, however the above 
experiment cannot unequivocally confirm that the lower molecular weight species were 
monoubiquitylated Elk-1. This was later verified by additional experiments performed by 
another member of the group (Jürgen Handwerger) where essential components for 
ubiquitylation were omitted (data not shown). In contrast to earlier experiments (Figure 4-1), 
this lower molecular weight species did not appear where a different source of HEK293 
WCE was used. The former WCE was prepared from normal growing HEK293 cells, 
whereas the later one was generated from HEK293 cells stably transfected with an 
expression cassette of inducible DN Ubc12 and treated with TC. The accumulation of this 
lower molecular weight species suggests the manipulation of HEK293 has altered Elk-1 
monoubiquitylation sensitivity. 
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A single protein can be ubiquitylated by multiple E3 ligases under different circumstances, 
such as subcellular location or extracellular stimuli. For example, the CDK inhibitor p27kip1 
is ubiquitylated by the SCF SKP2 E3 ligase in the nucleus, but by another E3 ligase KPC 
complex in the cytosol (Kamura, Hara et al. 2004).  Previous analysis of the fractions of 
HeLa cytosol extract has ruled out the presence of Elk-1 specific CRL ligase in the cytosol 
of HeLa cells (Figure 4-5), whereas analysis on HEK293 WCE containing DN Ubc12 
suggests Elk-1 can be ubiquitylated by a CRL. Nevertheless, given that a single protein can 
be ubiquitylated by multiple E3 ligases, it is possible that Elk-1 is ubiquitylated by a CRL in 
the nucleus while ubiquitylated by a different E3 ligase, other than a CRL, in the cytosol.   
The in vitro ubiquitylation assay offers an efficient way to detect Elk-1 ubiquitylation, 
however there are disadvantages. The addition of ubiquitylation enzymes may restrict or 
enhance ubiquitylation. E2 conjugating enzymes play an important role in E3 ligase selection, 
ubiquitin chain initiation, processivity and specificity (Ye and Rape 2009; David, Ziv et al. 
2010). The addition of the E2 conjugating enzyme UbcH5c enhanced Elk-1 
polyubiquitylation in vitro (Figure 4-1 & Figure 4-2), however it was restricted to those 
facilitated by this particular E2 enzyme and its interacting E3 ligase partners, thereby 
limiting the observation from the whole spectrum of Elk-1 ubiquitylation. Although a 
reasonable level of Elk-1 polyubiquitylation was observed in early experiments, it was not 
possible to achieve the same intensity in later experiments. In order to process and to study 
Elk-1 ubiquitylation in a more physiological relevant condition, it was decided to adopt a 
cell-based ubiquitylation assay.  
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5. Elk-1 is mono- and polyubiquitylated in 
HEK293 cells 
 
5.1. Elk-1 is polyubiquitylated in HEK293 cells  
Previous experiments demonstrated the presence of Elk-1 specific E3 ligase activity in 
HEK293 cells in vitro (Figure 4-1), therefore it was rational to use these cells for a cell-based 
assay. HEK293 cells were co-transfected with expression vectors encoding C-terminal His-
tagged Elk-1 and N-terminal HA-tagged ubiquitin. Whole cell extracts were prepared from 
the transfected cells treated with proteasome inhibitor (MG132) to inhibit proteasome-
mediated proteolysis with the aim of stabilizing polyubiquitylated proteins destined for 
destruction. A portion of each whole cell extract was used to analyse exogenous protein 
expression levels. His-tagged Elk-1 was isolated from the rest of the whole cell extract by 
Immobilized Metal Affinity Chromatography (IMAC) using Ni2+ beads under denaturing 
conditions and HA-tagged ubiquitylated Elk-1 was visualised by immunoblot. 
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Figure 5-1 Elk-1 is polyubiquitylated in HEK293 cells. Upper 
panels (IMAC): Whole cell extracts from HEK293 cells 
transfected with expression vectors encoding His-tagged Elk-1 and 
HA-tagged ubiquitin and treated with MG132 as indicated were 
subjected to IMAC under denaturing conditions. Isolated proteins 
were washed, resolved by SDS-PAGE and analysed by 
immunoblotting with the antibodies indicated. Lower panels 
(lysate): Five percent of the whole cell extracts were resolved by 
SDS-PAGE for immunoblotting. The Į3-Elk antibody targets 
phospho-serine 383 in Elk-1. Molecular weights are indicated on 
the right in kDa. 
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Elk-1 was covalently modified with ubiquitin in HEK293 cells (lane 3, top panel, Figure 5-1). 
The molecular weight of modified Elk-1 was between 72 to >300 kDa, which is equivalent 
to the range of a single to more than 30 units of ubiquitin attachment. The addition of 
MG132 mildly stabilized polyubiquitylated Elk-1 (compare lanes 3 with 6, top panel, Figure 
5-1), suggesting a portion of polyubiquitylated Elk-1 was degraded by the proteasome. 
Interestingly, phosphorylated Elk-1 accumulated and exhibited slower SDS-PAGE mobility 
with proteasomal inhibition (compare lanes 2 & 3 with 5 & 6, second panel, Figure 5-1), 
suggesting that the proteasome may selectively mediate degradation of phosphorylated Elk-1.   
 
5.2. Elk-1 is monoubiquitylated in HEK293 cells  
To confirm Elk-1 ubiquitylation in HEK293 cells, a similar experiment to Figure 5-1 was 
performed with the substitution of C-terminal His-tagged Elk-1 and N-terminal HA-tagged 
ubiquitin with N-terminal HA-tagged Elk-1 and N-terminal His-tagged ubiquitin. In contrast 
to the previous experiment, total ubiquitylated proteins were retrieved by IMAC and 
modified Elk-1 was visualised by immunoblot.  
 
 82 
 
 
Figure 5-2 Elk-1 is monoubiquitylated in HEK293 cells.  Upper 
panel (IMAC): Whole cell extracts from HEK293 cells transfected 
with expression vectors encoding HA-tagged Elk-1 and His-tagged 
ubiquitin and treated with MG132 as indicated were subjected to 
IMAC under denaturing conditions. Isolated proteins were washed, 
resolved by SDS-PAGE and analysed by immunoblotting with the 
indicated antibodies. Lower panels (lysate): Five percent of the 
whole cell extracts were resolved by SDS-PAGE for 
immunoblotting. 7KHĮ3-Elk antibody targets phospho-serine 383 
in Elk-1. Molecular weights are indicated on the right in kDa. 
 
A different pattern of ubiquitylated Elk-1 was detected compared to that in Figure 5-1. The 
size of the retrieved Elk-1 was about 80 - 110 kDa, which is equivalent to 1 - 3 units of 
ubiquitin attachment (lane 3, upper panel, Figure 5-2). The level of the modified Elk-1 was 
not stabilised by proteasome inhibitor, suggesting its non-proteolytic role (compare lanes 3 
with 6, upper panel, Figure 5-2). Elk-1 phosphorylation was significantly reduced when 
exogenous ubiquitin was co-expressed, which was inversely correlated to Elk-1 
 83 
 
ubiquitylation, indicating phosphorylated Elk-1 may be preferentially ubiquitylated (compare 
lanes 2 & 3 with 5 & 6, upper and bottom panel Figure 5-2). Many proteins are ubiquitylated 
in a phosphorylation-dependent manner via phosphodegron (Won and Reed 1996; Verma, 
Annan et al. 1997). The effect of Elk-1 phosphorylation on its ubiquitylation is investigated 
in chapter 8. 
Although the signals of Elk-1 attached with a single, double or triple ubiquitins were similar 
in this experiment, later experiments revealed that Elk-1 is predominantly modified with a 
single ubiquitin. To avoid confusion, the observed ubiquitylated Elk-1 species in Figure 5-2 
are collectively termed monoubiquitylated Elk-1 in this thesis.    
Distinct species of ubiquitylated Elk-1 were preferentially observed by the two experimental 
procedures (Figure 5-1 & Figure 5-2). The first experiment allows observation of a wider 
spectrum of ubiquitylated Elk-1 species from single to around 30 attachments, which may 
lead to either proteolytic or non-proteolytic functions (Figure 5-1). The second experiment 
detects a narrower scope of ubiquitylated Elk-1 species from single to up to three ubiquitin 
attachments, which only confers to non-proteolytic functions (Figure 5-2). An excess amount 
of Ni2+ beads were used in IMAC to retrieve His-tagged proteins in both experiments, 
therefore the dissimilar observations were unlikely due to different quantity of distinct 
ubiquitylated Elk-1 species, but more likely caused by the number of epitope tags attached 
on ubiquitylated Elk-1. In the first experiment (Figure 5-1), Elk-1 was isolated by IMAC and 
ubiquitylated Elk-1 was visualised by immunoblotting using antibodies against the epitope 
tag on each attached exogenous ubiquitin, therefore the more ubiquitin attachments the 
stronger the signal intensity. In other words, polyubiquitylated Elk-1 would have a stronger 
detection sensitivity compared to that of monoubiquitylated Elk-1 regardless of their quantity, 
thus the observed signal intensity doesn’t proportionally represent the amount of 
ubiquitylated Elk-1. In the second experiment (Figure 5-2), total ubiquitylated proteins were 
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isolated and ubiquitylated Elk-1 was visualised by immunoblotting using the antibodies 
against the epitope tag on Elk-1. In this case, the signal intensity proportionally correlates to 
the quantity of ubiquitylated Elk-1 disregarding of the number of ubiquitin attachment. 
Therefore the majority of ubiquitylated Elk-1 is conjugated with a single ubiquitin.  
It is worth noting that despite the relatively even signal of polyubiquitylated and 
monoubiquitylated Elk-1 observed using the first experimental procedure (Figure 5-1), only 
monoubiquitylated Elk-1 was detected using the second experimental procedure (Figure 5-2).  
This study was more interested in the non-proteolytic role of ubiquitylation to Elk-1. To 
avoid the ambiguity of mixed ubiquitylated species, attention was focused on the Elk-1 
species with fewer ubiquitin attachments, preferentially observed by the second experimental 
procedure.  
 
5.3. Mapping of Elk-1 monoubiquitylation site 
To investigate the function of Elk-1 monoubiquitylation, one aim was to generate an Elk-1 
derivative that is monoubiquitylation defective by eliminating the ubiquitin acceptor site(s). 
Lysine residues were substituted with arginine in combination in Elk-1 by site-directed 
mutagenesis with the aim of abolishing its ubiquitylation. The ubiquitylation sensitivity of 
Elk-1 derivatives was examined using the same cell-based ubiquitylation assay as described 
in Figure 5-2.  
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Figure 5-3 Elk-1 is monoubiquitylated in the ETS-domain. Top: 
Schematic representation of lysine residue distribution in Elk-1. 
Middle: Table of the location of the substitutions in Elk-1, lysine 
residues and arginine substitutions are represented with green 
circles and open circles respectively. Bottom: upper panel (IMAC): 
Whole cell extracts from HEK293 cells transfected with 
expression vectors encoding His-tagged ubiquitin and HA-tagged 
Elk-1 derivative as indicated were subjected to IMAC under 
denaturing conditions and resolved by SDS-PAGE for 
immunoblotting with the indicated antibodies. Bottom panel 
(lysate): Five percent of the whole cell extracts were resolved by 
SDS-PAGE for immunoblotting. 
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Wild type Elk-1 was monoubiquitylated similar to the previous observations in Figure 5-2 
(lane 1, second panel, Figure 5-3). Replacing all eight lysine residues in the ETS-domain 
completely abolished ubiquitylation, indicating the ubiquitin acceptor residue may be located 
in the ETS-domain (lane 2, second panel, Figure 5-3). Although the NTR8 protein level was 
slightly lower than that of the wild type (compare lanes 1 with 2, bottom panel, Figure 5-3) 
the difference in protein level cannot be sufficient to cause the distinct ubiquitylation 
sensitivity between the wild type and NTR8.  
The other Elk-1 derivatives with a combination of substitutions outside the ETS-domain had 
comparable monoubiquitylation levels to that of the wild type (lanes 3 - 5, second panel, 
Figure 5-3), indicating either that those lysine residues are not sites for Elk-1 
monoubiquitylation or that multiple, redundant ubiquitin acceptors are present in the 
carboxyl-terminus. In a later experiment, it was shown that a derivative lacking all ten 
carboxyl-terminal lysines (R10) can still be monoubiquitylated (lane 10, top panel, Figure 
5-5), eliminating the possibility of redundant carboxyl-terminal ubiquitin acceptor sites.     
In addition to the above experiments, another approach was used to examine and confirm 
that the ubiquitin acceptor site(s) is located in the ETS-domain. In this case, all lysine 
residues in Elk-1 were substituted with arginine to abolish its monoubiquitylation. Lysine 
residues were then put back sequentially downstream from the ETS-domain with the aim to 
rescue Elk-1 monoubiquitylation.  
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Figure 5-4 Confirmation of Elk-1 monoubiquitin acceptor site 
in the ETS-domain. Top: Table of the location of the substitutions 
in Elk-1, lysine residues and arginine substitutions are represented 
with green circles and open circles respectively. Bottom: Cell-
based ubiquitylation assay of Elk-1 was preformed as described for 
Figure 5-3 using Elk-1 derivatives as indicated.  
 
As expected, the substitution of all lysine residues to arginine in the R18 derivative 
completely abolished its monoubiquitylation (lane 2, upper panel, Figure 5-4). Putting back 
the lysine residues downstream of the ETS-domain did not rescue Elk-1 monoubiquitylation 
(lanes 3 - 6, upper panel, Figure 5-4), also consistent with the notion that the ubiquitin 
acceptor site is located in the ETS-domain.  
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To map the ubiquitin acceptor site(s) within the ETS-domain, another set of “put back” 
derivatives was used. This time, lysine residues were put back upstream from the ETS-
domain. The ubiquitylation sensitivity of Elk-1 derivatives was examined using the same 
cell-based ubiquitylation assay. 
 
 
 
Figure 5-5 Lysines 35/50/52 are important for Elk-1 
monoubiquitylation. Top: Table of the location of the 
substitutions in Elk-1, lysine residues and arginine substitutions 
are represented with green circles and open circles respectively. 
Bottom: Cell-based ubiquitylation assay of Elk-1 was performed as 
described for Figure 5-3 using Elk-1 derivatives as indicated.   
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Elk-1 derivatives lacking either lysine 35 or lysines 50/52 were not monoubiquitylated (lanes 
2 - 9 & 12 - 18, top panel, Figure 5-5). Monoubiquitylation was only regained when lysines 
35/50/52 were present in the R10 derivative (lane 10, top panel, Figure 5-5), suggesting these 
residues are essential for Elk-1 monoubiquitylation.  Replacing any of the three amino-
terminal lysine residues completely abolished monoubiquitylation (lanes 8 & 9, top panel, 
Figure 5-5) suggesting factors other than elimination of the ubiquitin acceptor site 
contributed to the loss of Elk-1 monoubiquitylation. In addition, the derivatives with or 
without lysine substitutions outside the ETS-domain did not differ in their ubiquitylation 
sensitivity (lanes 2 - 9 & 12 - 18, top panel, Figure 5-5), confirming those lysine residues are 
not involved in Elk-1 monoubiquitylation. 
The ubiquitin acceptor site has been located within the ETS-domain (Figure 5-3 & Figure 
5-4), where substituting any of the three amino-terminal lysine residues (K35/50/52) 
completely abolished Elk-1 monoubiquitylation (Figure 5-5). The ETS-domain is 
responsible for DNA binding, in which lysines 50 and 52 play a pivotal role (Mo, Vaessen et 
al. 2000). Loss of monoubiquitylation for Elk-1 derivatives lacking either lysine 35 or 
lysines 50/52 suggests all three residues are determinants for Elk-1 ubiquitylation. It is 
possible that replacing lysines 50 or 52 with arginine affects Elk-1 DNA binding, which in 
turn may be required for Elk-1 monoubiquitylation, despite both amino acids sharing 
similarity in charge and structure. This hypothesis prompted the investigation of the impact 
of lysine to arginine substitutions in Elk-1 on its DNA binding and the role of DNA binding 
on Elk-1 monoubiquitylation (chapter 7.3).  
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6. Elk-1 monoubiquitylation inhibits its 
transactivational ability  
 
6.1. Elk-1 monoubiquitylation inhibits its transactivation on the 
SRE upon mitogen stimulation 
Previous experiments have suggested that Elk-1 monoubiquitylation confers unknown non-
proteolytic functions (Figure 5-2). Elk-1 is a transcription factor responsible for 
transactivation of genes under the control of the SRE in response to extracellular stimuli.  It 
is possible that monoubiquitylation may influence the ability of Elk-1 to transactivate its 
target genes. The best studied SRE-induction is mediated through activation of TCFs via the 
MAPK signalling pathways. Among the three major MAPK pathways, the ERK pathway is 
activated by mitogens, whereas the JNK and p38 pathways are triggered by stress signals 
(Turjanski, Vaque et al. 2007). Initial experiments on Elk-1 monoubiquitylation were 
performed in HEK293 cells, however Elk-1 is constitutively active in these cells, as 
indicated by its high basal phosphorylation (Figure 5-1 & Figure 5-2). To overcome this 
problem, HeLa cells were used in which Elk-1 phosphorylation, hence activation can be 
manipulated by serum withdrawal followed by mitogen stimulation, demonstrated in Figure 
9-1, Figure 9-2 and Figure 9-3. Initial experiments were performed by another member of 
the group (Li Li) in HeLa cells and low SRE-induction by exogenous Elk-1 in response to 
mitogen stimulation was observed due to high basal SRE-dependent transcription (data not 
shown), which obscures the observation of Elk-1 mediated transactivation. To improve the 
observation of Elk-1-mediated SRE-induction, a different cell line (NIH3T3) was chosen 
which had previously been used to study Elk-1 transactivation (Gille, Kortenjann et al. 1995). 
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The transactivational ability of exogenous Elk-1 derivatives was examined in NIH3T3 cells 
using a luciferase reporter gene assay system. The cells were co-transfected with three 
different types of expression vector encoding Elk-1 derivatives, luciferase reporter placed 
under control of triplicate SRE promoters DQGȕ-galactosidase as a control for transfection 
efficiency. Mitogens (either TPA or serum) were used to activate the ERK pathway to induce 
Elk-1 mediated SRE-dependent luciferase protein expression. Elk-1 transactivational activity 
was indicated by the amount of luciferase activity in the transfected cells, normalized to the 
ȕ-galactosidase activity.  
 
 
Figure 6-1 Replacing lysine 35 in the ETS-domain of Elk-1 
confers dominant negative inhibition on SRE-induction upon 
mitogen stimulation. Whole cell extracts from NIH3T3 cells 
treated with either serum or TPA and co-transfected with Elk-1 
derivative expression vectors, (SRE)3-luciferase reporter vectors 
DQG ȕ-galactosidase expression vectors were measured by a 
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luminometer. The ratio of luciferase/ȕ-galactosidase activity was 
presented by the bars. Data shown are representative of triplicate 
repeats of a single experiment. Error bars represent standard 
deviation (n=3). The K35R derivative is hyper-monoubiquitylated 
in this experiment, which is explained in the text below and 
demonstrated in Figure 10-3.    
 
SRE-dependent transcription represented by luciferase activity increased by two fold when 
cells were treated with serum (grey bars) (compare bars 1 with 2, Figure 6-1) and by five 
fold with TPA (dotted bars) (compare bars 1 with 3, Figure 6-1), indicating that endogenous 
proteins were able to facilitate SRE-dependent transcription in a mitogen inducible manner 
in NIH3T3 cells.  Active ERK phosphorylates Elk-1, as well as other TCFs, Sap-1 and Net, 
to potentiate their transactivational ability at the SRE (Strahl, Gille et al. 1996; Ducret, Maira 
et al. 2000). In addition, serum can also induce SRE-dependent transcription, independent of 
TCFs (Graham and Gilman 1991; Johansen and Prywes 1994; Hill and Treisman 1995), 
through the RhoA-SRF pathway (Hill, Wynne et al. 1994; Hill, Wynne et al. 1995). 
Therefore the observed elevated SRE-dependent transcription was likely to be caused by a 
combination of TCF-dependent and TCF-independent SRE-induction. Compared to serum 
induction, TPA induced SRE-dependent transcription was more prominent (compare bars 2 
with 3, Figure 6-1). TPA is a phorbol ester that activates PKCs (Blumberg 1988) which in 
turn activates at least three signalling pathways to converge on the SRE; the ERK, JNK and 
RhoA-SRF pathways (Soh, Lee et al. 1999). PKCs are known for their sustained activation 
(Cheng, Wung et al. 2001), which explains the higher elevation in SRE-induction by TPA 
compared to that by serum.   
 93 
 
Exogenous expression of Elk-1 resulted in only a slight increase in the overall SRE-
induction in basal, serum- and TPA-stimulated NIH3T3 cells (compare bars 1 - 3 with 4 - 6, 
Figure 6-1), suggesting Elk-1- mediated transcription may be responsible for a portion of the 
SRE-induction.   
Phosphorylation at serine 383/389 is essential for Elk-1 transactivational activity (Gille, 
Kortenjann et al. 1995). Replacing these phospho-acceptor sites in Elk-1 reduced SRE- 
induction by approximately 60 % (compare bars 7 – 9 with 4 - 6, Figure 6-1). SRE-
dependent transcription was reduced to a level below that of the untransfected cells (compare 
bars 1 – 3 with 7 - 9, Figure 6-1), indicating that the transcriptionally defective Elk-1 
derivative (383/389A) possesses a dominant negative ability as observed in previous 
publications (Janknecht, Ernst et al. 1993; Gille, Kortenjann et al. 1995), possibly by 
competing with other activators for the SRE. Interestingly, the K35R derivative also 
exhibited a similar dominant negative inhibition on SRE-dependent transcription (compare 
bars 10 - 12, Figure 6-1). 
Previous experiments have suggested that lysine 35 may be the site of Elk-1 
monoubiquitylation ([NTR1 = K35R], lane 12, upper panel, Figure 5-5), therefore it was 
conceivable that Elk-1 monoubiquitylation may be required for its full transactivational 
ability at the SRE. However the location of the ubiquitin acceptor site was drawn into 
question due to artificial effects caused by the amino-terminal epitope tag on Elk-1 (chapter 
10). In this experiment, the Elk-1 derivatives were expressed from the pCMV5.HA 
expression vectors instead of the pcDNA3.HA expression vectors which were used in 
previous experiments for the mapping of Elk-1 ubiquitylation site(s) (Figure 5-5). The Elk-1 
derivatives generated from the two expression vectors contain a different linker for the HA 
tag (Figure 10-2) which alters their monoubiquitylation sensitivity. In this case, the K35R 
derivative exhibited higher monoubiquitylation level than the wild type (compare lanes 4 
 94 
 
with 5, Figure 10-3), therefore the dominant negative inhibition on SRE-dependent 
transcription could be conferred by Elk-1 hyper-monoubiquitylation.  
In later experiments, the substitution of lysine 35 with arginine was shown to mildly reduce 
the ability of Elk-1 to form ternary complexes at the SRE (compare lanes 3 with 6, left panel, 
Figure 7-3), which may contribute to the loss of Elk-1-mediated SRE-induction.  However 
the K35R derivative must be able to bind to the SRE to elicit the dominant negative 
inhibition in SRE-induction, eliminating the possibility that the K35R derivative reduces 
SRE-induction simply by its weakened ability to form a ternary complex on the SRE, 
consistent with the notion that Elk-1 monoubiquitylation confers a dominant negative effect 
on SRE-mediated transcription.    
In this experiment, the transcriptional activity of Elk-1 derivatives was estimated by the ratio 
RIOXFLIHUDVHDQGȕ-galactosidase activity to ensure that the observed different transcriptional 
activity of Elk-1 derivatives was not due to uneven transfection efficiency or protein 
expression. However this cannot unequivocally demonstrate the level of Elk-1 derivatives 
are the same in each experiment. The protein level of Elk-1 derivatives was shown to be 
equal using western blot analysis in similar experiments (data not shown), however it is 
worth noting that the level of Elk-1 derivatives was not examined in this experiment.  
 
6.2. Elk-1 monoubiquitylation inhibits its Raf-induced 
transactivational ability at the SRE  
Both extracellular stimuli used in figure 7.1 are able to stimulate SRE-induction via multiple 
pathways both dependent and independent of TCFs, which may obscure the observation of TCF-
mediated SRE-induction. To induce TCF-mediated SRE-dependent transcription specifically via 
the ERK pathway, NIH3T3 cells were transfected with an expression vector encoding 
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constitutively active c-Raf 259D, an upstream regulator of ERK (Morrison, Heidecker et al. 
1993).  
 
 
Figure 6-2 Replacing lysine 35 in the ETS-domain of Elk-1 
confers dominant negative inhibition on Raf-induced SRE-
induction. Whole cell extracts from NIH3T3 cells co-transfected 
with Elk-1 derivative expression vectors, (SRE)3-luciferase 
UHSRUWHU YHFWRUV ȕ-galactosidase expression vectors and 
with/without Raf expression vector were measured by a 
OXPLQRPHWHU 7KH UDWLR RI OXFLIHUDVHȕ-galactosidase activity is 
presented by the bars. Data shown are representative of triplicate 
repeats of a single experiment. Error bars represent standard 
deviation (n=3).    
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Elevated SRE-induction caused by endogenous proteins was observed with ectopic 
expression of c-Raf 259D (compare lanes 1 & 2, Figure 6-2). SRE-induction was also 
increased in the presence of exogenous Elk-1 (compare lanes 3 & 4, Figure 6-2). However 
the level of elevation was lower than that of the untransfected cells by two fold (compare 
lanes 1 & 2 with 3 & 4, Figure 6-2), suggesting exogenous Elk-1 was able to induce SRE-
induction but inhibit SRE-induction mediated by endogenous proteins. This could explain 
the low level of SRE-induction by exogenous Elk-1 in response to mitogen stimulation in the 
previous experiments (compare bars 1 - 3 with 4 - 6, Figure 6-1). Consistent with the 
previous results (Figure 6-1), both the S383/389A and K35R derivatives displayed dominant 
negative inhibition on SRE-induction (compare lanes 3 & 4 with 5 & 6 and 7 & 8, Figure 
6-2), consistent with the notion that Elk-1 monoubiquitylation exhibits dominant negative 
inhibition on SRE-induction. 
 
6.3. Lysine 35 is critical for the Elk-1 fusion derivative 
transactivation on the E74   
To facilitate efficient transactivation, Elk-1 must be able to bind to its cognate promoters as 
well as recruit other transcription mediators. The ETS-domain of Elk-1 is responsible for 
promoter binding, whereas recruitment of transcription mediators is mainly mediated by its 
transactivation domain. To focus on the role of Elk-1 monoubiquitylation on its promoter 
binding, constitutively active Elk-1 derivatives composed of the ETS-domain and the VP16 
viral transactivation domain were generated. The VP16 transactivation domain was attached 
either to the C-terminus of full length Elk-1 (Elk-1-VP16) or in place of the Elk-1 
transactivation domain (Elk-1ǻ$SD-VP16) (Kortenjann, Thomae et al. 1994). The 
luciferase reporter gene was placed under control of the E74 binding site, a stronger ETS-
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domain binding site than the SRE, to which Elk-1 is able to bind directly without SRF 
(Sharrocks 1995). Transactivational ability of the Elk-1 fusion derivatives on the E74 were 
examined using the same luciferase reporter gene assay. 
 
 
Figure 6-3 Lysine 35 is critical for the Elk-1 fusion derivative 
transactivation on the E74. Whole cell extracts from NIH3T3 
cells co-transfected with Elk-1 derivative expression vectors, 
(E74)3-OXFLIHUDVH UHSRUWHU YHFWRUV DQG ȕ-galactosidase expression 
vectors were measured by a luminometer. The ratio of 
OXFLIHUDVHȕ-galactosidase activity is presented by the bars. Data 
shown are representative of triplicate repeats of a single 
experiment with error bars representing standard deviation (n=3).    
 
The basal E74-dependent transcription in the presence of Elk-1 derivatives was low (lanes 2 
& 3, Figure 6-3), indicating that the full length Elk-1 derivatives are not transcriptionally 
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active under normal growing condition in NIH3T3 cells. The attachment of the VP16 
transactivation domain on full length Elk-1 significantly increased E74-dependent 
transcription, indicating this elevated activity was conferred by the VP16 transactivation 
domain (compare lanes 2 with 4, Figure 6-3).  
A reduced E74-mediated transcription was observed for the K35R fusion derivative 
(compare lanes 4 with 5, Figure 6-3), suggesting this residue is important for Elk-1 binding 
to the E74. The K35R derivative expressed from the pCMV5.HA expression vector exhibits 
stronger level of monoubiquitylation (compare lanes 4 with 5, upper panel, Figure 10-3) 
which led to the thought that the high level monoubiquitylation of the K35R derivative 
inhibits binding to the E74. However the K35R derivative was later shown to possess 
significantly weaker intrinsic binding to the E74 (compare lanes 3 with 6, left panel, Figure 
7-4), which suggests that the reduction in E74-mediated transcription was due to the loss of 
E74 binding, caused by the biochemical property alteration of the substitution of lysine 35 
with arginine instead of the alteration of monoubiquitylation. Furthermore, a similar 
reduction on E74-induction was observed for Elk-1 fusion derivatives lacking their own 
transactivation domain (lanes 6 & 7, Figure 6-3).  
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7. Ternary complex formation is important 
for Elk-1 monoubiquitylation  
 
Reporter gene assay data have shown that replacing lysine 35 in Elk-1 with arginine reduces 
its ability to transactivate gene expression (Chapter 6). The K35R derivative expressed from 
the pCMV5.HA expression vector exhibits stronger level of monoubiquitylation (compare 
lanes 4 with 5, upper panel, Figure 10-3), indicating Elk-1 monoubiquitylation may inhibit 
its transactivational ability. Lysine 35 is located in the ETS-domain which is responsible for 
DNA binding. Locations of lysine residues in respect to their proximity to the DNA 
interacting surface are illustrated in Figure 7-1. Although lysine 35 is situated away from the 
DNA recognition Į3 helix, it is possibly that the substitution of lysine 35 may affect its 
binding to DNA allosterically. Therefore the effects of each point mutation of individual or 
multiple lysine residues in the ETS-domain of Elk-1 on DNA binding must be examined.  
 
 
 100 
 
 
Figure 7-1 ETS/E74 binding. The 2.1Å crystal structure of the 
ETS-domain of Elk-1 bound to the E74 double-stranded 
oligonucleotide (Mo, Vaessen et al. 2000). The image was 
generated using the Cn3D software (NCBI). 
 
Elk-1 binding to DNA was examined in two contexts in which Elk-1 exhibits distinct 
binding characteristics. The first where Elk-1 cooperates with SRF to form ternary 
complexes on the SRE (Shaw 1992) and the second where Elk-1 is able to bind to the E74 
directly (Shore, Whitmarsh et al. 1996).  In addition to single or double lysine to arginine 
substitutions in Elk-1, double amino acid substitutions of R65A/Y66F and L158P/Y159A 
were introduced in Elk-1 separately. Arginine 65 and tyrosine 66 are located in the DNA 
UHFRJQLWLRQĮKHOL[ZKHUHDVOHXFLQHDQGW\URVLQHDUHVLWXDWHGLQWKH65)LQteracting 
B-domain. Mutations to these amino acids in Elk-1 were shown to disrupt its DNA or SRF 
interactions respectively and thus inhibit its binding to both the E74 and the SRE or the SRE 
alone (Ling, Lakey et al. 1997; Mo, Vaessen et al. 2000). The ability of Elk-1 derivatives to 
bind the SRE and the E74 were examined using Electrophoretic Mobility Shift Assay 
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(EMSA). Nuclear extracts containing exogenous Elk-1 derivatives were first prepared from 
HEK293 cells and examined by western blot analysis (Figure 7-2).  
 
 
Figure 7-2 Exogenous Elk-1 derivatives used in the EMSAs. 
Western blot analysis of nuclear extracts from HEK293 cells 
transfected with expression vectors encoding HA-tagged Elk-1 
derivatives. DM  and SM represent DNA and SRF binding 
defective derivative respectively. 
 
7.1. Elk-1 derivatives exhibit different binding to the SRE 
Ternary complex formation was reconstituted in vitro with [32P]-labelled double-stranded 
SRE oligonucleotide duplex; recombinant Core SRF, a minimal part of SRF required to form 
ternary complexes (Shaw 1992); and the obtained Elk-1 derivatives (Figure 7-2).  
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Figure 7-3 Elk-1 derivatives exhibit different binding ability to 
the SRE. Left: Nuclear extracts containing Elk-1 derivatives 
(Figure 7-2), [32P]-labelled, double-stranded SRE oligonucleotide 
duplex and recombinant Core SRF were incubated for 15 mins at 
room temperature. The complexes were resolved on a non-
denaturing gel and visualised by phosphor imager. Right: 
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Quantification of the level of Elk-1 derivatives binding to the SRE 
relative to the WT analysed using the Adia densitometry software.   
 
Ternary complexes containing wild type Elk-1 and Core SRF on the SRE were observed 
(lane 3, Figure 7-3). These complexes were verified by the decreased gel mobility on 
addition of antibodies against HA-tagged Elk-1 and the diminished level of SRF bound SRE 
(lane 2, Figure 7-3). As expected, the SRF binding defective derivative (SM) and DNA 
binding defective derivative (DM) were unable to form ternary complexes (lanes 4 & 5, 
Figure 7-36XEVWLWXWLRQRIHLWKHUO\VLQHRUGLVWDOIURPWKH'1$UHFRJQLWLRQĮKHOL[
reduced ternary complex formation by approximately 20 % (lanes 6 & 9, Figure 7-3). In 
FRQWUDVW WKH.5PXWDWLRQ LQWKHDGMDFHQWORRSWR WKHĮKHOL[GLPLQLVKHGWKHWHUQDU\
complex formation by almost 50% (lane 7, Figure 7-3 DQG WKH .5 PXWDWLRQ LQ WKH Į
helix significantly by over 90 % (lane 8, Figure 7-3).  
 
7.2. Elk-1 derivatives exhibit distinct binding to the E74 and the 
SRE 
To examine Elk-1 interactions with DNA directly, i.e. independent of SRF co-operative SRE 
binding, the E74 binding site was used instead of the SRE (Shaw 1992; Shore, Whitmarsh et 
al. 1996). The same source of nuclear extracts was used as the previous experiment with the 
SRE in Figure 7-3 (Figure 7-2). Elk-1 derivatives binding to the E74 were examined using 
the same EMSA.   
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Figure 7-4 Elk-1 derivatives exhibit distinct affinity to the E74, 
different from that for the SRE promoter. Left: Nuclear extracts 
containing Elk-1 derivatives (Figure 7-2), [32P]-labelled, double-
stranded E74 oligonucleotide duplex were incubated for 15 mins at 
room temperature. The complexes were resolved on a non-
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denaturing gel and visualised by phosphor imager. Right: 
Quantification of the level of Elk-1 derivatives binding to the E74 
relative to that of the WT analysed using the Adia densitometry 
software.   
 
Elk-1 derivatives exhibit different binding ability to the E74 compared to the SRE. Wild type 
Elk-1 and the SRF-binding defective derivative (SM) bound to the E74 to a similar level 
(lanes 3 & 5, Figure 7-4), whereas the DNA binding defective derivative (DM) was unable to 
bind to the E74 as expected (lane 4, Figure 7-4). Surprisingly, a single or double substitution 
of any amino-terminal lysine residues reduced Elk-1 binding to the E74 by at least 70 % 
(compare lanes with 3 with 6-9, Figure 7-4). The reductions were more severe compared to 
the SRE but retained a similar overall pattern in binding reduction, where replacing lysine 
residues close to the DNA rHFRJQLWLRQ Į KHOL[ KDG D PRUH SURPLQHQW UHGXFWLRQ LQ '1$
binding. The E74 is a stronger ETS-domain binding site compared to the SRE and it directly 
binds with the ETS-domain without SRF cooperative binding, therefore the E74 allows a 
more direct approach to examine the effect of each amino acid alteration in Elk-1 on its 
DNA binding. Although binding of the K35R and K70R derivatives to the SRE was only 
mildly weakened, significant reduction in the binding to the E74 revealed the importance of 
these residues in Elk-1 DNA binding. The different binding abilities of Elk-1 derivatives 
between the E74 and the SRE also suggest that SRF cooperative DNA binding compensate 
for the reduced binding ability when these lysine residues were replaced.  
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7.3. Ternary complex formation is essential for Elk-1 
monoubiquitylation 
Replacing any of the lysine residues 35/50/52 completely abolished Elk-1 
monoubiquitylation (Figure 5-3, Figure 5-4 & Figure 5-5), suggesting factors other than 
eliminating the ubiquitin acceptor residue may contribute to the loss of Elk-1 
monoubiquitylation. Lysine 50 and 52 are located in the major DNA interacting sites in Elk-
1 (Figure 7-1). Replacing these two residues in Elk-1 significantly reduced ternary complex 
formation on the SRE (compare lanes 3 with 7, left panel, Figure 7-3). To investigate the role 
of DNA binding on Elk-1 monoubiquitylation, exogenous Elk-1 derivatives with different 
DNA binding properties were examined using the cell-based ubiquitylation assay.  
 
 
Figure 7-5 Ternary complex formation is essential for Elk-1 
monoubiquitylation. Upper panel (IMAC): Whole cell extracts 
from HEK293 cells transfected with expression vectors encoding 
His-tagged ubiquitin and HA-tagged Elk-1 as indicated were 
subjected to IMAC under denaturing conditions. Isolated proteins 
were washed, resolved by SDS-PAGE and analysed by 
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immunoblotting with the indicated antibodies. Lower panel 
(lysate): Five percent of the whole cell extracts were resolved by 
SDS-PAGE for analysis by immunoblotting. Molecular weights 
are indicated on the right in kDa. 
 
The DNA binding defective derivative (DM), unable to interact with both the SRE and E74 
binding sites (lane 4, left panel, Figure 7-3; lane 4, left panel, Figure 7-4), was not 
monoubiquitylated (lane3, upper panel, Figure 7-5), indicating DNA binding is required for 
Elk-1 monoubiquitylation. Interestingly the SRF binding defective derivative (SM), able to 
interact with the E74 but unable to form a ternary complex on the SRE (lane 5, left panel, 
Figure 7-2; lane 5, left panel, Figure 7-3), was also not monoubiquitylated (lane 4, upper 
panel, Figure 7-5), suggesting ternary complex formation is important for Elk-1 
monoubiquitylation . 
Substitution of single or double lysine residues in the ETS-domain with arginine affected 
ternary complex formation and Elk-1 monoubiquitylation differently. Both the K35R and 
K70R derivatives possess a similar ability to form ternary complexes on the SRE as the wild 
type (compare lanes 3 with 6 & 9, left panel, Figure 7-3). The K35R derivative was not 
monoubiquitylated (lane 5, upper panel, Figure 7-5) whereas the K70R derivative was 
monoubiquitylated (lane 8, upper panel, Figure 7-5). This inhibition suggests lysine 35 is 
important for ubiquitin conjugation, possibly by serving as an ubiquitin acceptor site. 
Surprisingly the K50/52R substitution significantly weakened the ability of Elk-1 to form 
ternary complex and it was not monoubiquitylated (lane 7, upper panel, Figure 7-5), 
suggesting strong ternary complex formation is important for this modification. Moreover 
the K59R derivative, unable to form ternary complex, was not monoubiquitylated (lane 8, 
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upper panel, Figure 7-5), consistent with the notion that ternary complex formation is 
important for its monoubiquitylation.  
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8. Elk-1 monoubiquitylation is independent of 
ERK-mediated phosphorylation  
 
8.1. Elk-1 monoubiquitylation is independent of single/double 
phosphorylation sites  
Phosphorylation of proteins can create a phosphodegron, which often serves as a signal for 
E3 ligase recognition to mediate ubiquitylation (Lang, Janzen et al. 2003). Upon proteasomal 
inhibition, phosphorylated Elk-1 attained lower mobility in SDS-Page (Figure 5-1), 
suggesting phosphorylation of Elk-1 may trigger ubiquitylation-dependent proteasomal 
degradation, possibly mediated by inducible E3 ligase interactions via a phosphodegron. 
Furthermore a diminished level of phosphorylated Elk-1 coincided with co-expression of 
ubiquitin (Figure 5-2), supporting the notion that phosphorylated Elk-1 may be subjected to 
ubiquitylation-dependent proteasomal degradation. To investigate this hypothesis, serine or 
threonine residues at MAPK consensus sites in Elk-1 were substituted with alanine either 
individually or in pairs to abolish site specific phosphorylation (Gille, Kortenjann et al. 
1995). The ubiquitylation sensitivity of the Elk-1 derivatives was examined using the same 
cell-based ubiquitylation assay described in Figure 5-2. 
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Figure 8-1 Elk-1 monoubiquitylation is independent of 
single/double phosphorylation site. Upper panels (IMAC): 
Whole cell extracts from HEK293 cells transfected with 
expression vectors encoding His-tagged ubiquitin and HA-tagged 
Elk-1 derivatives as indicated were subjected to IMAC under 
denaturing conditions. Isolated proteins were washed, resolved by 
SDS-PAGE and analysed by immunoblotting with the indicated 
antibodies. Lower panels (lysate): Five percent of the whole cell 
extracts were resolved by SDS-PAGE for immunoblotting. The 
Į3-Elk antibody targets phospho-serine 383 in Elk-1.  Molecular 
weights are indicated on the right in kDa. 
 
Wild type Elk-1 and derivatives lacking either a single or double phosphorylation sites were 
all phosphorylated at serine 383 (lanes 1-6 & 8, fourth panel, Figure 8-1), except for 
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383/389A (lane 7, fourth panel, Figure 8-1). Antibodies targeting other phosphorylation sites 
in Elk-1 are not commercially available. Most Elk-1 derivatives exhibited 
monoubiquitylation levels comparable to that of the wild type (lanes 2 - 8, top panel, Figure 
8-1), except for 336A and 368A which displayed a mild reduction (lanes 3 & 6, top panel, 
Figure 8-1). However as the protein levels of these two derivatives were low compared to the 
wild type (compare lanes 1 with 3 & 6, third & fourth panels, Figure 8-1), this could explain 
the reduction in their monoubiquitylation. 
Moreover, phosphorylated Elk-1 was retrieved by IMAC, indicating that Elk-1 can be 
simultaneously monoubiquitylated and phosphorylated at serine 383 (lanes 1 - 6 & 8, second 
panel, Figure 8-1).  
Protein ubiquitylation can be triggered by active transcription, where components of the 
transcription machinery facilitate ubiquitylation of transcription activators (Chi, Huddleston 
et al. 2001). Elk-1 phosphorylation at serine 383/389 correlates with its transactivational 
ability. Inhibiting phosphorylation on these residues did not have any effect on its 
monoubiquitylation, suggesting Elk-1 transactivation is not a prerequisite for its 
monoubiquitylation (lane 7, top panel, Figure 8-1). 
 
8.2. Elk-1 monoubiquitylation is independent of ERK-mediated 
phosphorylation  
Inhibition on a single or double phosphorylation did not halt Elk-1 monoubiquitylation, 
possibly due to redundancy of adjacent phosphorylation (Figure 8-1), therefore multiple 
phosphorylation alterations may be required to elicit the potential effect on Elk-1 
monoubiquitylation sensitivity. Elk-1 is phosphorylated at multiple sites by the MAPK 
family members ERK and JNK (Gille, Kortenjann et al. 1995; Gille, Strahl et al. 1995; 
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Cruzalegui, Cano et al. 1999), dependent on two interaction sites in Elk-1, the D-domain and 
the FXFP-motif. ERK interacts with Elk-1 via both the D-domain and the FXFP-motif (Yang, 
Yates et al. 1998; Jacobs, Glossip et al. 1999), whereas JNK binds to Elk-1 via the D-domain 
only (Yang, Whitmarsh et al. 1998). Elk-1 is also phosphorylated by another MAPK p38, 
however its interaction site is currently unknown. To further elucidate the effect of Elk-1 
phosphorylation on its monoubiquitylation, either a ten amino acid deletion in the D-domain 
(amino residues 312 to 321) or a double amino acid substitution of F395L/Q396A in the 
FXFP-motif was introduced in Elk-1 individually or together, aiming to abolish its MAPK 
interaction thus multiple phosphorylations (Zhang, Vougier et al. 2010). The ubiquitylation 
sensitivity of the Elk-1 derivatives was examined using the cell-based ubiquitylation assay. 
 
               
Figure 8-2 Elk-1 monoubiquitylation is independent of ERK-
mediated phosphorylation. Upper panel (IMAC): Whole cell 
extracts from HEK293 cells transfected with expression vectors 
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encoding His-tagged ubiquitin and HA-tagged Elk-1 derivatives as 
indicated were subjected to IMAC under denaturing conditions. 
Isolated proteins were washed, resolved by SDS-PAGE and 
analysed by immunoblotting with the indicated antibodies. Lower 
panels (lysate): Five percent of the whole cell extracts were 
resolved by SDS-PAGE and analysed by immunoblotting.  
 
Elk-1 derivatives lacking either a single or double MAPK binding sites exhibit a similar 
monoubiquitylation sensitivity compared to that of the wild type (top panel, Figure 8-2), 
indicating ERK interaction is not required for Elk-1 monoubiquitylation. Elk-1 specifically 
binds to  ERK via both the FXFP-motif and the D-domain, where the FXFP-motif mediates 
phosphorylation at serine 383 and the D-domain directs phosphorylation at other sites (Fantz, 
Jacobs et al. 2001). Deletion of the D-domain slightly reduced Elk-1 phosphorylation at 
serine 383, (compare lanes 2 with 3, third panel, Figure 8-2) whereas mutation in the FXFP-
motif significantly diminished this phosphorylation (compare lanes 2 with 4 & 5, third panel, 
Figure 8-2), confirming phosphorylation at serine 383 is primarily dependent on the FXFP-
motif. It has been shown that ERK is able to phosphorylate at least six sites in Elk-1 
(Cruzalegui, Cano et al. 1999). Currently, it is difficult to distinguish Elk-1 phosphorylation 
at other sites, however unaffected monoubiquitylation sensitivity between Elk-1 and Elk-1 
derivatives that cannot interact with ERK indicates Elk-1 ubiquitylation is independent of 
ERK- mediated Elk-1 phosphorylation.  
Elk-1 interacts with JNK only via its D-domain, deleting this interaction site did not abolish 
Elk-1 monoubiquitylation, suggesting the observed Elk-1 phosphorylation at serine 383 was 
not mediated by JNK. Moreover Elk-1 appeared to be unphosphorylated when the FXFP-
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motif was replaced, supporting the notion that JNK was not responsible for Elk-1 
phosphorylation in this experiment.  
Previous experiments have ruled out the influence of specific single or double 
phosphorylation on Elk-1 monoubiquitylation (Figure 8-1) and this experiment has 
eliminated the effect of ERK-interaction and ERK-mediated Elk-1 phosphorylation on its 
monoubiquitylation (Figure 8-2). 
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9. Elk-1 monoubiquitylation is diminished in 
response to ERK activation  
 
9.1. Elk-1 monoubiquitylation is diminished post TPA stimulation 
in HeLa cells  
Protein ubiquitylation is often governed by extracellular stimuli (Gao and Karin 2005). To 
investigate the fate of monoubiquitylated Elk-1, exogenous Elk-1 was examined upon 
mitogen stimulation of HeLa cells. HeLa cells were co-transfected with expression vectors 
encoding N-terminal HA-tagged Elk-1 and N-terminal His-tagged ubiquitin. The cells were 
treated with TPA at different time intervals to induce Elk-1 phosphorylation and hence 
activation, the impact on Elk-1 ubiquitylation was examined using the cell-based 
ubiquitylation assay as described in Figure 5-2. 
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Figure 9-1. Elk-1 monoubiquitylation is diminished post TPA 
stimulation in HeLa cells. HeLa cells were transfected with 
expression vectors encoding His-tagged ubiquitin and HA-tagged 
Elk-1 as indicated, before being serum starved for 24 hours and 
stimulated with TPA for the indicated times. Upper panel (IMAC): 
Whole cell extracts from the cells were subjected to IMAC under 
denaturing conditions. Isolated proteins were washed, resolved by 
SDS-PAGE and analysed by immunoblotting. Lower panels 
(lysate): Five percent of the whole cell extracts were resolved by 
SDS-PAGE for analysis by immunoblotting.  
 
Under serum starvation, Elk-1 monoubiquitylation was at its peak level (lane 2, upper panel, 
Figure 9-1), whilst the basal Elk-1 phosphorylation at serine 383 was low (lane 2, second 
panel, Figure 9-1). With TPA stimulation, Elk-1 monoubiquitylation gradually declined 
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(lanes 2 - 6, upper panel, Figure 9-1), while its phosphorylation was elevated and remained 
stable after 120 mins (lanes 2 - 6, second panel, Figure 9-1). Phosphorylation at serine 383 
corresponds to Elk-1 transactivation (Gille, Kortenjann et al. 1995). This inverse correlation 
of Elk-1 phosphorylation and monoubiquitylation suggests Elk-1 activation, or Elk-1 
phosphorylation per se, may be able to alter its interactions with ubiquitin enzymes (either 
E3 ligase or deubiquitylase), resulting in the net loss of Elk-1 monoubiquitylation. 
Alternatively, TPA-induced kinase activation may alter the catalytic activities of Elk-1 
specific ubiquitin enzymes via phosphorylation, resulting in the diminished level of Elk-1 
monoubiquitylation.  
ERK is the best characterised kinase for Elk-1 and it is activated by phosphorylation (Crews, 
Alessandrini et al. 1992). ERK phosphorylation was elevated upon TPA stimulation and 
gradually declined (fourth panel, Figure 9-1), which does not completely correlate to the 
sustained Elk-1 phosphorylation (compare second panel with fourth panel, Figure 9-1). 
Besides ERK activation, TPA also activates another MAPK, JNK, which can in turn 
phosphorylate and activate Elk-1 (Soh, Lee et al. 1999). It is possible that other kinases may 
be activated by TPA in this experiment and Elk-1 may be phosphorylated by those kinases. It 
is clear that the level of Elk-1 monoubiquitylation is diminished in response to TPA 
stimulation in HeLa cells. To determine which signal pathway was responsible for the 
observed loss of Elk-1 monoubiquitylation in the above experiment, the role of ERK was 
examined in Figure 9-2.  
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9.2. The loss of Elk-1 monoubiquitylation is rescued by ERK 
inhibition      
To examine whether the loss of Elk-1 monoubiquitylation was caused by ERK-activation, an 
inhibitor (U0126) was used to inhibit specifically the ERK pathway, aiming to abolish ERK-
mediate phosphorylation to rescue Elk-1 monoubiquitylation. U0126 is a specific inhibitor 
for MEK, the upstream activator for ERK. Elk-1 can also be phosphorylated by stress-
induced MAPKs, JNK and p38. To show Elk-1 phosphorylation is mainly mediated by ERK, 
an inhibitor specific for the p38 pathway (SB202190) was used as a negative control. HeLa 
cells were treated with MAPK inhibitors and TPA for an hour, when significant loss of Elk-1 
ubiquitylation was observed (upper panel, Figure 9-1). Elk-1 monoubiquitylation was 
examined using the same cell-based ubiquitylation assay. 
 
 
 119 
 
Figure 9-2 Elk-1 monoubiquitylation is rescued by ERK 
inhibitor post TPA stimulation. HeLa cells transfected with 
expression vectors encoding His-tagged ubiquitin and HA-tagged 
Elk-1 as indicated were serum starved for 24 hours and treated 
with TPA and MAPK inhibitors for one hour as indicated. Upper 
panel (IMAC): Whole cell extracts from those cells were subjected 
to IMAC under denaturing conditions. Isolated proteins were 
washed, resolved by SDS-PAGE and analysed by immunoblotting. 
Lower panels (lysate): Five percent of the whole cell extracts were 
resolved by SDS-PAGE for analysis by immunoblotting.  
 
Under serum starvation, Elk-1 phosphorylation was minimal and significantly elevated 
phosphorylation was observed one hour post-TPA stimulation (compare lanes 2 with 7, 
second panel, Figure 9-2), whereas Elk-1 monoubiquitylation level was reduced as expected 
(compare lanes 2 with 7, top panel, Figure 9-2). Interestingly, the reduction of 
monoubiquitylation was rescued by the addition of U0126 (compare lanes 2 & 7 with 3 & 8, 
top panel, Figure 9-2) as Elk-1 phosphorylation remained at basal level (lanes 3 & 8, second 
panel, Figure 9-2), suggesting the reduction of Elk-1 monoubiquitylation and elevated Elk-1 
phosphorylation was specifically facilitated by ERK. Addition of the p38-MAPK inhibitor 
did not affect Elk-1 phosphorylation or monoubiquitylation level (compare lanes 7 with 9, 
top and second panels, Figure 9-2), eliminating the role of p38 in TPA-induced Elk-1 
phosphorylation in HeLa cells.  
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9.3. Monoubiquitylated Elk-1 is diminished post ERK-mediated 
phosphorylation  
Loss of Elk-1 monoubiquitylation was observed following ERK-mediated activation (Figure 
9-1 & Figure 9-2), however it is uncertain how Elk-1 monoubiquitylation was diminished. 
The decline of monoubiquitylated Elk-1 could be explained by four possible causes: 1) 
monoubiquitylated Elk-1 can be deubiquitylated, triggered by either Elk-1 activation or 
ERK-activated deubiquitylase activity; 2) Elk-1 can be deubiquitylated constitutively, TPA 
stimulation reduces Elk-1 specific E3 ligase activity, resulting in the net loss of Elk-1 
monoubiquitylation; 3) the conjugated ubiquitin on Elk-1 can be elongated to generate an 
ubiquitin polymer for proteolysis or 4) monoubiquitylated Elk-1 can be polyubiquitylated at 
another lysine different from the monoubiquitylation site. To understand the basis of the loss 
of Elk-1 monoubiquitylation post ERK-mediated activation, an ubiquitin derivative (Ub.K0) 
was used to prevent polyubiquitin chain formation and proteolysis, therefore distinguishing 
if the reduction of Elk-1 monoubiquitylation was due to proteolysis (possible causes 3 & 4). 
All the lysine residues in this ubiquitin derivative were replaced by arginine to prevent self 
conjugation, acting as a chain terminator. Elk-1 was co-expressed with either the wild type 
(Ub) or the lysine-less ubiquitin (Ub.K0), its monoubiquitylation was examined at different 
TPA stimulation intervals using the cell-based ubiquitylation assay. 
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Figure 9-3. Monoubiquitylated Elk-1 is deubiquitylated post 
TPA-induced ERK-mediated phosphorylation. HeLa cells were 
transfected with expression vectors encoding HA-tagged Elk-1, 
His-tagged ubiquitin (Ub) or His-tagged lysine-less ubiquitin 
(Ub.K0) as indicated, before being serum starved for 24 hours and 
treated with TPA for times indicated. Upper panel (IMAC): Whole 
cell extracts from the cells were subjected to IMAC under 
denaturing conditions. Isolated proteins were washed, resolved by 
SDS-PAGE and analysed by immunoblotting. Lower panels 
(lysate): Five percent of the whole cell extracts were resolved by 
SDS-PAGE for analysis by immunoblotting. 
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As expected, Elk-1 monoubiquitylation declined upon TPA stimulation (lanes 2 - 5, top 
panel, Figure 9-3), in inverse correlation with Elk-1 phosphorylation as previously observed 
in Figure 9-1 (lanes 2 – 5, second panel, Figure 9-3). Interestingly, a similar result was 
obtained when wild type ubiquitin (Ub) was replaced with lysine-less ubiquitin (Ub.K0) 
(lanes 7 - 10, Figure 9-3). Given that polyubiquitylation was prevented by Ub.K0, Elk-1 
monoubiquitylation would be retained if it was normally lost by polyubiquitylation and 
proteolysis following ERK-mediated activation. Moreover, the monoubiquitylated Elk-1 
retrieved by IMAC consisted of His-tagged Ub.K0 which could not be extended. Therefore 
this result indicates that monoubiquitylated Elk-1 is not destined to degradation. However it 
remains uncertain whether the reduction of Elk-1 monoubiquitylation is caused by the 
increased activity of Elk-1 specific deubiquitylase or by the combination of the reduced 
activity of Elk-1 specific E3 ligase and the constitutive Elk-1 specific deubiquitylase activity. 
Intriguingly, phosphorylated Elk-1 was stabilized in the presence of Ub.K0 (compare lanes 3 
– 5 with 8 - 10, second panel, Figure 9-3), suggesting that Elk-1 phosphorylation leads to its 
degradation and coinciding with the previous observation that MG132 stabilizes 
phosphorylated Elk-1 (compare lanes 2 & 3 with 5 & 6, second panel, Figure 5-1).  
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10. N-terminal HA tag influences Elk-1 
monoubiquitylation  
 
10.1. The Ternary complex family member Net is ubiquitylated  
Elk-1 was shown to be monoubiquitylated both in vitro and in cells (chapters 4 & 5). Elk-1 
shares many structural and regulatory similarities with family members of the ternary 
complex factor (TCF), Sap-1a and Net (Shaw and Saxton 2003; Buchwalter, Gross et al. 
2004). It is conceivable that Sap-1a and Net may also be subjected to monoubiquitylation. 
To investigate this hypothesis, a similar experiment was performed as described in Figure 
5-2. HEK293 cells were co-transfected with expression vectors encoding N-terminal HA-
tagged TCF and N-terminal His-tagged ubiquitin. The ubiquitylation sensitivity of 
exogenous Net and Sap-1a were examined using the same cell-based ubiquitylation assay. 
In previous experiments, Elk-1 protein was generated from the pcDNA3.HA expression 
vector, which contains the T7 promoter for in vitro protein expression (chapter 4) and the 
CMV promoter for exogenous protein expression in mammalian cells (chapters 5, 7, 8 & 9). 
Sap-1a and Net were expressed from a different vector, pCMV5.HA, which utilizes the same 
CMV promoter to mediate protein expression in mammalian cells, but lacks the T7 promoter.  
To ensure consistency, Elk-1 was also expressed from the pCMV5.HA vector. All TCF 
proteins contain an N-terminal HA-tag. 
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Figure 10-1 Sap-1 and Net are ubiquitylated in HEK293 cells.  
Upper panel (IMAC): Whole cell extracts from HEK293 cells 
transfected with expression vectors encoding HA-tagged TCFs 
and His-tagged ubiquitin as indicated were subjected to IMAC 
under denaturing conditions. Isolated proteins were washed, 
resolved by SDS-PAGE and analysed by immunoblotting with 
the indicated antibodies. Lower panels (lysate): Five percent of 
the whole cell extracts were resolved by SDS-PAGE for 
analysis by immunoblotting. The Įactin immunoblot was 
SUHYLRXVO\XVHGIRUĮ+$LPPXQREORWWLQJ 
 
The 453 amino acid Sap-1a appeared as two species with molecular weights of 
approximately 65 and 62 kDa (lane 3, second panel, Figure 10-1). The lower molecular 
weight species was more abundant than the higher species. It is uncertain why Sap-1a 
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appeared as two species; however the N-terminal HA tag on Sap-1a eliminates the possibility 
of internal transcription initiation. It may have arisen from premature termination of 
transcription or post-translational modification of Sap-1a protein. Ubiquitylated protein was 
retrieved by IMAC and located at 80 kDa (lane 3, top panel, Figure 10-1). The approximate 
20 kDa molecular weight increase indicates a possible attachment of two ubiquitins to Sap-
1a. The level of the retrieved ubiquitylated protein was low and proteins with similar size 
were retrieved in all other lanes (lanes 1, 2 & 4, top panel, Figure 10-1). Without an 
appropriate negative control (an experiment without exogenous expression of TCF), it is 
difficult to verify the retrieved ubiquitylated species represent ubiquitylated Sap-1a.  
The 409 amino acid Net also appeared as a duplex with molecular weights of 54 and 52 kDa 
respectively (lane 4, second panel, Figure 10-1). The abundance of the two species was 
similar. Ubiquitylated Net appeared in a smear from 56 kDa to 130 kDa, indicating Net was 
ubiquitylated with different ubiquitin moieties (lane 4, top panel, Figure 10-1).  
Elk-1 was monoubiquitylated as previously observed in Figure 5-2 (lane 2, top panel, Figure 
10-1). Surprisingly, the K35R derivative was also monoubiquitylated (lane 1, top panel, 
Figure 10-1), which contradicts the previous observations (Figure 5-5 & Figure 7-5). Elk-1 
was generated from a different expression vector in this experiment compared to the 
previous experiments. This prompted the investigation of the difference between the two 
HA-tag Elk-1 proteins expressed from either pcDNA3.HA or pCMV5.HA on their 
monoubiquitylation.  
 
10.2.  N-terminal HA tag influences Elk-1 monoubiquitylation  
The coding sequence of the N-terminal HA tag was grafted differently to Elk-1 in the two 
expression vectors, resulting in a different linker region (Figure 10-2). It appeared that the 
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two HA-tagged Elk-1 lacking lysine 35 exhibit distinct monoubiquitylation sensitivity 
(Figure 5-5, Figure 7-5 & Figure 10-1). To confirm this observation, either HA-tagged or 
untagged Elk-1 derivatives were examined in HEK293 cells using the cell-based 
ubiquitylation assay. 
 
 
Figure 10-2 Schematic representation of a different linker 
region between the HA-tag and Elk-1. 
 
 
Figure 10-3 N-terminal HA-tag in Elk-1 derivatives alter 
their monoubiquitylation sensitivity. Upper panel (IMAC): 
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Whole cell extracts from HEK293 cells transfected with 
expression vectors encoding HA-tagged TCF and His-tagged 
ubiquitin as indicated were subjected to IMAC under denaturing 
conditions. Isolated proteins were washed, resolved by SDS-
PAGE and analysed by immunoblotting with the indicated 
antibodies. Lower panels (lysate): Five percent of the whole cell 
extracts were resolved by SDS-PAGE for analysis by 
immunoblotting. 
 
Wild type Elk-1 expressed from the pcDNA3.HA vector was monoubiquitylated, whereas 
the K35R derivative from the same vector was not monoubiquitylated as previously 
observed in Figure 5-5 & Figure 7-5 (lanes 2 & 3, upper panel, Figure 10-3). Although the 
K35R derivative protein level was relatively low compared to that of the wild type (compare 
lanes 2 with 3, second panel, Figure 10-3), previous experiments have clearly demonstrated 
the loss of monoubiquitylation was caused by the replacement of lysine 35 in this HA-tagged 
Elk-1 derivatives (Figure 5-5 & Figure 7-5).  
Both wild type and the K35R derivative expressed from the pCMV5.HA vector were 
monoubiquitylated as obesrved in Figure 10-1 (lanes 4 & 5, upper panel, Figure 10-3). The 
monoubiquitylation level of the wild type was slightly lower than that of the K35R 
derivative (compare lanes 4 with 5, upper panel, Figure 10-3). Similar to this, untagged Elk-
1 expressed from the pCMV5 vector exhibited a lower monoubquitylation level that 
increased significantly with the K35R substitution (compare lanes 6 with 7, upper panel, 
Figure 10-3).  
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The only difference between the two N-terminal tagged HA-tagged Elk-1 is the linker 
connecting the HA tag and Elk-1 protein. It is not certain why different linker contributes to 
the different monoubiquitylation sensitivity. The HA tag is attached to the N-terminus and 
different linkers may position the HA tag differently. Several lysine residues in Elk-1  (K35, 
K50, K52, K70, K75 & K84) are located close to the N-terminus (Figure 7-1). It is possible 
that the N-terminal linked HA tag can mask the ubiquitin acceptor residue, therefore 
influencing Elk-1 monoubiquitylation.   
Elk-1 monoubiquitylation is dependent on ternary complex formation at the SRE (Figure 7-5 
& Figure 10-6), therefore this modification must be carried out in the nucleus. However the 
linker region does not contain any obvious nuclear localisation or export signals. 
Nevertheless the above experiments have clearly demonstrated distinct monoubiquitylation 
sensitivity between the two N-terminal HA-tagged Elk-1 derivative expressed from different 
vectors.  
 
10.3. Confirmation of the reduction of Elk-1 monoubiquitylation 
post ERK activation  
Untagged Elk-1 is physiologically relevant compared to those with an immuno-tag 
attachment. Elk-1 was generated from the pcDNA3.HA expression vector in previous 
experiments and its N-terminal HA tag influences its  monoubiquitylation sensitivity (Figure 
10-3). To verify the previous observation that Elk-1 monoubiquitylation is diminished post 
ERK-mediated activation, exogenous untagged Elk-1 was examined using the same cell-
based ubiquitylation assay. The experiment was performed as descibed in Figure 9-3, except 
for the replacement of the Elk-1 expression vector from pcDNA3.HA.Elk with pCMV5.Elk.  
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Figure 10-4 Verification of the reduction of Elk-1 
monoubiquitylation post ERK-mediated phosphorylation. 
HeLa cells were transfected with expression vectors encoding 
untagged Elk-1, His-tagged ubiquitin (Ub) or His-tagged lysine-
less ubiquitin (Ub.K0) as indicated, before serum starved for 24 
hours and treated with TPA for the times indicated. Upper panel 
(IMAC): Whole cell extracts from the cells were subjected to 
IMAC under denaturing conditions. Isolated proteins were washed, 
resolved by SDS-PAGE and analysed by immunoblotting. Lower 
panels (lysate): Five percent of the whole cell extracts were 
resolved by SDS-PAGE for analysis by immunoblotting.  
 
Untagged-Elk-1 expressed from the pCMV5 vector exhibited weaker monoubiquitylation 
level compared to those expressed from either the pcDNA3.HA or the pCMV5 vectors 
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(compare lanes 6 with 2 & 4, upper panel, Figure 10-3), which renders it harder to detect. 
Despite this downside, a reasonable level of untagged Elk-1 monoubiquitylation can still be 
detected (lane 2, top panel, Figure 10-4). Elk-1 monoubiquitylation was diminished upon 
mitogen stimulation with inverse correlation to ERK-mediated phosphorylation (lanes 2 - 5, 
top and second panels, Figure 10-4), consistent with the previous observation in Figure 9-1. 
Moreover, the level of Elk-1 monoubiquitylation was reduced in the presence of Ub.K0 upon 
TPA stimulation (lanes 6 - 10, top panel, Figure 10-4), again consistent with the idea that 
monoubiquitylated Elk-1 is not destined to degradation following TPA stimulation as 
previously observed (Figure 9-3).  
 
10.4. Mapping of untagged Elk-1 monoubiquitylation site  
Distinct monoubiquitylation sensitivity was observed on the K35R derivative with the 
differently attached N-terminal HA tag (Figure 10-4), suggesting lysine 35 is not the 
ubiquitin acceptor site in untagged Elk-1. To map the bona fide ubiquitin acceptor, the same 
approach to Figure 5-3 was used. Lysine residues were replaced with arginine residues in 
combination, aiming to abolish Elk-1 monoubiquitylation by eliminating the ubiquitin 
acceptor residue. The monoubiquitylation sensitivity of Elk-1 derivatives was examined 
using the cell-based ubiquitylation assay. HEK293 cells were initially used in the previous 
mapping experiments because of their high transfection efficiency (chapter 5.3), however 
Elk-1 was constitutively active in HEK293 cells. Functional studies of later experiments 
were performed using HeLa cells (chapter 9), in which Elk-1 activation can be manipulated. 
To ensure consistency, HeLa cells were used instead of HEK293 cells in the following 
mapping experiments.   
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Figure 10-5 Verification of Elk-1 monoubiquitylated in the 
ETS-domain. Upper panel: Whole cell extracts from HeLa cells 
transfected with expression vectors encoding untagged Elk-1 
derivatives and His-tagged ubiquitin as indicated were subjected to 
IMAC under denaturing conditions. Isolated proteins were washed, 
resolved by SDS-PAGE and analysed by immunoblotting with the 
indicated antibodies. Lower panels: Five percent of the whole cell 
extracts were resolved by SDS-PAGE for analysis by 
immunoblotting.  
 
The protein levels of Elk-1 derivatives were different in HeLa cells (lanes 2 – 5, second 
panel, Figure 10-5), compared to those in HEK293 cells (chapter 5.3). The NTR8 derivative 
protein level was slightly lower compared to the wild type (compare lanes 2 with 4, second 
panel, Figure 10-5), whereas the R10 derivative protein level was relatively high (compare 
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lanes 2 with 5, second panel, Figure 10-5). One obvious explanation for this observation 
would be that lysine substitutions removed a polyubiquitylation site important for proteolysis, 
however the protein level of the R18 derivative lacking all lysine residues was comparable to 
the wild type. It is uncertain why these two Elk-1 derivatives exhibit different protein levels. 
Wild type Elk-1 was weakly monoubiquitylated as previously observed in Figure 10-3 (lane 
2, top panel, Figure 10-5), whereas the R18 derivative was not monoubiquitylated (lane 3, 
top panel, Figure 10-5). The R10 derivative, containing only the lysine residues in the ETS-
domain, was strongly monoubiquitylated compared to the wild type (compare lanes 2 with 5, 
top panel, Figure 10-5), suggesting the acceptor site is situated in the ETS-domain. It is 
worth noting that the protein level of the R10 derivative was relatively high (compare lanes 2 
with 5, second panel, Figure 10-5) which could contributes to the stronger level of Elk-1 
monoubiquitylation.  Replacing all the lysine residues in the ETS-domain in the NTR8 
derivative completely abolished monoubiquitylation (lane 4, top panel, Figure 10-5), 
consistent with the notion that Elk-1 is monoubiquitylated within the ETS-domain.  
 
10.5. Untagged Elk-1 monoubiquitylation is dependent on ternary 
complex formation.  
To verify Elk-1 monoubiquitylation is dependent on ternary complex formation, a similar 
approach was used as described in Figure 7-5. Double amino acid mutations were introduced 
into Elk-1, aiming to inhibit its interactions with the SRE and hence inhibit ternary complex 
formation. The DNA binding (DM) and the SRF binding (SM) defective derivative contains 
the double mutations of R65A/Y66F and L158P/Y159A respectively. Their 
monoubiquitylation sensitivity was examined using the cell-based ubiquitylation assay. 
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Figure 10-6 Verification of Elk-1 monoubiquitylation is 
dependent on ternary complex formation. Upper panel (IMAC): 
Whole cell extracts from HeLa cells transfected with expression 
vectors encoding HA-tagged Elk-1 derivatives and His-tagged 
ubiquitin as indicated were subjected to IMAC under denaturing 
conditions. Isolated proteins were washed, resolved by SDS-PAGE 
and analysed by immunoblotting with the indicated antibodies. 
Lower panels (lysate): Five percent of the whole cell extracts were 
resolved by SDS-PAGE for analysis by immunoblotting. DM  and 
SM represent DNA and SRF binding defective derivative 
respectively.  
 
Replacing critical DNA binding residues in Elk-1 abolished its monoubiquitylation (lane 3, 
upper panel, Figure 10-6), indicating that DNA binding is essential for Elk-1 
monoubiquitylation. Inhibiting ternary complex formation by abolishing SRF interaction 
also inhibited Elk-1 monoubiquitylation (lane 4, upper panel, Figure 10-6), consistent with 
the previous observation that ternary complex formation is critical for Elk-1 
monoubiquitylation (Figure 7-5). Although the N-terminal HA-tag influences the acceptor 
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site for Elk-1 monoubiquitylation, it does not appear to affect the regulation and other 
determinants of this modification.  
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11. Discussion 
 
MAPK signalling pathways relay extracellular signals to the nucleus, where ternary complex 
factors (TCFs) are among their primary nuclear targets. The ternary complex factor Elk-1 is 
subjected to several post-translational modifications. Elk-1 phosphorylation potentiates its 
transactivational ability (Gille, Sharrocks et al. 1992; Janknecht, Ernst et al. 1993; Marais, 
Wynne et al. 1993; Gille, Kortenjann et al. 1995), whereas sumoylation represses it (Yang, 
Jaffray et al. 2003; Yang and Sharrocks 2004). It has also been shown that Elk-1 is 
ubiquitylated in vitro (Fuchs, Xie et al. 1997), however little work has been done on Elk-1 
ubiquitylation.  
This thesis has provided some insights into Elk-1 ubiquitylation. Several features of the Elk-
1 specific E3 ligases have been revealed. It has also demonstrated that Elk-1 can be either 
monoubiquitylated or polyubiquitylated, where ternary complex formation at the SRE is 
important for monoubiquitylation. A strongly monoubiquitylated Elk-1 derivative was 
shown to exhibit reduced capability to transactivate gene expression at the SRE. Furthermore 
monoubiquitylated Elk-1 is diminished, triggered by ERK-mediated phosphorylation, hence 
activation. By investigating the regulation and function of Elk-1 monoubiquitylation, a 
clearer understanding can be drawn for Elk-1 mediated transcription, hereby providing a 
paradigm for signal-induced gene expression control.  
 
11.1.  Is Elk-1 ubiquitylated by multiple E3 ligases? 
E3 ligases play a pivotal role in ubiquitylation by selecting substrates. E3 ligase activity 
specific for Elk-1 polyubiquitylation was detected in both HEK293 whole cell extracts and 
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HeLa cytosolic extracts in vitro (Figure 4-1 & Figure 4-3). Although the E3 ligase(s) 
responsible for this modification remains unknown, some features of Elk-1 specific E3 
ligase(s) have been revealed. Cullin RING Ligases (CRLs) comprise the largest group of E3 
ligases and neddylation is required for their activity (Podust, Brownell et al. 2000; Read, 
Brownell et al. 2000; Wu, Chen et al. 2000). Inhibition of neddylation by DN Ubc12 
significantly reduced Elk-1 polyubiquitylation in vitro (Figure 4-7), indicating that at least 
one E3 ligase specific for Elk-1 polyubiquitylation is a CRL. A single substrate can be 
targeted by multiple ligases, as exemplified by the case of p53 (Brooks and Gu 2006) and 
different ligases often facilitate distinct ubiquitin attachments at different acceptor sites. Elk-
1 monoubiquitylation levels remained unchanged in the presence of DN Ubc12 (Figure 4-7), 
suggesting that Elk-1 monoubiquitylation is facilitated by an E3 ligase other than a CRL. In 
addition, chromatographic separation of HeLa cytosolic extract revealed that the size of a 
Elk-1 specific E3 ligase is approximately between 29 and 50 kDa (Figure 4-4 & Figure 4-5), 
which is too small for a CRL that typically consists of a cullin (~776a.a.), a RING (~108 
a.a.), an adaptor (~163a.a.) and substrate recognition unit (430 to >1000 a.a.) with an 
approximate size of >200kDa (Zheng, Schulman et al. 2002). This is consistent with the idea 
that Elk-1 mono- and polyubiquitylation are facilitated by different E3 ligases. E3 ligases for 
the same substrate can be situated in distinct subcellular locations, for example in either the 
cytosol  or the nucleus (Kamura, Hara et al. 2004). From the above observations, it is 
conceivable that Elk-1 is regulated by multiple E3 ligases, where Elk-1 ubiquitylation is 
mediated by a CRL in the nucleus and by an E3 ligase other than a CRL, in the cytosol.  
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11.2. Patterns of Elk-1 ubiquitylation 
11.2.1. Elk-1 polyubiquitylation  
Elk-1 was monoubiquitylated and polyubiquitylated both in vitro (Chapter 4) and in cells 
(Chapter 5). Polyubiquitylated Elk-1 appeared at ~300 kDa in vitro (Figure 4-1, Figure 4-3, 
Figure 4-4, Figure 4-5 & Figure 4-7), indicating an attachment of around 30 units of 
ubiquitins (Elk-1 and ubiquitin are 62 kDa and 8 kDa respectively). In contrast, Elk-1 
polyubiquitylation appeared as smear from 72 kDa to > 300 kDa in HEK293 cells (Figure 
5-1). The cause of this different observation of Elk-1 polyubiquitylation is uncertain. 
Ubiquitylation is a continuous process in cells, which could be reversed by deubiquitinases 
(Komander, Clague et al. 2009). The addition of ubiquitin enzymes in the in vitro assay may 
shift the balance between ubiquitylation and deubiquitylation. Moreover both processes are 
tightly regulated by extracellular stimuli, for example: cytokine-induced phosphorylation of 
the deubiquitinase CYLD inhibits its activity (Reiley, Zhang et al. 2005), whereas   
phosphorylation of the E3 ligase Itch by JNK activates its activity in cells under stress 
stimuli (Gallagher, Gao et al. 2006). Monoubiquitylated Elk-1 is deubiquitylated following 
mitogen-induced activation (Figure 9-3 & Figure 10-4), suggesting an Elk-1 specific 
deubiquitinases(s) is also regulated by extracellular stimuli. In the absence of appropriate 
stimuli, the balanced activity between E3 ligases and deubiquitinases could be inclined 
toward to one side. 
Ubiquitin can be self-conjugated via any of its seven lysine residues to form ubiquitin 
polymers with distinct linkage, which confer different activities to the attached proteins. It 
has been shown that a minimal chain of four ubiquitins via lysine 48 is sufficient to induce 
proteasome-mediated proteolysis (Thrower, Hoffman et al. 2000), whereas 
polyubiquitylation via lysine 63 linkage can lead to non-proteolytic functions, such as 
protein complex assembly (Hofmann and Pickart 1999; Deng, Wang et al. 2000). The 
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linkage of the observed ubiquitin polymer on Elk-1 is unknown. To unequivocally define the 
role of Elk-1 polyubiquitylation, the linkage of Elk-1 polyubiquitylation must be identified. 
Currently, several techniques can be employed to study ubiquitin chain linkage (Volk, Wang 
et al. 2005). Mass spectrometry has served as a powerful tool to investigate the “ubiquitome”, 
i.e. linkage specificity of the total ubiquitylated protein population (Peng, Schwartz et al. 
2003; Xu, Duong et al. 2009), as well as linkage specificity of individual proteins. For 
example, this technique has revealed  that lysine 48- and  lysine 29-linked polyubiquitylation 
by the HECT-domain ligase KIAA10 (Wang, Cheng et al. 2006) and the lysine 6 linkage by 
the RING-domain ligase BRCA1 (Nishikawa, Ooka et al. 2004). In addition, ubiquitin 
derivatives with lysine to arginine substitutions have also been used to provide insights into  
lysine 63-linked polyubiquitylation in IKK activation (Deng, Wang et al. 2000) and 
LUBAC-mediated linear ubiquitin chain (Kirisako, Kamei et al. 2006). Recently, linkage-
specific antibodies against lysine 48-, lysine 63-linked and linear ubiquitin polymer have 
been developed (Newton, Matsumoto et al. 2008; Wang, Matsuzawa et al. 2008; Tokunaga, 
Sakata et al. 2009). Although linkage specificity for Elk-1 polyubiquitylation remained 
undefined, phosphorylated Elk-1 was stabilized when the 26S proteasome was inhibited 
(Figure 5-1), suggesting at least one role of Elk-1 polyubiquitylation is to direct Elk-1 for 
destruction. 
  
11.2.2. Elk-1 monoubiquitylation  
Elk-1 was conjugated with a single ubiquitin in vitro (Figure 4-7) and in both HEK293 and 
HeLa cells (Figure 5-2, Figure 9-1 & Figure 10-3). Albeit up to three ubiquitin attachments 
can be detected in these cells, Elk-1 was conjugated predominantly with a single ubiquitin 
(Figure 5-3, Figure 5-4 & Figure 5-5). E3 ligase activity specific for Elk-1 
monoubiquitylation was detected in HEK293 whole cell extracts in vitro (Figure 4-7), but 
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not in HeLa cytosolic extracts (Figure 4-3), suggesting the E3 ligase for this modification is 
located in the nucleus. This was later verified by another member of the group (Jürgen 
Handwerger), where E3 ligase activity specific for Elk-1 monoubiquitylation was detected in 
HeLa nuclear extracts using the in vitro assay. Moreover ternary complex formation is 
important for Elk-1 monoubiquitylation in both HEK293 and HeLa cells (Figure 7-5 & 
Figure 10-6), consistent with the notion that the E3 ligase specific for Elk-1 
monoubiquitylation is located in the nucleus.  
 
11.3. Elk-1 monoubiquitylation acceptor site  
To investigate the role of Elk-1 monoubiquitylation, the ubiquitin acceptor site must be 
identified. An initial attempt indicated that three amino-terminal lysines 35, 50 and 52 are 
critical for this modification of HA-tagged Elk-1 expressed from the pcDNA3.HA vector 
(Figure 5-5). This requirement of all three lysines for Elk-1 monoubiquitylation cannot be 
explained simply by the elimination of the ubiquitin acceptor residues. These three lysine 
residues are located in the ETS-domain (Figure 7-1), where O\VLQH OLHV LQ WKHȕVWUDQG
and lysines 50/5OLHLQWKHORRSEHWZHHQWKHĮDQGWKHĮ helices. Each of those residues 
contribute to ternary complex formation at the SRE to different extents (Figure 7-3). 
Replacing lysine 35 with arginine had little effect on ternary complex formation (Figure 7-3), 
whereas replacing lysines 50 and 52 reduced complex formation by ~50%. It was later 
shown that ternary complex formation is important for Elk-1 monoubiquitylation (Figure 
7-5), which provides an explanation for the absolute requirement of all three lysines for Elk-
1 monoubiquitylation. For the HA-tagged Elk-1 expressed from the pcDNA3.HA vector, 
replacement of both lysines 50 and 52 inhibited Elk-1 monoubiquitylation by disrupting its 
ternary complex formation (Figure 5-5), whereas the replacement of lysine 35 eliminated the 
ubiquitin acceptor site of this HA-tagged Elk-1.  
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Elk-1 is a member of the ternary complex factor family and lysine 35 is conserved among 
family members, Sap-1a and Net, which led to the investigation of whether the same lysine 
also serves as an ubiquitin acceptor site in these two ternary complex factors. A pilot 
experiment to examine if Sap-1a and Net are ubiquitylated in HEK293 cells (Figure 10-1) 
revealed that HA-tagged Elk-1 with a different linker expressed from the pCMV5.HA vector 
exhibits different monoubiquitylation sensitivity. In this case, replacing lysine 35 did not 
abolish Elk-1 monoubiquitylation, indicating that ubiquitin is not conjugated to lysine 35 of 
the HA-tagged Elk-1 expressed from the pCMV5.HA vector, inconsistent with the previous 
observation that lysine 35 is the monoubiquitylation site in the HA-tagged Elk-1 expressed 
from the pcDNA3.HA vector (Figure 5-5, Figure 10-1 & Figure 10-3). Moreover, the K35R 
derivative expressed from the pCMV5.HA vector appeared to be monoubiquitylated more 
strongly compared to the wild type and the same effect was also observed with untagged 
Elk-1. 
The only difference between the two HA-tagged Elk-1 is the linker connecting the HA tag to 
Elk-1 (Figure 10-2). Both linkers do not contain amino acid residues which may have an 
obvious influence on ubiquitylation or protein subcellular location, such as groups of 
positive-charged lysine and arginine or patterns of hydrophobic residues that are normally 
found in a nuclear localisation or an export signal. Therefore it is unlikely that the residues in 
these two linkers affect ubiquitylation directly or through restriction of subcelluar location. 
However the linkers may affect Elk-1 monoubiquitylation indirectly by determining the 
spatial position of the HA tag. The location of lysine 35 LQWKHȕVWUDQGLVFORVHWRWKH1-
terminal HA tag, so it is possible that the different linkers could position the HA tag 
differently, in turn restricting the availability of different lysine residues and resulting in a 
change in the preference of the acceptor site for Elk-1 monoubiquitylation. Lysines 35, 75 80 
and 84 are located in proximity (Figure 11-1), where the side chains of lysines 35, 80 and 84 
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are all equally accessible, but not the side chain of lysine 75 which is hidden inside the ETS-
domain. Restricted accessibility of one ubiquitin acceptor may lead to increased modification 
of other lysines.  
 
 
Figure 11-1 ETS/DNA binding. The 2.1Å crystal structure of the 
ETS-domain of Elk-1 bound to the E74 double-stranded 
oligonucleotides (Mo, Vaessen et al. 2000). The image was 
generated using the Cn3D software (NCBI). The ETS-domain is in 
light grey. lysines 35, 75 , 80 and 84 are in yellow. The E74 duplex 
is in purple and dark blue.  Carbon, oxygen and nitrogen atom are 
in light grey, red and light blue respectively   
 
To avoid the unexpected side effect of the N-terminal HA tag on Elk-1 monoubiquitylation, 
untagged Elk-1 was used for the mapping for Elk-1 monoubiquitylation acceptor residue and 
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other experiments assessing changes in Elk-1 monoubiquitylation. Consistent with the HA-
tagged Elk-1, ubiquitin was shown to be attached to the ETS-domain (Figure 10-5), however 
the exact ubiquitin acceptor residue still remains to be identified. 
The replacement of lysine residues with arginine in the ETS-domain affects both Elk-1 
monoubiquitylation (Figure 5-5 & Figure 7-5) and ternary complex formation at the SRE 
(Figure 7-3). Ternary complex formation was shown to be essential for Elk-1 
monoubiquitylation (Figure 7-5), therefore it is difficult to demonstrate unequivocally the 
role of lysine residues as ubiquitin acceptor using Elk-1 derivatives with lysine to arginine 
substitutions. Mass spectrometry would provide an alternative approach to locate the 
ubiquitin acceptor site, with which Elk-1 can be examined without alteration of lysine 
residues.  
 
11.4. Regulation and function of Elk-1 monoubiquitylation 
Phosphorylation triggers Elk-1 transactivation of SRE-dependent transcription (Janknecht, 
Ernst et al. 1993; Marais, Wynne et al. 1993; Gille, Kortenjann et al. 1995; Yang, Shore et al. 
1999). Elk-1 was monoubiquitylated in serum-starved HeLa cells, inversely correlating with 
its phosphorylation (Figure 9-1), indicating that Elk-1 is monoubiquitylated when it is not 
transcriptionally active. Interestingly, Elk-1 monoubiquitylation was found to be dependent 
on its ability to form ternary complexes (Figure 7-5), suggesting Elk-1 monoubiquitylation is 
carried out at the SRE yet has a negative role in transcriptional regulation.  
The K35R derivative expressed from the pCMV5.HA vector exhibits stronger 
monoubiquitylation level compared to the wild type. Luciferase reporter gene data 
demonstrated that this K35R derivative exhibits a dominant negative effect on SRE-
dependent transcription, similar to the transcriptionally defective derivative S383/389A 
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(Figure 6-1 & Figure 6-2), indicating Elk-1 monoubiquitylation reduces its transactivational 
ability, in agreement with the observation that Elk-1 is monoubiquitylated when it is not 
transcriptionally active. Moreover the dominant negative effect on SRE-induction indicates 
that monoubiquitylated Elk-1 must be able to bind to the SRE.  
The level of Elk-1 monoubiquitylation was diminished upon mitogen stimulation in HeLa 
cells, coinciding with the increase of its phosphorylation (Figure 9-1). The addition of the 
MEK inhibitor U0126 to inhibit the ERK/MAPK pathway clearly demonstrated that this Elk-
1 phosphorylation was mediated by ERK (Figure 9-2). Although reduction of 
monoubiquitylation was observed, it was not completely abolished, indicating that Elk-1 can 
be simultaneously monoubiquitylated and phosphorylated, supported by the observation that 
phosphorylated Elk-1 was retrieved by IMAC against ubiquitin (Figure 8-1).  
Using lysine-less ubiquitin to prevent ubiquitin self conjugation, monoubiquitylated Elk-1 
was shown not to be destined to degradation following ERK activation (Figure 9-3). 
However the cause of the reduction of Elk-1 monoubiquitylation remains elusive. One 
possible answer is that Elk-1 is deubiquitylated post ERK-medicated phosphorylation, hence 
activation. Alternatively, monoubiquitylated Elk-1 may be deubiquitylated constitutively. 
Activation of ERK may inhibit Elk-1 specific E3 ligase activity, resulting in the net 
reduction of Elk-1 monoubiquitylation. Although it is widely reported that phosphorylation 
can create a binding surface (phosphodegron) for E3 ligase recognition (Sheaff, Groudine et 
al. 1997; Verma, Annan et al. 1997), phosphorylation-induced interactions with 
deubiquitinases have not been reported. Theoretically Elk-1 specific deubiquitinases could 
be recruited in this manner. Alternatively, Elk-1 phosphorylation can induce deubiquitylation 
indirectly. Elk-1 phosphorylation correlated to its transactivation, resulting in the recruitment 
of transcription mediators and the general transcription machinery. It was reported that the 
transcription mediator Med8 can recruit an E3 ligase to the transcription complex (Brower, 
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Sato et al. 2002), again the same mechanism may be utilised by deubiquitinases. Upon 
stimulation, ERK is recruited to the SRE by Elk-1 to phosphorylate other proteins in the 
vicinity (Zhang, Li et al. 2008). Activity of many ubiquitin enzymes was shown to be 
regulated by phosphorylation (Sarcevic, Mawson et al. 2002; Ichimura, Yamamura et al. 
2005; Gallagher, Gao et al. 2006). There is an indication that monoubiquitylated and 
phosphorylated Elk-1 is located at the SRE, therefore ERK may also regulate Elk-1 
deubiquitylation by mediating ubiquitin enzyme phosphorylation, thereby providing another 
possible regulatory dimension. Nevertheless, the intertwined relationship between Elk-1 
monoubiquitylation and ERK-mediated phosphorylation remains to be explored.  
 
11.5. The cycle of Elk-1 monoubiquitylation   
To summarise, a model for Elk-1 monoubiquitylation cycle is proposed (Figure 11-2). In un-
stimulated cells, Elk-1 is either monoubiquitylated at the SRE or unmodified. The 
monoubiquitylated Elk-1 is transcriptionally inactive and situated at the SRE waiting for an 
appropriate signal to activate transcription. Upon mitogen stimulation, monoubiquitylated 
Elk-1 is phosphorylated by ERK, but Elk-1 remains transcriptionally inactive. 
Phosphorylation of monoubiquitylated Elk-1 then triggers the recruitment of a 
deubiquitinase either directly or indirectly to remove its ubiquitin conjugation. The 
phosphorylated Elk-1 becomes transcriptionally active to mediate SRE-induction. 
Alternatively, transcriptional inactive Elk-1 conjugated with both ubiquitin and phosphate at 
the SRE can be replaced by phosphorylated Elk-1. Finally, phosphorylated Elk-1 is either 
polyubiquitylated for destruction or dephosphorylated to recycle for a new round of 
transcription.  
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Figure 11-2 A proposed model for Elk-1 monoubiquitylation 
cycle at the SRE. For clarity reasons, multiple phosphorylations at 
Elk-1 and ERK are presented as one. The SRF dimer in the ternary 
complex is omitted   
 
11.6. Experimental limitations  
The addition of the E1 activating enzyme Ube1 and the E2 conjugating enzyme Ubc5Hc 
enhanced Elk-1 ubiquitylation in the in vitro assay (Figure 4-1, Figure 4-3 & Figure 4-5) but 
providing purified components limits ubiquitylation to those facilitated by this particular set 
of ubiquitin enzymes. E2 conjugating enzymes facilitate ubiquitylation partly by selecting 
their interacting partners, i.e. E1 activating enzymes and E3 ligases. The E1 activating 
enzymes select the appropriate protein modifier, while the E3 ligases determine substrate 
targets. Ube1 specifically activates ubiquitin protein and transfers activated ubiquitin to 
numerous  ubiquitin E2 enzymes, but does not mediate the transfer of ubiquitin-like proteins 
(Groettrup, Pelzer et al. 2008). Ube1 was the only known E1 activating enzyme at the time 
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of the experiments, another E1 activating enzyme (Uba6) was later identified (Jin, Li et al. 
2007; Pelzer, Kassner et al. 2007). The two E1 activating enzymes cooperate with only a 
partially overlapping pool of E2 conjugating enzymes, nevertheless Ube1 was able to 
transfer activated-ubiquitin to UbcH5c. UbcH5c belongs to the UbcH5 family and members 
of this family are able to interact with a wide range of E3 ligases, including both HECT- and 
RING-domain E3 ligases (Jensen, Bates et al. 1995; Hatakeyama, Jensen et al. 1997; Lorick, 
Jensen et al. 1999; Brzovic, Lissounov et al. 2006; Kirkpatrick, Hathaway et al. 2006). 
Nevertheless the limited observation of the whole spectrum of Elk-1 ubiquitylation would 
inevitably restrict the identification of the Elk-1 specific E3(s).  
All experiments in this study were performed with either recombinant or exogenous proteins. 
Recombinant proteins used in chapter 4 were generated using the TNT Quick Coupled 
Transcription/Translation System. This system utilizes the translational machinery of rabbit 
reticulocyte lysate (immature red blood cells) for protein synthesis using messenger RNA 
transcribed by the T7 or T3 RNA polymerase as a template. Protein activities are often 
governed by extracellular stimuli via PTMs. Although this system offers a quick way for 
protein synthesis, recombinant proteins may not be modified with PTMs without appropriate 
signals, relevant to those physiologically. Furthermore enzymes responsible for such PTMs 
may not be present in the rabbit reticulocytes.  
For all cell-based assays, Elk-1 derivatives were expressed ectopically. The use of 
exogenous proteins can increase the level of a particular protein in cells, and also allows 
alteration of the recombinant proteins, such as an addition of immune-tag or mutations in 
proteins. It is not clear how elevated expression of a protein would affect its activity or 
stability. In initial experiments, Elk-1 derivatives expressed from the pcDNA3.HA and the 
pCMV5.HA vectors contain an N-terminal HA-tag for immunoblotting, which was later 
demonstrated to confer an artificial effect on monoubiquitylation sensitivity, possibly by 
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altering the position of the monoubiquitylation acceptor site. The results with HA-tagged 
Elk-1 derivatives were later verified using untagged Elk-1 derivatives (Figure 10-4, Figure 
10-5 & Figure 10-6). 
 
11.7. Conclusion and future work  
This thesis has clearly demonstrated that monoubiquitylated Elk-1 is reduced following 
ERK-mediated phosphorylation (Figure 10-4), the importance of ternary complex formation 
on Elk-1 monoubiquitylation (Figure 10-6), and that the monoubiquitylation acceptor site is 
located in the ETS-domain (Figure 10-5). Although the reporter gene data revealed that the 
strongly monoubiquitylated HA-tagged Elk-1 derivative displays a reduced ability for 
transactivation (Figure 6-1 & Figure 6-2), there is no direct evidence that this reduction is 
caused by monoubiquitylation. In order to confirm this, the ubiquitin acceptor of the 
untagged Elk-1 has to be identified and mutated to generate an Elk-1 monoubiquitylation-
defective derivative. In addition, an Elk-1 fusion derivative with a single ubiquitin 
attachment via peptide linkage would provide a useful tool to examine the role of 
monoubiquitylation on Elk-1 DNA binding and transcriptional ability. An Elk-1 derivative 
with a single ubiquitin fused at the C-terminus generated in previous experiments was highly 
unstable in cells (Sam Shelton). As Elk-1 is monoubiquitylated within the ETS-domain in 
cells, it is possible that fusing an ubiquitin at the N-terminus may not render it unstable. 
Finally, to demonstrate unequivocally the role of Elk-1 monoubiquitylation, experiments 
have to be performed with endogenous Elk-1 to ensure the physiological relevance of this 
modification.  
 
 
 148 
 
 
Bibliography 
Aravind, L. and E. V. Koonin (2000). "The U box is a modified RING finger - a common 
domain in ubiquitination." Curr Biol
Archer, C. T., L. Burdine, et al. (2008). "Physical and functional interactions of 
monoubiquitylated transactivators with the proteasome." 
 10(4): R132-134. 
J Biol Chem
Archer, C. T., A. Delahodde, et al. (2008). "Activation domain-dependent 
monoubiquitylation of Gal4 protein is essential for promoter binding in vivo." 
 283(31): 
21789-21798. 
J Biol 
Chem
Ardley, H. C. and P. A. Robinson (2005). "E3 ubiquitin ligases." 
 283(18): 12614-12623. 
Essays Biochem
Auld, K. L., C. R. Brown, et al. (2006). "Genomic association of the proteasome 
demonstrates overlapping gene regulatory activity with transcription factor 
substrates." 
 41: 15-30. 
Mol Cell
Aviel, S., G. Winberg, et al. (2000). "Degradation of the epstein-barr virus latent membrane 
protein 1 (LMP1) by the ubiquitin-proteasome pathway. Targeting via 
ubiquitination of the N-terminal residue." 
 21(6): 861-871. 
J Biol Chem
Baboshina, O. V. and A. L. Haas (1996). "Novel Multiubiquitin Chain Linkages Catalyzed by 
the Conjugating Enzymes E2 and RAD6 Are Recognized by 26 S Proteasome Subunit 
5." 
 275(31): 23491-23499. 
Journal of Biological Chemistry
Bai, C., P. Sen, et al. (1996). "SKP1 connects cell cycle regulators to the ubiquitin proteolysis 
machinery through a novel motif, the F-box." 
 271(5): 2823-2831. 
Cell
Barboric, M., F. Zhang, et al. (2005). "Ubiquitylation of Cdk9 by Skp2 facilitates optimal Tat 
transactivation." 
 86(2): 263-274. 
J Virol
Ben-Saadon, R., D. Zaaroor, et al. (2006). "The Polycomb Protein Ring1B Generates Self 
Atypical Mixed Ubiquitin Chains Required for Its In Vitro Histone H2A Ligase 
Activity."  24(5): 701-711. 
 79(17): 11135-11141. 
Benaroudj, N., P. Zwickl, et al. (2003). "ATP hydrolysis by the proteasome regulatory 
complex PAN serves multiple functions in protein degradation." Mol Cell
Besson, A., M. Gurian-West, et al. (2006). "A pathway in quiescent cells that controls 
p27Kip1 stability, subcellular localization, and tumor suppression." 
 11(1): 69-
78. 
Genes & 
Development
Bienko, M., C. M. Green, et al. (2005). "Ubiquitin-binding domains in Y-family polymerases 
regulate translesion synthesis." 
 20(1): 47-64. 
Science
Bienko, M., C. M. Green, et al. (2009). "Regulation of translesion synthesis DNA polymerase 
eta by monoubiquitination." 
 310(5755): 1821-1824. 
Mol Cell
Blumberg, P. M. (1988). "Protein kinase C as the receptor for the phorbol ester tumor 
promoters: sixth Rhoads memorial award lecture." 
 37(3): 396-407. 
Cancer Res
Borden, K. L. and P. S. Freemont (1996). "The RING finger domain: a recent example of a 
sequence-structure family." 
 48(1): 1-8. 
Curr Opin Struct Biol
Boros, J., A. O'Donnell, et al. (2009). "Overlapping promoter targeting by Elk-1 and other 
divergent ETS-domain transcription factor family members." 
 6(3): 395-401. 
Nucleic Acids Res 
37(22): 7368-7380. 
 149 
 
Boyer, T. G., M. E. D. Martin, et al. (1999). "Mammalian Srb/Mediator complex is targeted 
by adenovirus E1A protein." Nature
Braun, B. C., M. Glickman, et al. (1999). "The base of the proteasome regulatory particle 
exhibits chaperone-like activity." 
 399(6733): 276-279. 
Nat Cell Biol
Breitschopf, K., E. Bengal, et al. (1998). "A novel site for ubiquitination: the N-terminal 
residue, and not internal lysines of MyoD, is essential for conjugation and 
degradation of the protein." 
 1(4): 221-226. 
EMBO J
Brocchieri, L. and S. Karlin (2005). "Protein length in eukaryotic and prokaryotic 
proteomes." 
 17(20): 5964-5973. 
Nucleic Acids Res
Brooks, C. L. and W. Gu (2006). "p53 Ubiquitination: Mdm2 and Beyond."  21(3): 307-315. 
 33(10): 3390-3400. 
Brower, C. S., S. Sato, et al. (2002). "Mammalian mediator subunit mMED8 is an Elongin BC-
interacting protein that can assemble with Cul2 and Rbx1 to reconstitute a 
ubiquitin ligase." Proceedings of the National Academy of Sciences of the United 
States of America
Brown, L. A., S. H. Yang, et al. (1999). "Molecular characterization of a zebrafish TCF ETS-
domain transcription factor." 
 99(16): 10353-10358. 
Oncogene
Brzovic, P. S. and R. E. Klevit (2006). "Ubiquitin transfer from the E2 perspective: why is 
UbcH5 so promiscuous?" 
 18(56): 7985-7993. 
Cell Cycle
Brzovic, P. S., A. Lissounov, et al. (2006). "A UbcH5/ubiquitin noncovalent complex is 
required for processive BRCA1-directed ubiquitination." 
 5(24): 2867-2873. 
Mol Cell
Buchwalter, G., C. Gross, et al. (2004). "Ets ternary complex transcription factors." 
 21(6): 873-880. 
Gene
Cahill, M. A., A. Nordheim, et al. (1994). "Co-occurrence of CArG boxes and TCF sites within 
viral genomes." 
 324: 
1-14. 
Biochem Biophys Res Commun
Capili, A. D., D. C. Schultz, et al. (2001). "Solution structure of the PHD domain from the 
KAP-1 corepressor: structural determinants for PHD, RING and LIM zinc-binding 
domains." 
 205(1): 545-551. 
EMBO J
Cavigelli, M., F. Dolfi, et al. (1995). "Induction of c-fos expression through JNK-mediated 
TCF/Elk-1 phosphorylation." 
 20(1-2): 165-177. 
EMBO J
Cesari, F., V. Rennekampff, et al. (2004). "Elk-1 knock-out mice engineered by Flp 
recombinase-mediated cassette exchange." 
 14(23): 5957-5964. 
Genesis
Cheng, J. J., B. S. Wung, et al. (2001). "Sequential activation of protein kinase C (PKC)-alpha 
and PKC-epsilon contributes to sustained Raf/ERK1/2 activation in endothelial cells 
under mechanical strain." 
 38(2): 87-92. 
J Biol Chem
Chew, E. H., T. Poobalasingam, et al. (2007). "Characterization of cullin-based E3 ubiquitin 
ligases in intact mammalian cells--evidence for cullin dimerization." 
 276(33): 31368-31375. 
Cell Signal
Chi, Y., M. J. Huddleston, et al. (2001). "Negative regulation of Gcn4 and Msn2 transcription 
factors by Srb10 cyclin-dependent kinase." 
 19(5): 
1071-1080. 
Genes Dev
Clurman, B. E., R. J. Sheaff, et al. (1996). "Turnover of cyclin E by the ubiquitin-proteasome 
pathway is regulated by cdk2 binding and cyclin phosphorylation." 
 15(9): 1078-1092. 
Genes Dev
Conaway, R. C., C. S. Brower, et al. (2002). "Emerging roles of ubiquitin in transcription 
regulation." 
 
10(16): 1979-1990. 
Science
Crews, C. M., A. Alessandrini, et al. (1992). "The primary structure of MEK, a protein kinase 
that phosphorylates the ERK gene product." 
 296(5571): 1254-1258. 
Science
Cruzalegui, F. H., E. Cano, et al. (1999). "ERK activation induces phosphorylation of Elk-1 at 
multiple S/T-P motifs to high stoichiometry." 
 258(5081): 478-480. 
Oncogene 18(56): 7948-7957. 
 150 
 
Dalton, S. and R. Treisman (1992). "Characterization of SAP-1, a protein recruited by serum 
response factor to the c-fos serum response element." Cell
David, Y., T. Ziv, et al. (2010). "The E2 Ubiquitin-conjugating Enzymes Direct 
Polyubiquitination to Preferred Lysines." 
 68(3): 597-612. 
Journal of Biological Chemistry
Deng, L., C. Wang, et al. (2000). "Activation of the  IkappaB Kinase Complex by TRAF6 
Requires a Dimeric Ubiquitin-Conjugating Enzyme Complex and a Unique 
Polyubiquitin Chain."  103(2): 351-361. 
 285(12): 
8595-8604. 
Deng, L., C. Wang, et al. (2000). "Activation of the IkappaB Kinase Complex by TRAF6 
Requires a Dimeric Ubiquitin-Conjugating Enzyme Complex and a Unique 
Polyubiquitin Chain."  103(2): 351-361. 
Dennis, A. P., D. M. Lonard, et al. (2005). "Inhibition of the 26S proteasome blocks 
progesterone receptor-dependent transcription through failed recruitment of RNA 
polymerase II." J Steroid Biochem Mol Biol
Dias, D. C., G. Dolios, et al. (2002). "CUL7: A DOC domain-containing cullin selectively binds 
Skp1 center dot Fbx29 to form an SCF-like complex." 
 94(4): 337-346. 
Proceedings of the National 
Academy of Sciences of the United States of America
Doil, C., N. Mailand, et al. (2009). "RNF168 Binds and Amplifies Ubiquitin Conjugates on 
Damaged Chromosomes to Allow Accumulation of Repair Proteins."  136(3): 435-
446. 
 99(26): 16601-16606. 
Donaldson, L. W., J. M. Petersen, et al. (1994). "Secondary structure of the ETS domain 
places murine Ets-1 in the superfamily of winged helix-turn-helix DNA-binding 
proteins." Biochemistry
Donaldson, L. W., J. M. Petersen, et al. (1996). "Solution structure of the ETS domain from 
murine Ets-1: a winged helix-turn-helix DNA binding motif." 
 33(46): 13509-13516. 
EMBO J
Ducret, C., S. M. Maira, et al. (2000). "The ternary complex factor Net contains two distinct 
elements that mediate different responses to MAP kinase signalling 
cascades." 
 15(1): 125-134. 
Oncogene
Duda, D. M., L. A. Borg, et al. (2008). "Structural insights into NEDD8 activation of cullin-
RING ligases: conformational control of conjugation." 
 19(44): 5063-5072. 
Cell
Duncan, L. M., S. Piper, et al. (2006). "Lysine-63-linked ubiquitination is required for 
endolysosomal degradation of class I molecules." 
 134(6): 995-1006. 
EMBO J
Ea, C.-K., L. Deng, et al. (2006). "Activation of IKK by TNF± Requires Site-Specific 
Ubiquitination of RIP1 and Polyubiquitin Binding by NEMO."  22(2): 245-257. 
 25(8): 1635-1645. 
Eddins, M. J., C. M. Carlile, et al. (2006). "Mms2-Ubc13 covalently bound to ubiquitin 
reveals the structural basis of linkage-specific polyubiquitin chain formation." Nat 
Struct Mol Biol
Elsasser, S., D. Chandler-Militello, et al. (2004). "Rad23 and Rpn10 serve as alternative 
ubiquitin receptors for the proteasome." 
 13(10): 915-920. 
J Biol Chem
Enesa, K., K. Ito, et al. (2008). "Hydrogen peroxide prolongs nuclear localization of NF-
kappaB in activated cells by suppressing negative regulatory mechanisms." 
 279(26): 26817-26822. 
J Biol 
Chem
Enslen, H., J. Raingeaud, et al. (1998). "Selective activation of p38 mitogen-activated protein 
(MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6." 
 283(27): 18582-18590. 
J Biol Chem
Ezhkova, E. and W. P. Tansey (2004). "Proteasomal ATPases link ubiquitylation of histone 
H2B to methylation of histone H3." 
 
273(3): 1741-1748. 
Mol Cell 13(3): 435-442. 
 151 
 
Fang, S. and A. M. Weissman (2004). "A field guide to ubiquitylation." Cell Mol Life Sci
Fantz, D. A., D. Jacobs, et al. (2001). "Docking Sites on Substrate Proteins Direct 
Extracellular Signal-regulated Kinase to Phosphorylate Specific Residues." 
 
61(13): 1546-1561. 
Journal of 
Biological Chemistry
Feldman, R. M., C. C. Correll, et al. (1997). "A complex of Cdc4p, Skp1p, and Cdc53p/cullin 
catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p." 
 276(29): 27256-27265. 
Cell
Ferdous, A., F. Gonzalez, et al. (2001). "The 19S regulatory particle of the proteasome is 
required for efficient transcription elongation by RNA polymerase II." 
 91(2): 221-
230. 
Mol Cell
Ferdous, A., D. Sikder, et al. (2007). "The role of the proteasomal ATPases and activator 
monoubiquitylation in regulating Gal4 binding to promoters." 
 7(5): 
981-991. 
Genes Dev
Fitzsimmons, D., W. Hodsdon, et al. (1996). "Pax-5 (BSAP) recruits Ets proto-oncogene 
family proteins to form functional ternary complexes on a B-cell-specific 
promoter." 
 21(1): 
112-123. 
Genes Dev
Friedberg, E. C., A. R. Lehmann, et al. (2005). "Trading places: how do DNA polymerases 
switch during translesion DNA synthesis?" 
 10(17): 2198-2211. 
Mol Cell
Fuchs, S. Y., V. Adler, et al. (1998). "Mdm2 association with p53 targets its 
ubiquitination." 
 18(5): 499-505. 
Oncogene
Fuchs, S. Y., B. Xie, et al. (1997). "c-Jun NH2-terminal Kinases Target the Ubiquitination of 
Their Associated Transcription Factors." 
 17(19): 2543-2547. 
Journal of Biological Chemistry
Gallagher, E., M. Gao, et al. (2006). "Activation of the E3 ubiquitin ligase Itch through a 
phosphorylation-induced conformational change." 
 272(51): 
32163-32168. 
Proc Natl Acad Sci U S A
Gao, M. and M. Karin (2005). "Regulating the Regulators: Control of Protein Ubiquitination 
and Ubiquitin-like Modifications by Extracellular Stimuli."  19(5): 581-593. 
 103(6): 
1717-1722. 
Geetha, T., J. Jiang, et al. (2005). "Lysine 63 Polyubiquitination of the Nerve Growth Factor 
Receptor TrkA Directs Internalization and Signaling."  20(2): 301-312. 
Geyer, R., S. Wee, et al. (2003). "BTB/POZ domain proteins are putative substrate adaptors 
for cullin 3 ubiquitin ligases." Mol Cell
Giles, J. (2004). "Chemistry Nobel for trio who revealed molecular death-tag." 
 12(3): 783-790. 
Nature
Gille, H., M. Kortenjann, et al. (1995). "ERK phosphorylation potentiates Elk-1-mediated 
ternary complex formation and transactivation." 
 
431(7010): 729-729. 
Embo J
Gille, H., A. D. Sharrocks, et al. (1992). "Phosphorylation of transcription factor p62TCF by 
MAP kinase stimulates ternary complex formation at c-fos promoter." 
 14(5): 951-962. 
Nature
Gille, H., T. Strahl, et al. (1995). "Activation of ternary complex factor Elk-1 by stress-
activated protein kinases." 
 
358(6385): 414-417. 
Current Biology
Gillette, T. G., F. Gonzalez, et al. (2004). "Physical and functional association of RNA 
polymerase II and the proteasome." 
 5(10): 1191-1200. 
Proc Natl Acad Sci U S A
Giovane, A., A. Pintzas, et al. (1994). "Net, a new ets transcription factor that is activated by 
Ras." 
 101(16): 5904-5909. 
Genes & Development
Glickman, M. H. and A. Ciechanover (2002). "The ubiquitin-proteasome proteolytic pathway: 
destruction for the sake of construction." 
 8(13): 1502-1513. 
Physiol Rev 82(2): 373-428. 
 152 
 
Goldman, D., M. K. Sapru, et al. (1998). "Cloning and characterization of GETS-1, a goldfish 
Ets family member that functions as a transcriptional repressor in muscle." Biochem 
J
Gong, L. and E. T. H. Yeh (1999). "Identification of the Activating and Conjugating Enzymes 
of the NEDD8 Conjugation Pathway." 
 335 ( Pt 2): 267-275. 
Journal of Biological Chemistry
Graham, R. and M. Gilman (1991). "Distinct protein targets for signals acting at the c-fos 
serum response element." 
 274(17): 
12036-12042. 
Science
Groettrup, M., C. Pelzer, et al. (2008). "Activating the ubiquitin family: UBA6 challenges the 
field." 
 251(4990): 189-192. 
Trends in Biochemical Sciences
Guterman, A. and M. H. Glickman (2004). "Complementary roles for Rpn11 and Ubp6 in 
deubiquitination and proteolysis by the proteasome." 
 33(5): 230-237. 
J Biol Chem
Haglund, K., S. Sigismund, et al. (2003). "Multiple monoubiquitination of RTKs is sufficient 
for their endocytosis and degradation." 
 279(3): 1729-
1738. 
Nat Cell Biol
Hallows, K. R., V. Bhalla, et al. (2010). "Phosphopeptide screen uncovers novel Nedd4-2 
phosphorylation sites that potentiate its inhibition of the epithelial Na+ 
channel." 
 5(5): 461-466. 
Journal of Biological Chemistry
Hassler, M. and T. J. Richmond (2001). "The B-box dominates SAP-1-SRF interactions in the 
structure of the ternary complex." 
: -. 
EMBO J
Hatakeyama, S., J. P. Jensen, et al. (1997). "Subcellular Localization and Ubiquitin-
conjugating Enzyme (E2) Interactions of Mammalian HECT Family Ubiquitin Protein 
Ligases." 
 20(12): 3018-3028. 
Journal of Biological Chemistry
Haupt, Y., R. Maya, et al. (1997). "Mdm2 promotes the rapid degradation of p53." 
 272(24): 15085-15092. 
Nature
Hill, C. S., R. Marais, et al. (1993). "Functional analysis of a growth factor-responsive 
transcription factor complex." 
 
387(6630): 296-299. 
Cell
Hill, C. S. and R. Treisman (1995). "Differential activation of c-fos promoter elements by 
serum, lysophosphatidic acid, G proteins and polypeptide growth factors." 
 73(2): 395-406. 
EMBO J
Hill, C. S., J. Wynne, et al. (1994). "Serum-regulated transcription by serum response factor 
(SRF): a novel role for the DNA binding domain." 
 
14(20): 5037-5047. 
EMBO J
Hill, C. S., J. Wynne, et al. (1995). "The Rho family GTPases RhoA, Rac1, and CDC42Hs 
regulate transcriptional activation by SRF." 
 13(22): 5421-5432. 
Cell
Hipskind, R. A., M. Baccarini, et al. (1994). "Transient activation of RAF-1, MEK, and ERK2 
coincides kinetically with ternary complex factor phosphorylation and immediate-
early gene promoter activity in vivo." 
 81(7): 1159-1170. 
Mol Cell Biol
Hipskind, R. A., V. N. Rao, et al. (1991). "Ets-related protein Elk-1 is homologous to the c-fos 
regulatory factor p62TCF." 
 14(9): 6219-6231. 
Nature
Hodge, C., J. Liao, et al. (1998). "Growth hormone stimulates phosphorylation and 
activation of elk-1 and expression of c-fos, egr-1, and junB through activation of 
extracellular signal-regulated kinases 1 and 2." 
 354(6354): 531-534. 
J Biol Chem
Hoege, C., B. Pfander, et al. (2002). "RAD6-dependent DNA repair is linked to modification 
of PCNA by ubiquitin and SUMO." 
 273(47): 31327-31336. 
Nature
Hoege, C., B. Pfander, et al. (2002). "RAD6-dependent DNA repair is linked to modification 
of PCNA by ubiquitin and SUMO." 
 419(6903): 135-141. 
Nature 419(6903): 135-141. 
 153 
 
Hofmann, R. M. and C. M. Pickart (1999). "Noncanonical MMS2-Encoded Ubiquitin-
Conjugating Enzyme Functions in Assembly of Novel Polyubiquitin Chains for DNA 
Repair."  96(5): 645-653. 
Hori, T., F. Osaka, et al. (1999). "Covalent modification of all members of human cullin 
family proteins by NEDD8." Oncogene
Hsu, T., M. Trojanowska, et al. (2004). "Ets proteins in biological control and cancer." 
 18(48): 6829-6834. 
J Cell 
Biochem
Huang, L., E. Kinnucan, et al. (1999). "Structure of an E6AP-UbcH7 Complex: Insights into 
Ubiquitination by the E2-E3 Enzyme Cascade." 
 91(5): 896-903. 
Science
Huen, M. S. Y., R. Grant, et al. (2007). "RNF8 Transduces the DNA-Damage Signal via Histone 
Ubiquitylation and Checkpoint Protein Assembly."  131(5): 901-914. 
 286(5443): 1321-1326. 
Huibregtse, J. M., M. Scheffner, et al. (1995). "A family of proteins structurally and 
functionally related to the E6-AP ubiquitin-protein ligase." Proc Natl Acad Sci U S A
Ichimura, T., H. Yamamura, et al. (2005). "14-3-3 Proteins Modulate the Expression of 
Epithelial Na+ Channels by Phosphorylation-dependent Interaction with Nedd4-2 
Ubiquitin Ligase." 
 
92(7): 2563-2567. 
Journal of Biological Chemistry
Jacobs, D., D. Glossip, et al. (1999). "Multiple docking sites on substrate proteins form a 
modular system that mediates recognition by ERK MAP kinase." 
 280(13): 13187-13194. 
Genes & 
Development
Janknecht, R., W. H. Ernst, et al. (1993). "Activation of ternary complex factor Elk-1 by MAP 
kinases." 
 13(2): 163-175. 
EMBO J
Janknecht, R. and A. Nordheim (1992). "Elk-1 protein domains required for direct and SRF-
assisted DNA-binding." 
 12(13): 5097-5104. 
Nucl. Acids Res.
Janknecht, R. and A. Nordheim (1996). "MAP Kinase-Dependent Transcriptional 
Coactivation by Elk-1 and Its Cofactor CBP." 
 20(13): 3317-3324. 
Biochemical and Biophysical Research 
Communications
Jensen, J. P., P. W. Bates, et al. (1995). "Identification of a family of closely related human 
ubiquitin conjugating enzymes." 
 228(3): 831-837. 
J Biol Chem
Jin, J., X. Li, et al. (2007). "Dual E1 activation systems for ubiquitin differentially regulate E2 
enzyme charging." 
 270(51): 30408-30414. 
Nature
Jin, L., A. Williamson, et al. (2008). "Mechanism of Ubiquitin-Chain Formation by the Human 
Anaphase-Promoting Complex."  133(4): 653-665. 
 447(7148): 1135-1138. 
Johansen, F. E. and R. Prywes (1994). "Two pathways for serum regulation of the c-fos 
serum response element require specific sequence elements and a minimal domain 
of serum response factor." Mol Cell Biol
Joseph, T. W., A. Zaika, et al. (2003). "Nuclear and cytoplasmic degradation of endogenous 
p53 and HDM2 occurs during down-regulation of the p53 response after multiple 
types of DNA damage." 
 14(9): 5920-5928. 
FASEB J
Kamsteeg, E.-J., G. Hendriks, et al. (2006). "Short-chain ubiquitination mediates the 
regulated endocytosis of the aquaporin-2 water channel." 
 17(12): 1622-1630. 
Proceedings of the 
National Academy of Sciences
Kamura, T., T. Hara, et al. (2004). "Cytoplasmic ubiquitin ligase KPC regulates proteolysis of 
p27Kip1 at G1 phase." 
 103(48): 18344-18349. 
Nat Cell Biol
Kamura, T., D. M. Koepp, et al. (1999). "Rbx1, a component of the VHL tumor suppressor 
complex and SCF ubiquitin ligase." 
 6(12): 1229-1235. 
Science 284(5414): 657-661. 
 154 
 
Kamura, T., S. Sato, et al. (1998). "The Elongin BC complex interacts with the conserved 
SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin 
repeat families." Genes Dev
Kanayama, A., R. B. Seth, et al. (2004). "TAB2 and TAB3 Activate the NF-ºB Pathway through 
Binding to Polyubiquitin Chains."  15(4): 535-548. 
 12(24): 3872-3881. 
Kanemori, Y., K. Uto, et al. (2005). "Beta-TrCP recognizes a previously undescribed 
nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases." Proc 
Natl Acad Sci U S A
Kannouche, P. L., J. Wing, et al. (2004). "Interaction of human DNA polymerase eta with 
monoubiquitinated PCNA: a possible mechanism for the polymerase switch in 
response to DNA damage." 
 102(18): 6279-6284. 
Mol Cell
Karin, M. and Y. Ben-Neriah (2000). "Phosphorylation Meets Ubiquitination: The Control of 
NFkB Activity." 
 14(4): 491-500. 
Annual Review of Immunology
Kawakami, T., T. Chiba, et al. (2001). "NEDD8 recruits E2-ubiquitin to SCF E3 ligase." 
 18(1): 621-663. 
Embo J
Kayagaki, N., Q. Phung, et al. (2007). "DUBA: a deubiquitinase that regulates type I 
interferon production." 
 
20(15): 4003-4012. 
Science
Kee, Y. and J. M. Huibregtse (2007). "Regulation of catalytic activities of HECT ubiquitin 
ligases." 
 318(5856): 1628-1632. 
Biochemical and Biophysical Research Communications
Kim, H. T., K. P. Kim, et al. (2007). "Certain Pairs of Ubiquitin-conjugating Enzymes (E2s) and 
Ubiquitin-Protein Ligases (E3s) Synthesize Nondegradable Forked Ubiquitin Chains 
Containing All Possible Isopeptide Linkages." 
 354(2): 329-333. 
Journal of Biological Chemistry
Kim, H. T., K. P. Kim, et al. (2009). "S5a promotes protein degradation by blocking synthesis 
of nondegradable forked ubiquitin chains." 
 
282(24): 17375-17386. 
EMBO J
Kim, Y. J., S. Bjorklund, et al. (1994). "A multiprotein mediator of transcriptional activation 
and its interaction with the C-terminal repeat domain of RNA polymerase II." 
 28(13): 1867-1877. 
Cell
Kimura, Y. and K. Tanaka (2010). "Regulatory mechanisms involved in the control of 
ubiquitin homeostasis." 
 
77(4): 599-608. 
J Biochem
Kipreos, E. T. and M. Pagano (2000). "The F-box protein family." 
 147(6): 793-798. 
Genome Biol
Kirisako, T., K. Kamei, et al. (2006). "A ubiquitin ligase complex assembles linear 
polyubiquitin chains." 
 1(5): 
REVIEWS3002. 
EMBO J
Kirisako, T., K. Kamei, et al. (2006). "A ubiquitin ligase complex assembles linear 
polyubiquitin chains." 
 25(20): 4877-4887. 
Embo J
Kirkpatrick, D. S., N. A. Hathaway, et al. (2006). "Quantitative analysis of in vitro 
ubiquitinated cyclin B1 reveals complex chain topology." 
 25(20): 4877-4887. 
Nat Cell Biol
Klein, P., T. Pawson, et al. (2003). "Mathematical modeling suggests cooperative 
interactions between a disordered polyvalent ligand and a single receptor 
site." 
 8(7): 700-710. 
Curr Biol
Kodadek, T., D. Sikder, et al. (2006). "Keeping transcriptional activators under control." 
 13(19): 1669-1678. 
Cell
Komander, D. (2009). "The emerging complexity of protein ubiquitination." 
 
127(2): 261-264. 
Biochemical 
Society Transactions
Komander, D., M. J. Clague, et al. (2009). "Breaking the chains: structure and function of the 
deubiquitinases." 
 037(5): 937-953. 
Nat Rev Mol Cell Biol 10(8): 550-563. 
 155 
 
Kornberg, R. D. (2005). "Mediator and the mechanism of transcriptional activation." Trends 
Biochem Sci
Kornberg, R. D. (2007). "The molecular basis of eukaryotic transcription." 
 30(5): 235-239. 
Proc Natl Acad Sci 
U S A
Kortenjann, M., O. Thomae, et al. (1994). "Inhibition of v-raf-dependent c-fos expression 
and transformation by a kinase-defective mutant of the mitogen-activated protein 
kinase Erk2." 
 104(32): 12955-12961. 
Mol Cell Biol
Kramer, O. H., P. Zhu, et al. (2003). "The histone deacetylase inhibitor valproic acid 
selectively induces proteasomal degradation of HDAC2." 
 14(7): 4815-4824. 
EMBO J
Kubbutat, M. H., R. L. Ludwig, et al. (1998). "Regulation of Mdm2-directed degradation by 
the C terminus of p53." 
 22(13): 3411-3420. 
Mol Cell Biol
Kurosu, T. and B. M. Peterlin (2004). "VP16 and ubiquitin; binding of P-TEFb via its 
activation domain and ubiquitin facilitates elongation of transcription of target 
genes." 
 18(10): 5690-5698. 
Curr Biol
Kurz, T., N. Ozlu, et al. (2005). "The conserved protein DCN-1/Dcn1p is required for cullin 
neddylation in C. elegans and S. cerevisiae." 
 14(12): 1112-1116. 
Nature
Lamothe, B., A. Besse, et al. (2007). "Site-specific Lys-63-linked tumor necrosis factor 
receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa 
B kinase activation." 
 435(7046): 1257-1261. 
J Biol Chem
Lang, V., J. Janzen, et al. (2003). "{beta}TrCP-Mediated Proteolysis of NF-{kappa}B1 p105 
Requires Phosphorylation of p105 Serines 927 and 932." 
 282(6): 4102-4112. 
Mol. Cell. Biol.
Lanker, S., M. H. Valdivieso, et al. (1996). "Rapid degradation of the G1 cyclin Cln2 induced 
by CDK-dependent phosphorylation." 
 23(1): 402-
413. 
Science
Lee, D., E. Ezhkova, et al. (2005). "The proteasome regulatory particle alters the SAGA 
coactivator to enhance its interactions with transcriptional activators." 
 271(5255): 1597-1601. 
Cell
Lehmann, A. R., A. Niimi, et al. (2007). "Translesion synthesis: Y-family polymerases and the 
polymerase switch." 
 123(3): 
423-436. 
DNA Repair (Amst)
Leprince, D., A. Gegonne, et al. (1983). "A putative second cell-derived oncogene of the 
avian leukaemia retrovirus E26." 
 6(7): 891-899. 
Nature
Leung, A., F. Geng, et al. (2008). "Transcriptional control and the ubiquitin-proteasome 
system." 
 306(5941): 395-397. 
Ernst Schering Found Symp Proc
Li, M., C. L. Brooks, et al. (2003). "Mono- versus polyubiquitination: differential control of 
p53 fate by Mdm2." 
(1): 75-97. 
Science
Li, Q. J., S. H. Yang, et al. (2003). "MAP kinase phosphorylation-dependent activation of Elk-
1 leads to activation of the co-activator p300." 
 302(5652): 1972-1975. 
EMBO J
Lin, Y., W. C. Hwang, et al. (2002). "Structural and functional analysis of the human mitotic-
specific ubiquitin-conjugating enzyme, UbcH10." 
 22(2): 281-291. 
J Biol Chem
Linares, L. t. K., A. Hengstermann, et al. (2003). "HdmX stimulates Hdm2-mediated 
ubiquitination and degradation of p53." 
 277(24): 21913-21921. 
Proceedings of the National Academy of 
Sciences of the United States of America
Ling, Y., J. H. Lakey, et al. (1997). "Molecular characterization of the B-box protein-protein 
interaction motif of the ETS-domain transcription factor Elk-1." 
 100(21): 12009-12014. 
EMBO J
Ling, Y., A. G. West, et al. (1998). "Interaction of Transcription Factors with Serum Response 
Factor." 
 16(9): 2431-
2440. 
Journal of Biological Chemistry 273(17): 10506-10514. 
 156 
 
Lipford, J. R. and R. J. Deshaies (2003). "Diverse roles for ubiquitin-dependent proteolysis in 
transcriptional activation." Nat Cell Biol
Lipford, J. R., G. T. Smith, et al. (2005). "A putative stimulatory role for activator turnover in 
gene expression." 
 5(10): 845-850. 
Nature
Liu, C. W., M. J. Corboy, et al. (2003). "Endoproteolytic activity of the proteasome." 
 438(7064): 113-116. 
Science
Lopez, M., P. Oettgen, et al. (1994). "ERP, a new member of the ets transcription 
factor/oncoprotein family: cloning, characterization, and differential expression 
during B-lymphocyte development." 
 
299(5605): 408-411. 
Mol. Cell. Biol.
Lorick, K. L., J. P. Jensen, et al. (1999). "RING fingers mediate ubiquitin-conjugating enzyme 
(E2)-dependent ubiquitination." 
 14(5): 3292-3309. 
Proceedings of the National Academy of Sciences 
of the United States of America
Mailand, N., S. Bekker-Jensen, et al. (2007). "RNF8 Ubiquitylates Histones at DNA Double-
Strand Breaks and Promotes Assembly of Repair Proteins."  131(5): 887-900. 
 96(20): 11364-11369. 
Mao, Y., F. Senic-Matuglia, et al. (2005). "Deubiquitinating function of ataxin-3: insights 
from the solution structure of the Josephin domain." Proc Natl Acad Sci U S A
Marais, R., J. Wynne, et al. (1993). "The SRF accessory protein Elk-1 contains a growth 
factor-regulated transcriptional activation domain." 
 
102(36): 12700-12705. 
Cell
Marchenko, N. D. and U. M. Moll (2007). "The role of ubiquitination in the direct 
mitochondrial death program of p53." 
 73(2): 381-393. 
Cell Cycle
Marchenko, N. D., S. Wolff, et al. (2007). "Monoubiquitylation promotes mitochondrial p53 
translocation." 
 6(14): 1718-1723. 
Embo J
McCullough, J., M. J. Clague, et al. (2004). "AMSH is an endosome-associated ubiquitin 
isopeptidase." 
 26(4): 923-934. 
The Journal of Cell Biology
Meimoun, A., T. Holtzman, et al. (2000). "Degradation of the transcription factor Gcn4 
requires the kinase Pho85 and the SCF(CDC4) ubiquitin-ligase complex." 
 166(4): 487-492. 
Mol Biol 
Cell
Merlet, J., J. Burger, et al. (2009). "Regulation of cullin-RING E3 ubiquitin-ligases by 
neddylation and dimerization." 
 11(3): 915-927. 
Cellular and Molecular Life Sciences
Metivier, R., G. Penot, et al. (2003). "Estrogen receptor-alpha directs ordered, cyclical, and 
combinatorial recruitment of cofactors on a natural target promoter." 
 66(11): 1924-
1938. 
Cell
Meulmeester, E., M. Kunze, et al. (2008). "Mechanism and consequences for paralog-
specific sumoylation of ubiquitin-specific protease 25." 
 115(6): 
751-763. 
Mol Cell
Michel, J. J. and Y. Xiong (1998). "Human CUL-1, but not other cullin family members, 
selectively interacts with SKP1 to form a complex with SKP2 and cyclin A." 
 30(5): 610-619. 
Cell 
Growth Differ
Mizuno, E., N. Kitamura, et al. (2007). "14-3-3-dependent inhibition of the deubiquitinating 
activity of UBPY and its cancellation in the M phase." 
 9(6): 435-449. 
Exp Cell Res
Mo, Y., B. Vaessen, et al. (1998). "Structures of SAP-1 Bound to DNA Targets from the E74 
and c-fos Promoters: Insights into DNA Sequence Discrimination by Ets 
Proteins." 
 313(16): 3624-
3634. 
Molecular Cell
Mo, Y., B. Vaessen, et al. (2000). "Structure of the Elk-1-DNA complex reveals how DNA-
distal residues affect ETS domain recognition of DNA." 
 2(2): 201-212. 
Nat Struct Mol Biol 7(4): 
292-297. 
 157 
 
Moldovan, G.-L., B. Pfander, et al. (2007). "PCNA, the Maestro of the Replication Fork."  
129(4): 665-679. 
Montagnoli, A., F. Fiore, et al. (1999). "Ubiquitination of p27 is regulated by Cdk-dependent 
phosphorylation and trimeric complex formation." Genes Dev
Morrison, D. K., G. Heidecker, et al. (1993). "Identification of the major phosphorylation 
sites of the Raf-1 kinase." 
 13(9): 1181-1189. 
J Biol Chem
Mueller, C. G. and A. Nordheim (1991). "A protein domain conserved between yeast MCM1 
and human SRF directs ternary complex formation." 
 268(23): 17309-17316. 
EMBO J
Muratani, M., C. Kung, et al. (2005). "The F box protein Dsg1/Mdm30 is a transcriptional 
coactivator that stimulates Gal4 turnover and cotranscriptional mRNA 
processing." 
 10(13): 4219-4229. 
Cell
Newton, K., M. L. Matsumoto, et al. (2008). "Ubiquitin Chain Editing Revealed by 
Polyubiquitin Linkage-Specific Antibodies."  134(4): 668-678. 
 120(6): 887-899. 
Nikolaev, A. Y., M. Li, et al. (2003). "Parc: a cytoplasmic anchor for p53." Cell
Nishikawa, H., S. Ooka, et al. (2004). "Mass Spectrometric and Mutational Analyses Reveal 
Lys-6-linked Polyubiquitin Chains Catalyzed by BRCA1-BARD1 Ubiquitin 
Ligase." 
 112(1): 29-40. 
Journal of Biological Chemistry
Nissen, L. J., J. C. Gelly, et al. (2001). "Induction-independent recruitment of CREB-binding 
protein to the c-fos serum response element through interactions between the 
bromodomain and Elk-1." 
 279(6): 3916-3924. 
J Biol Chem
Nozaki, M., Y. Onishi, et al. (1996). "Molecular cloning of Elk-3, a new member of the Ets 
family expressed during mouse embryogenesis and analysis of its transcriptional 
repression activity." 
 276(7): 5213-5221. 
DNA Cell Biol
Nunn, M. F., P. H. Seeburg, et al. (1983). "Tripartite structure of the avian erythroblastosis 
virus E26 transforming gene." 
 15(10): 855-862. 
Nature
Ogunjimi, A. A., D. J. Briant, et al. (2005). "Regulation of Smurf2 Ubiquitin Ligase Activity by 
Anchoring the E2 to the HECT Domain." 
 306(5941): 391-395. 
Molecular Cell
Ohta, T., J. J. Michel, et al. (1999). "ROC1, a homolog of APC11, represents a family of cullin 
partners with an associated ubiquitin ligase activity." 
 19(3): 297-308. 
Mol Cell
Ordureau, A., H. Smith, et al. (2008). "The IRAK-catalysed activation of the E3 ligase 
function of Pellino isoforms induces the Lys63-linked polyubiquitination of 
IRAK1." 
 3(4): 535-541. 
Biochem J
Orlicky, S., X. Tang, et al. (2003). "Structural basis for phosphodependent substrate 
selection and orientation by the SCFCdc4 ubiquitin ligase." 
 409(1): 43-52. 
Cell
Osaka, F., M. Saeki, et al. (2000). "Covalent modifier NEDD8 is essential for SCF ubiquitin-
ligase in fission yeast." 
 112(2): 243-256. 
Embo J
Ostendorff, H. P., R. I. Peirano, et al. (2002). "Ubiquitination-dependent cofactor exchange 
on LIM homeodomain transcription factors." 
 19(13): 3475-3484. 
Nature
Ozkan, E., H. Yu, et al. (2005). "Mechanistic insight into the allosteric activation of a 
ubiquitin-conjugating enzyme by RING-type ubiquitin ligases." 
 416(6876): 99-103. 
Proc Natl Acad Sci U 
S A
Panier, S. and D. Durocher (2009). "Regulatory ubiquitylation in response to DNA double-
strand breaks." 
 102(52): 18890-18895. 
DNA Repair
Passmore, L. A. and D. Barford (2004). "Getting into position: the catalytic mechanisms of 
protein ubiquitylation." 
 8(4): 436-443. 
Biochem J
Pelzer, C., I. Kassner, et al. (2007). "UBE1L2, a Novel E1 Enzyme Specific for 
Ubiquitin." 
 379(Pt 3): 513-525. 
Journal of Biological Chemistry 282(32): 23010-23014. 
 158 
 
Peng, J., D. Schwartz, et al. (2003). "A proteomics approach to understanding protein 
ubiquitination."  
Nat Biotech
Perissi, V., A. Aggarwal, et al. (2004). "A corepressor/coactivator exchange complex 
required for transcriptional activation by nuclear receptors and other regulated 
transcription factors." 
 21(8): 921-926. 
Cell
Petroski, M. D. and R. J. Deshaies (2005). "Function and regulation of cullin-RING ubiquitin 
ligases." 
 116(4): 511-526. 
Nat Rev Mol Cell Biol
Petroski, M. D. and R. J. Deshaies (2005). "Mechanism of Lysine 48-Linked Ubiquitin-Chain 
Synthesis by the Cullin-RING Ubiquitin-Ligase Complex SCF-Cdc34."  123(6): 1107-
1120. 
 6(1): 9-20. 
Pickart, C. M. (2001). "MECHANISMS UNDERLYING UBIQUITINATION." Annual Review of 
Biochemistry
Podust, V. N., J. E. Brownell, et al. (2000). "A Nedd8 conjugation pathway is essential for 
proteolytic targeting of p27Kip1 by ubiquitination." 
 70(1): 503-533. 
Proceedings of the National 
Academy of Sciences of the United States of America
Price, M. A., F. H. Cruzalegui, et al. (1996). "The p38 and ERK MAP kinase pathways 
cooperate to activate Ternary Complex Factors and c-fos transcription in response 
to UV light." 
 97(9): 4579-4584. 
EMBO J
Price, M. A. and D. Kalderon (2002). "Proteolysis of the Hedgehog signaling effector Cubitus 
interruptus requires phosphorylation by Glycogen Synthase Kinase 3 and Casein 
Kinase 1." 
 15(23): 6552-6563. 
Cell
Rao, V. N., K. Huebner, et al. (1989). "elk, tissue-specific ets-related genes on chromosomes 
X and 14 near translocation breakpoints." 
 108(6): 823-835. 
Science
Read, M. A., J. E. Brownell, et al. (2000). "Nedd8 modification of cul-1 activates 
SCF(beta(TrCP))-dependent ubiquitination of IkappaBalpha." 
 244(4900): 66-70. 
Mol Cell Biol
Reiley, W., M. Zhang, et al. (2005). "Regulation of the deubiquitinating enzyme CYLD by 
IkappaB kinase gamma-dependent phosphorylation." 
 20(7): 
2326-2333. 
Mol Cell Biol
Reinstein, E., M. Scheffner, et al. (2000). "Degradation of the E7 human papillomavirus 
oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of 
the N-terminal residue." 
 25(10): 3886-
3895. 
Oncogene
Rodrigo-Brenni, M. C. and D. O. Morgan (2007). "Sequential E2s Drive Polyubiquitin Chain 
Assembly on APC Targets." 
 19(51): 5944-5950. 
Cell
Rotin, D. and S. Kumar (2009). "Physiological functions of the HECT family of ubiquitin 
ligases." 
 130(1): 127-139. 
Nat Rev Mol Cell Biol
Row, P. E., I. A. Prior, et al. (2006). "The ubiquitin isopeptidase UBPY regulates endosomal 
ubiquitin dynamics and is essential for receptor down-regulation." 
 10(6): 398-409. 
J Biol Chem
Rubin, D. M., O. Coux, et al. (1996). "Identification of the gal4 suppressor Sug1 as a subunit 
of the yeast 26S proteasome." 
 
281(18): 12618-12624. 
Nature
Russell, S. J., U. G. Sathyanarayana, et al. (1996). "Isolation and characterization of SUG2. A 
novel ATPase family component of the yeast 26 S proteasome." 
 379(6566): 655-657. 
J Biol Chem
Saha, A. and R. J. Deshaies (2008). "Multimodal activation of the ubiquitin ligase SCF by 
Nedd8 conjugation." 
 271(51): 
32810-32817. 
Mol Cell 32(1): 21-31. 
 159 
 
Sakata, E., Y. Yamaguchi, et al. (2007). "Direct interactions between NEDD8 and ubiquitin E2 
conjugating enzymes upregulate cullin-based E3 ligase activity." Nat Struct Mol Biol
Salghetti, S. E., A. A. Caudy, et al. (2001). "Regulation of transcriptional activation domain 
function by ubiquitin." 
 
14(2): 167-168. 
Science
Salghetti, S. E., S. Y. Kim, et al. (1999). "Destruction of Myc by ubiquitin-mediated 
proteolysis: cancer-associated and transforming mutations stabilize Myc." 
 293(5535): 1651-1653. 
EMBO J
Salghetti, S. E., M. Muratani, et al. (2000). "Functional overlap of sequences that activate 
transcription and signal ubiquitin-mediated proteolysis." 
 
18(3): 717-726. 
Proc Natl Acad Sci U S A
Salvat, C., I. Jariel-Encontre, et al. (1998). "Differential directing of c-Fos and c-Jun proteins 
to the proteasome in serum-stimulated mouse embryo fibroblasts." 
 
97(7): 3118-3123. 
Oncogene
Sarcevic, B., A. Mawson, et al. (2002). "Regulation of the ubiquitin-conjugating enzyme 
hHR6A by CDK-mediated phosphorylation." 
 
17(3): 327-337. 
EMBO J
Scheffner, M., J. M. Huibregtse, et al. (1994). "Identification of a human ubiquitin-
conjugating enzyme that mediates the E6-AP-dependent ubiquitination of 
p53." 
 21(8): 2009-2018. 
Proceedings of the National Academy of Sciences of the United States of 
America
Schulman, B. A., A. C. Carrano, et al. (2000). "Insights into SCF ubiquitin ligases from the 
structure of the Skp1-Skp2 complex." 
 91(19): 8797-8801. 
Nature
Seol, J. H., R. M. Feldman, et al. (1999). "Cdc53/cullin and the essential Hrt1 RING-H2 
subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme 
Cdc34." 
 408(6810): 381-386. 
Genes Dev
Sharrocks, A. D. (1995). "ERK2/p42 MAP kinase stimulates both autonomous and SRF-
dependent DNA binding by Elk-1." 
 13(12): 1614-1626. 
FEBS Letters
Sharrocks, A. D. (2001). "The ETS-domain transcription factor family." 
 368(1): 77-80. 
Nat Rev Mol Cell Biol
Sharrocks, A. D., S.-H. Yang, et al. (2000). "Docking domains and substrate-specificity 
determination for MAP kinases." 
 
2(11): 827-837. 
Trends in Biochemical Sciences
Shaw, P. E. (1992). "Ternary complex formation over the c-fos serum response element: 
p62TCF exhibits dual component specificity with contacts to DNA and an extended 
structure in the DNA-binding domain of p67SRF." 
 25(9): 448-453. 
EMBO J
Shaw, P. E. and J. Saxton (2003). "Ternary complex factors: prime nuclear targets for 
mitogen-activated protein kinases." 
 11(8): 3011-3019. 
Int J Biochem Cell Biol
Shaw, P. E., H. Schröter, et al. (1989). "The ability of a ternary complex to form over the 
serum response element correlates with serum inducibility of the human c-fos 
promoter." 
 35(8): 1210-1226. 
Cell
Sheaff, R. J., M. Groudine, et al. (1997). "Cyclin E-CDK2 is a regulator of p27Kip1." 
 56(4): 563-572. 
Genes 
Dev
Shore, P. and A. D. Sharrocks (1994). "The transcription factors Elk-1 and serum response 
factor interact by direct protein-protein contacts mediated by a short region of Elk-
1." 
 11(11): 1464-1478. 
Mol. Cell. Biol.
Shore, P., A. Whitmarsh, et al. (1996). "Determinants of DNA-binding specificity of ETS-
domain transcription factors." 
 14(5): 3283-3291. 
Mol. Cell. Biol.
Skaug, B., X. Jiang, et al. (2009). "The Role of Ubiquitin in NF-ʃ ZĞŐƵůĂƚŽƌǇ
Pathways." 
 16(7): 3338-3349. 
Annual Review of Biochemistry 78(1): 769-796. 
 160 
 
Skowyra, D., K. L. Craig, et al. (1997). "F-box proteins are receptors that recruit 
phosphorylated substrates to the SCF ubiquitin-ligase complex." Cell
Soh, J. W., E. H. Lee, et al. (1999). "Novel roles of specific isoforms of protein kinase C in 
activation of the c-fos serum response element." 
 91(2): 209-219. 
Mol Cell Biol
Stebbins, C. E., W. G. Kaelin, Jr., et al. (1999). "Structure of the VHL-ElonginC-ElonginB 
complex: implications for VHL tumor suppressor function." 
 19(2): 1313-1324. 
Science
Stevens, J. L., G. T. Cantin, et al. (2002). "Transcription control by E1A and MAP kinase 
pathway via Sur2 mediator subunit." 
 284(5413): 455-
461. 
Science
Stewart, G. S., S. Panier, et al. (2009). "The RIDDLE Syndrome Protein Mediates a Ubiquitin-
Dependent Signaling Cascade at Sites of DNA Damage."  136(3): 420-434. 
 296(5568): 755-758. 
Strahl, T., H. Gille, et al. (1996). "Selective response of ternary complex factor Sap1a to 
different mitogen-activated protein kinase subgroups." Proc Natl Acad Sci U S A
Sundqvist, A. and J. Ericsson (2003). "Transcription-dependent degradation controls the 
stability of the SREBP family of transcription factors." 
 
93(21): 11563-11568. 
Proc Natl Acad Sci U S A
Swaffield, J. C., J. F. Bromberg, et al. (1992). "Alterations in a yeast protein resembling HIV 
Tat-binding protein relieve requirement for an acidic activation domain in 
GAL4." 
 
100(24): 13833-13838. 
Nature
Swaffield, J. C., K. Melcher, et al. (1995). "A highly conserved ATPase protein as a mediator 
between acidic activation domains and the TATA-binding protein 
 357(6380): 698-700. 
" Nature
Tan, P., S. Y. Fuchs, et al. (1999). "Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and 
HOS to catalyze the ubiquitination of I kappa B alpha." 
 374(6517): 88-91. 
Mol Cell
Thomas, M. C. and C. M. Chiang (2006). "The general transcription machinery and general 
cofactors." 
 3(4): 527-533. 
Crit Rev Biochem Mol Biol
Thrower, J. S., L. Hoffman, et al. (2000). "Recognition of the polyubiquitin proteolytic 
signal." 
 41(3): 105-178. 
Embo J
Tokunaga, F., S.-i. Sakata, et al. (2009). "Involvement of linear polyubiquitylation of NEMO 
in NF- ?ŬĂƉƉĂ ?ĂĐƚŝǀĂƚŝŽŶ ? ?
 19(1): 94-102. 
Nat Cell Biol
Treisman, R. (1990). "The SRE: a growth factor responsive transcriptional regulator." 
 11(2): 123-132. 
Semin 
Cancer Biol
Treisman, R. (1992). "The serum response element." 
 1(1): 47-58. 
Trends in Biochemical Sciences
Treisman, R. (1995). "Journey to the surface of the cell: Fos regulation and the SRE." 
 17(10): 
423-426. 
EMBO 
J
Treisman, R., R. Marais, et al. (1992). "Spatial flexibility in ternary complexes between SRF 
and its accessory proteins." 
 14(20): 4905-4913. 
EMBO J
Tsai, E. Y., J. V. Falvo, et al. (2000). "A lipopolysaccharide-specific enhancer complex 
involving Ets, Elk-1, Sp1, and CREB binding protein and p300 is recruited to the 
tumor necrosis factor alpha promoter in vivo." 
 11(12): 4631-4640. 
Mol Cell Biol
Turjanski, A. G., J. P. Vaque, et al. (2007). "MAP kinases and the control of nuclear 
events." 
 20(16): 6084-6094. 
Oncogene
van Wijk, S. J. and H. T. Timmers (2010). "The family of ubiquitin-conjugating enzymes (E2s): 
deciding between life and death of proteins." 
 26(22): 3240-3253. 
FASEB J 24(4): 981-993. 
 161 
 
Vanhoutte, P., J. L. Nissen, et al. (2001). "Opposing roles of Elk-1 and its brain-specific 
isoform, short Elk-1, in nerve growth factor-induced PC12 differentiation." J Biol 
Chem
Verdecia, M. A., C. A. P. Joazeiro, et al. (2003). "Conformational Flexibility Underlies 
Ubiquitin Ligation Mediated by the WWP1 HECT Domain E3 Ligase." 
 276(7): 5189-5196. 
Molecular Cell
Verma, R., R. S. Annan, et al. (1997). "Phosphorylation of Sic1p by G1 Cdk required for its 
degradation and entry into S phase." 
 
11(1): 249-259. 
Science
Verma, R., L. Aravind, et al. (2002). "Role of Rpn11 metalloprotease in deubiquitination and 
degradation by the 26S proteasome." 
 278(5337): 455-460. 
Science
Verma, R., R. Oania, et al. (2004). "Multiubiquitin chain receptors define a layer of substrate 
selectivity in the ubiquitin-proteasome system." 
 298(5593): 611-615. 
Cell
Vickers, E. R., A. Kasza, et al. (2004). "Ternary complex factor-serum response factor 
complex-regulated gene activity is required for cellular proliferation and inhibition 
of apoptotic cell death." 
 118(1): 99-110. 
Mol Cell Biol
Volk, S., M. Wang, et al. (2005). Chemical and Genetic Strategies for Manipulating 
Polyubiquitin Chain Structure. 
 24(23): 10340-10351. 
Methods in Enzymology
von der Lehr, N., S. Johansson, et al. (2003). "The F-box protein Skp2 participates in c-Myc 
proteosomal degradation and acts as a cofactor for c-Myc-regulated 
transcription." 
, Academic Press. Volume 
399: 3-20. 
Mol Cell
Wada, H., E. T. H. Yeh, et al. (2000). "A Dominant-negative UBC12 Mutant Sequesters 
NEDD8 and Inhibits NEDD8 Conjugation in Vivo." 
 11(5): 1189-1200. 
Journal of Biological Chemistry
Wang, C., L. Deng, et al. (2001). "TAK1 is a ubiquitin-dependent kinase of MKK and 
IKK." 
 
275(22): 17008-17015. 
Nature
Wang, H., A. Matsuzawa, et al. (2008). "Analysis of nondegradative protein ubiquitylation 
with a monoclonal antibody specific for lysine-63-linked polyubiquitin." 
 412(6844): 346-351. 
Proceedings 
of the National Academy of Sciences
Wang, M., D. Cheng, et al. (2006). "Molecular determinants of polyubiquitin linkage 
selection by an HECT ubiquitin ligase." 
 105(51): 20197-20202. 
Embo J
Watanabe, K., S. Tateishi, et al. (2004). "Rad18 guides poleta to replication stalling sites 
through physical interaction and PCNA monoubiquitination." 
 25(8): 1710-1719. 
EMBO J
Welcker, M., J. Singer, et al. (2003). "Multisite phosphorylation by Cdk2 and GSK3 controls 
cyclin E degradation." 
 23(19): 3886-
3896. 
Mol Cell
Whitmarsh, A. J., P. Shore, et al. (1995). "Integration of MAP kinase signal transduction 
pathways at the serum response element." 
 12(2): 381-392. 
Science
Williams, R. L. and S. Urbe (2007). "The emerging shape of the ESCRT machinery." 
 269(5222): 403-407. 
Nat Rev 
Mol Cell Biol
Winborn, B. J., S. M. Travis, et al. (2008). "The deubiquitinating enzyme ataxin-3, a 
polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin 
chains." 
 8(5): 355-368. 
J Biol Chem
Windheim, M., M. Peggie, et al. (2008). "Two different classes of E2 ubiquitin-conjugating 
enzymes are required for the mono-ubiquitination of proteins and elongation by 
polyubiquitin chains with a specific topology." 
 283(39): 26436-26443. 
Biochem J 409(3): 723-729. 
 162 
 
Won, K. A. and S. I. Reed (1996). "Activation of cyclin E/CDK2 is coupled to site-specific 
autophosphorylation and ubiquitin-dependent degradation of cyclin E." EMBO J
Wood, A., J. Schneider, et al. (2005). "The Bur1/Bur2 Complex Is Required for Histone H2B 
Monoubiquitination by Rad6/Bre1 and Histone Methylation by COMPASS."  20(4): 
589-599. 
 
15(16): 4182-4193. 
Wu, C.-J., D. B. Conze, et al. (2006). "Sensing of Lys 63-linked polyubiquitination by NEMO is 
a key event in NF- ?ŬĂƉƉĂ ?ĂĐƚŝǀĂƚŝŽŶ ? ?Nat Cell Biol
Wu, K., A. Chen, et al. (2000). "Conjugation of Nedd8 to CUL1 Enhances the Ability of the 
ROC1-CUL1 Complex to Promote Ubiquitin Polymerization." 
 8(4): 398-406. 
Journal of Biological 
Chemistry
Wu, R. C., Q. Feng, et al. (2007). "SRC-3 coactivator functional lifetime is regulated by a 
phospho-dependent ubiquitin time clock." 
 275(41): 32317-32324. 
Cell
Wu, Z.-H., Y. Shi, et al. (2006). "Molecular Linkage Between the Kinase ATM and NF-
{kappa}B Signaling in Response to Genotoxic Stimuli." 
 129(6): 1125-1140. 
Science
Xu, P., D. M. Duong, et al. (2009). "Quantitative proteomics reveals the function of 
unconventional ubiquitin chains in proteasomal degradation." 
 311(5764): 1141-
1146. 
Cell
Yamoah, K., T. Oashi, et al. (2008). "Autoinhibitory regulation of SCF-mediated 
ubiquitination by human cullin 1's C-terminal tail." 
 137(1): 133-145. 
Proc Natl Acad Sci U S A
Yang, C., W. Zhou, et al. (2006). "Negative Regulation of the E3 Ubiquitin Ligase Itch via Fyn-
Mediated Tyrosine Phosphorylation."  21(1): 135-141. 
 105(34): 
12230-12235. 
Yang, S.-H., D. C. Bumpass, et al. (2002). "The ETS Domain Transcription Factor Elk-1 
Contains a Novel Class of Repression Domain." Mol. Cell. Biol.
Yang, S.-H., E. Jaffray, et al. (2003). "Dynamic Interplay of the SUMO and ERK Pathways in 
Regulating Elk-1 Transcriptional Activity." 
 22(14): 5036-5046. 
Molecular Cell
Yang, S.-H. and A. D. Sharrocks (2004). "SUMO Promotes HDAC-Mediated Transcriptional 
Repression."  13(4): 611-617. 
 12(1): 63-74. 
Yang, S.-H., P. Shore, et al. (1999). "The mechanism of phosphorylation-inducible activation 
of the ETS-domain transcription factor Elk-1." EMBO J
Yang, S.-H., E. Vickers, et al. (2001). "Temporal Recruitment of the mSin3A-Histone 
Deacetylase Corepressor Complex to the ETS Domain Transcription Factor Elk-
1." 
 18(20): 5666-5674. 
Mol. Cell. Biol.
Yang, S. H., A. D. Sharrocks, et al. (2003). "Transcriptional regulation by the MAP kinase 
signaling cascades." 
 21(8): 2802-2814. 
Gene
Yang, S. H., A. J. Whitmarsh, et al. (1998). "Differential targeting of MAP kinases to the ETS-
domain transcription factor Elk-1." 
 320: 3-21. 
EMBO J
Yang, S. H., P. R. Yates, et al. (1998). "The Elk-1 ETS-domain transcription factor contains a 
mitogen-activated protein kinase targeting motif." 
 17(6): 1740-1749. 
Mol Cell Biol
Yaron, A., A. Hatzubai, et al. (1998). "Identification of the receptor component of the 
IkappaBalpha-ubiquitin ligase." 
 18(2): 710-720. 
Nature
Yates, P. R., G. T. Atherton, et al. (1999). "Id helix-loop-helix proteins inhibit nucleoprotein 
complex formation by the TCF ETS-domain transcription factors." 
 396(6711): 590-594. 
EMBO J
Ye, Y. and M. Rape (2009). "Building ubiquitin chains: E2 enzymes at work." 
 18(4): 
968-976. 
Nat Rev Mol 
Cell Biol 10(11): 755-764. 
 163 
 
You, Z., K. Harvey, et al. (2002). "Xic1 degradation in Xenopus egg extracts is coupled to 
initiation of DNA replication." Genes Dev
Yu, H., J. M. Peters, et al. (1998). "Identification of a cullin homology region in a subunit of 
the anaphase-promoting complex." 
 16(10): 1182-1194. 
Science
Zachariae, W., A. Shevchenko, et al. (1998). "Mass spectrometric analysis of the anaphase-
promoting complex from yeast: identification of a subunit related to 
cullins." 
 279(5354): 1219-1222. 
Science
Zhang, H. M., L. Li, et al. (2008). "Mitogen-induced recruitment of ERK and MSK to SRE 
promoter complexes by ternary complex factor Elk-1." 
 279(5354): 1216-1219. 
Nucleic Acids Res
Zhang, H. M., S. Vougier, et al. (2010). "Integration of protein kinases into transcription 
complexes: identifying components of immobilised in vitro pre-initiation 
complexes." 
 36(8): 
2594-2607. 
Methods Mol Biol
Zheng, N., B. A. Schulman, et al. (2002). "Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF 
ubiquitin ligase complex." 
 647: 291-303. 
Nature
Zheng, N., B. A. Schulman, et al. (2002). "Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF 
ubiquitin ligase complex." 
 416(6882): 703-709. 
Nature
 
 416(6882): 703-709. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 164 
 
Appendices  
Plasmid:  pcDNA3.HA.Elk-1 
Clone chart 
Description:  Cell-free and mammalian expression vector for N-terminal HA-
tagged human wild-type Elk-1 cDNA 
Bacterial strain:  NM522 
Resistances:   Ampicillin, neomycin 
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Plasmid:  pCMV5.Elk-1 
Description:  Mammalian expression vector for human Elk-1 cDNA  
Bacterial strain: NM522 
Resistances:   Ampicillin 
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Plasmid:  pCMV5.HA.Elk-1 
Description:  Mammalian expression vector for N-terminal HA-tagged human 
wild-type Elk-1 cDNA 
Bacterial strain:  NM522 
Resistances:   Ampicillin 
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